A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC) by Kitchener, Henry C. et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 20 ISSUE 68 SEPTEMBER 2016
ISSN 1366-5278
DOI 10.3310/hta20680
A cluster randomised trial of strategies to increase 
cervical screening uptake at first invitation 
(STRATEGIC)
Henry C Kitchener, Matthew Gittins, Oliver Rivero-Arias,  
Apostolos Tsiachristas, Margaret Cruickshank, Alastair Gray,  
Loretta Brabin, David Torgerson, Emma J Crosbie, Alexandra Sargent  
and Chris Roberts on behalf of the STRATEGIC Study Group

A cluster randomised trial of strategies to
increase cervical screening uptake at first
invitation (STRATEGIC)
Henry C Kitchener,1* Matthew Gittins,2
Oliver Rivero-Arias,3 Apostolos Tsiachristas,4
Margaret Cruickshank,5 Alastair Gray,4
Loretta Brabin,1 David Torgerson,6 Emma J Crosbie,1
Alexandra Sargent7 and Chris Roberts2 on behalf of
the STRATEGIC Study Group
1Institute of Cancer Sciences, University of Manchester, St Mary’s Hospital,
Manchester, UK
2Centre for Biostatistics, Institute of Population Health, University of Manchester,
Manchester, UK
3National Perinatal Epidemiology Unit, Nuffield Department of Population
Health, University of Oxford, Oxford, UK
4Health Economics Research Centre, Nuffield Department of Population Health,
University of Oxford, Oxford, UK
5Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital,
Aberdeen, UK
6Department of Health Sciences, University of York, York, UK
7Virology Department, Central Manchester University Hospitals NHS Foundation
Trust, Manchester, UK
*Corresponding author
Declared competing interests of authors: Henry Kitchener is chairperson of the Advisory Committee for
Cervical Screening, but views expressed here are those of the author and not those of Public Health
England. Emma Crosbie is a National Institute for Health Research (NIHR) Clinician Scientist and has
received funding from the NIHR, Medical Research Council, Wellbeing of Women, Wellcome Trust and
Central Manchester University Hospitals NHS Foundation Trust for research projects unrelated to the
submitted work. She is an executive scientific editor for the British Journal of Obstetrics and Gynaecology.
Published September 2016
DOI: 10.3310/hta20680

This report should be referenced as follows:
Kitchener HC, Gittins M, Rivero-Arias O, Tsiachristas A, Cruickshank M, Gray A, et al. A cluster
randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC).
Health Technol Assess 2016;20(68).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.058
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 09/164/01. The contractual start date
was in November 2011. The draft report began editorial review in January 2016 and was accepted for publication in June 2016. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning
contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and
study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement
is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre,
Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief
Health Technology Assessment 
NIHR Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor John Norrie Health Services Research Unit, University of Aberdeen, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.uk
Professor Geoffrey Meads Professor of Health Sciences Research, Health and Wellbeing Research and
Development Group, University of Winchester, UK
Editor-in-Chief
Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the
Centre of Evidence-Based Dermatology, University of Nottingham, UK
Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK
Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School,
University of Warwick, UK
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
A cluster randomised trial of strategies to increase cervical
screening uptake at first invitation (STRATEGIC)
Henry C Kitchener,1* Matthew Gittins,2 Oliver Rivero-Arias,3
Apostolos Tsiachristas,4 Margaret Cruickshank,5 Alastair Gray,4
Loretta Brabin,1 David Torgerson,6 Emma J Crosbie,1
Alexandra Sargent7 and Chris Roberts2 on behalf of the STRATEGIC
Study Group
1Institute of Cancer Sciences, University of Manchester, St Mary’s Hospital, Manchester, UK
2Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, UK
3National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of
Oxford, Oxford, UK
4Health Economics Research Centre, Nuffield Department of Population Health, University of
Oxford, Oxford, UK
5Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, Aberdeen, UK
6Department of Health Sciences, University of York, York, UK
7Virology Department, Central Manchester University Hospitals NHS Foundation Trust,
Manchester, UK
*Corresponding author henry.c.kitchener@manchester.ac.uk
Background: Falling participation by young women in cervical screening has been observed at a time
that has seen an increase in the incidence of cervical cancer in the UK in women aged < 35 years.
Various barriers to screening have been documented, including fear, embarrassment and inconvenience.
Objectives: To measure the feasibility, clinical effectiveness and cost-effectiveness of a range of
interventions to increase the uptake of cervical screening among young women.
Design: A cluster randomised trial based on general practices performed in two phases.
Setting: Primary care in Greater Manchester and the Grampian region in Scotland.
Participants: Phase 1: 20,879 women receiving their first invitation for cervical screening. Phase 2:
10,126 women who had not attended by 6 months.
Interventions: Phase 1: pre-invitation leaflet or not, and access to online booking (Manchester only).
Phase 2: (1) vaginal self-sampling kits (SSKs) sent unrequested (n = 1141); or (2) offered on request
(n = 1290); (3) provided with a timed appointment (n = 1629); (4) offered access to a nurse navigator (NN)
(n = 1007); or (5) offered a choice between a NN or a SSK (n = 1277); and 3782 women in control practices.
Main outcome measures: Uplift in screening compared with control practices, cost-effectiveness of
interventions, and the women’s preferences explored in a discrete choice experiment.
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Results: The pre-invitation leaflet and offer of online booking were ineffective when compared with control
practices at 3 months, 18.8% versus 19.2% [odds ratio (OR) 0.96, 95% confidence interval (CI) 0.88 to
1.06; p = 0.485] and 17.8% versus 17.2% (OR 1.02, 95% CI 0.87 to 1.20; p = 0.802), respectively.
The uptake of screening at 3 months was higher among previously human papillomavirus (HPV)-vaccinated
women than unvaccinated women, 23.7% versus 11% (OR 2.07, 95% CI 1.69 to 2.53; p < 0.001).
Among non-attenders, the SSK sent intervention showed a statistically significant increase in uptake at
12 months post invitation, 21.3% versus 16.2% (OR 1.51, 95% CI 1.20 to 1.91; p = 0.001), as did timed
appointments, 19.8% versus 16.2% (OR 1.41, 95% CI 1.14 to 1.74; p = 0.001). The offer of a NN, a SSK
on request, and a choice between timed appointments and NN were ineffective. Overall, there was a
gradual rather than prompt response, as demonstrated by uptake among control practices. A discrete
choice experiment indicated that women invited who had not yet attended valued the attributes inherent in
self-sampling. The health economic analysis showed that both timed appointments and unsolicited SSK sent
were likely to be cost-effective at a cost per quality-adjusted life-year (QALY) gained of £7593 and £8434,
respectively, if extended across the national 25-year-old cohort throughout the duration of screening.
The certainty of these being cost-effective at a ceiling ratio of £20,000 per QALY gained was > 90%.
Conclusion: Women receiving their initial screening invitation frequently delay taking up the offer and the
net impact of interventions was small. Timed appointments and SSKs sent to non-attenders at 6 months
are likely to be a cost-effective means of increasing uptake and should be considered further. HPV
vaccination in the catch-up programme was associated with an increased uptake of cervical screening.
Future work should focus on optimising self-sampling in terms of age range, timing of offer for non-
attenders and use of urine testing instead of vaginal samples.
Trial registration: Current Controlled Trials ISRCTN52303479.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 68. See the NIHR Journals Library website
for further project information.
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Plain English summary
The STRATEGIC trial tested new methods (interventions) to encourage young women to attend their firstcervical screen.
The trial involved two groups of women registered with a general practitioner: one group aged 24.75 years
in Greater Manchester and one group aged 20 years in the Grampian region of Scotland, all of whom had
been offered the human papillomavirus vaccination on the national programme. The trial allocated general
practices by chance (randomised) to different interventions and was performed in two phases. The first
phase involved all women invited for their first cervical screen and the second phase involved women who
had not attended within 6 months. Phase 1 tested a specially designed pre-invitation leaflet and online
booking. In phase 2, self-sampling kits (SSKs) were sent and offered, and a nurse navigator (NN), timed
appointments and a choice between SSKs and NNs were tested. In both phases a number of general
practices did not test any new interventions, and these were the control practices. Phase 1 involved
20,879 women and phase 2 involved 10,126 women. The effectiveness of the new methods was
demonstrated by comparing screening uptake with that in the control practices.
Neither the pre-invitation leaflet nor online booking had any impact on uptake of cervical screening
coverage after 3 and 6 months. In phase 2, both SSK sent and timed appointments interventions did
achieve a small but significant increase in the uptake of screening, and economic analysis indicated that
these methods were likely to be cost-effective. Women who had chosen not to attend for screening
indicated a preference for SSKs being sent.
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Scientific summary
Background
Cervical screening depends on high coverage to achieve its aim of preventing cancer and deaths from
cancer. In recent years, uptake among young women has fallen despite public concern expressed over the
decision to raise the age threshold for cervical screening in England from 20 to 25 years. In Manchester,
for example, uptake of cervical screening among women aged 25 years receiving their first invitation to
screening has been around 30% at 6 months after their invitation, compared with an aimed for coverage
of 80%, in line with national coverage across the screening age range. Women do have a choice
regarding participation in cervical screening, but some women may not fully understand the benefits of
cervical screening, and, for others, day-to-day challenges mean that screening is not one of their priorities.
A systematic review suggested that there are different reasons for non-participation among women.
Although reminders, which are already built into the screening process, have been shown to be effective,
our hypothesis was that overcoming barriers to screening young women would require different types of
interventions to be explored in order to address these different factors. These should address issues such as
anxiety, convenience, dislike of a gynaecological procedure, indifference and not feeling at risk of cervical
cancer. It was also felt that the transtheoretical model was relevant, whereby women could be persuaded
to progress from pre-contemplation to action. There has been concern that the level of protection from
human papillomavirus (HPV) prophylactic vaccination could induce a sense of immunity from cervical
cancer in young women, making them less likely to participate in cervical screening and we wished to
study this in a Scottish cohort where screening of vaccinated females began in 2010.
Objectives
1. To evaluate the clinical effectiveness of a range of interventions in:
i. all women receiving their first invitation for cervical screening
ii. those who had not attended by 6 months.
2. To evaluate the cost-effectiveness of these interventions.
3. To study preferences for cervical screening among non-attenders.
Methods
Uptake of screening
This study involved two sets of interventions that were offered to two cohorts of women who were to
receive their first invitation to cervical screening. The first cohort comprised all such women in Manchester,
Salford and Trafford primary care trusts (PCTs) (now redesignated Clinical Commissioning Groups) in
Greater Manchester, north-west England, between April 2012 and June 2014 who were approaching their
25th birthday. The second cohort comprised women who had just reached their 20th birthday and who
were receiving their first screening invitation in the Grampian region of north-east Scotland, between
October 2012 and December 2014. Around 65–70% of the Grampian women had been HPV vaccinated
in the national catch-up vaccination campaign of 2008–10. The study had a complex design based on
cluster randomisation of general practices, and involved two phases:
1. In phase 1, all women who were eligible for cervical screening were, in parallel with a control group,
cluster randomised to receive a specially designed pre-invitation leaflet 4–6 weeks prior to receiving
their initial routine invitation. Women in the Manchester PCT were also cluster randomised to an offer
of online booking using a factorial design to balance pre-leaflet groups. A feasibility pilot study was
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performed during phase 1 on a prior cohort of non-attenders to assess the feasibility and uptake of
several novel interventions to be used in phase 2. These included self-sampling offered and kits sent
unsolicited, a nurse navigator (NN) to advise and support women, timed appointments and a choice of
the last two.
2. In phase 2, all non-attenders in the cohort were offered the piloted interventions at 7.5 months after
the standard invitation, again in a general practice cluster randomised trial with a factorial design to
balance the phase 1 interventions. In phase 2 there was, again, a set of control practices with no
study intervention.
All of the interventions were offered initially by mail from the screening agency in Greater Manchester and
by the study team in Grampian. The pre-leaflet had been designed on the basis of issues raised by young
women in focus groups. The online booking could be made available only to women in the Manchester
PCT, through the community sexual health clinics. The study research nurse acted as the NN, who could be
contacted by telephone. Self-sampling, whether by request or unsolicited, involved a vaginal sample that
was returned dry and then tested using the Cobas 4800 assay (Roche Diagnostics, Pleasanton, CA, USA).
Timed appointments were offered by almost all of the randomly allocated general practices and were
booked at the women’s request.
Data on uptake were obtained from the screening agency (Lancashire and South Cumbria Agency) in
Greater Manchester and from the research team in Grampian. The primary outcome in phase 1 was
uptake of screening 3 months following the standard invitation and in phase 2, it was uptake 12 months
following the standard invitation. Data analysis was performed using a generalised estimating equation in
the form of a population average model to adjust for practice size and pre-study coverage.
Health economic study
The economic analysis complied with methodological guidelines issued by the National Institute for Health
and Care Excellence and followed the reporting standards of the Consolidated Health Economic Evaluation
Reporting Standards statement. For each intervention, the cost per attendance was calculated together
with the unit costs of the screening tests. Other screening-related costs, such as colposcopy and treatment,
were estimated. A literature review was conducted to obtain information about costs of lifetime
quality-adjusted life-years (QALYs) of women who have attended cervical screening and those who have
not. A meta-analysis was performed to pool the lifetime costs and outcomes reported in the selected
studies, using a specified random-effects model. Costs were inflated from each study price reference year
to 2014, and life expectancy adjusted to the UK context. A decision model was constructed to determine
cost-effectiveness and cost–utility analyses. Incremental cost-effectiveness ratios (ICERs) were expressed as
incremental costs per attendee and incremental costs per QALY. Uncertainty and scenario analyses were
also performed, using probabilistic sensitivity analysis, and the results plotted in cost-effectiveness planes.
Discrete choice experiment
In order to gauge the importance that young women attached to cervical screening, as well as the
elements of the screening that they valued, a discrete choice experiment (DCE) was undertaken. This
involved an initial set of interviews with non-attenders to determine the relevant attributes included in the
scenarios presented to women in a subsequent much larger postal survey. The design and statistical
analysis used in the DCE were informed by recent guidance on the conduct of stated preference exercises.
Results
Phase 1
Between April 2012 and December 2013, a total of 20,879 women in 276 practices (193 in Greater
Manchester and 83 in Grampian) were cluster randomised, in phase 1, to either pre-leaflet or no
pre-leaflet. In the Manchester PCT, 9734 women in 102 practices were cluster randomised to the offer of
online booking or not. At the 3-month time point, 18.8% of the pre-leaflet arm had been screened,
compared with 19.2% of the controls [odds ratio (OR) 0.96, 95% confidence interval (CI) 0.88 to 1.06;
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p = 0.485]. At 6 months, the equivalent uptake was 31.1% and 30.6%, respectively (OR 1.01, 95% CI
0.93 to 1.10; p = 0.747). These data show that the pre-leaflet had no effect. Online booking also showed
no impact on uptake. After 3 months, uptake was 17.8% in the group offered online booking, compared
with 17.2% in those not offered online booking (OR 1.02, 95% CI 0.87 to 1.20; p = 0.802). At 6 months,
the equivalent data were 28.8% versus 26.6% (OR 1.09, 95% CI 0.94 to 1.28; p = 0.242). There was no
interaction between these two interventions. Among the Grampian population, however, there was
evidence of increased uptake among previously vaccinated women compared with unvaccinated women:
23.7% versus 11.0% at 3 months (OR 2.07, 95% CI 1.69 to 2.53; p < 0.001) and 40.1% versus 18.2% at
6 months (OR 2.57, 95% CI 2.2 to 2.9; p < 0.001).
Phase 2
During phase 1, 6454 women were screened, 2330 were excluded from the study cohort because of a
delay in operationalising the interventions and 1969 were excluded resulting from a change of address.
Therefore, between April 2013 and December 2014, a total of 10,126 non-attenders were cluster
randomised in phase 2 to the interventions, and 30 practices served as a control. At the primary time
point of 12 months following the standard invitations, uptake was 16.2% among the controls, compared
with 21.3%, 16.2%, 14.5%, 19.8% and 18.8% for self-sample sent, self-sample offered, NN, timed
appointment and choice, respectively. Self-sampling kits (SSKs) sent and timed appointments showed a
significant increment in uptake, with an OR of 1.51 (95% CI 1.20 to 1.91) and 1.4 (95% CI 1.14 to 1.74),
respectively. At the secondary time point of 18 months following the standard invitation, uptake in the
control group was 27.1% and the SSK sent group was 30%, with an OR of 1.29 (95% CI 1.06 to 1.57),
but timed appointments was no longer significantly different (OR 1.19, 95% CI 0.97 to 1.46).
Health economic study
The meta-analysis revealed a lifetime quality-adjusted life expectancy gain from participating in screening of
0.0947 QALYs per woman attending, and a lifetime additional cost of £566. In phase 1, the pre-leaflet
intervention was less costly but less effective than controls. Although online booking was more effective
and more costly, with a cost-effectiveness ratio of £8344 per QALY gained, there was low certainty of
cost-effectiveness. In phase 2, HPV self-sampling on request was more costly but more effective than
controls, with an ICER of £6784 per QALY gained. SSKs sent unsolicited was also more costly but more
effective at an ICER of £8434 per QALY. NNs were less costly but less effective. Timed appointments were
more costly but more effective than controls, at an ICER of £7593 per QALY. Offering a choice between a
NN and the offer of a HPV self-sample sent was also more costly but more effective at an ICER of £7382 per
QALY. The probabilistic sensitivity analyses demonstrate, however, that only timed appointments and SSKs
sent unsolicited has a high likelihood of cost-effectiveness at a ceiling ratio of £20,000 per QALY gained.
Discrete choice experiment
A questionnaire was sent to 4000 non-attenders outside the STRATEGIC trial cohort with a response rate
of 5.5%. Questionnaire responses showed that women who were non-attenders at 6 months following
the standard invitation understood the value of cervical screening. It also demonstrated preferences for
the screening process where minimal personal action is required for the screening test, where the test is
performed privately at home and where a nurse is available for discussion. It also demonstrated that
women valued testing that was cheaper for the NHS. Some of these characteristics are in line with
self-sampling, especially if the kit is sent unsolicited.
Discussion
Phase 1
The pre-invitation leaflet, which had been designed with the transtheoretical framework in mind, proved
ineffective in persuading more young women to attend for screening. We had hypothesised that it would
prepare women ahead of receiving their invitation to be more likely to move from thinking about
screening to deciding to attend. The leaflet contained messages that young women had highlighted as
relevant to them at prior focus group meetings, but clearly this approach did not work. We do not know
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whether or not women actually read the leaflet as it was simply mailed to them by the screening agency.
Online booking was taken up by around 6% of women offered. Many did not actually attend the booked
appointment and, in absolute terms, the uptake at 3 months was very similar to controls. Although a 2%
higher uptake than that seen in the control group after 6 months of follow-up was observed, this did not
achieve statistical significance. One important observation made in phase 1 was that among the Grampian
women, prior vaccination was associated with a significantly increased uptake, and that overall uptake
among unvaccinated women was < 20% after 6 months. This minority who are unvaccinated and
unscreened remain at a higher risk of cervical cancer.
Phase 2
All of the interventions were successfully implemented. Compared with controls, a SSK sent and timed
appointment were associated with a statistically significantly increased uptake at 12 months following the
standard invitation with an increased uplift over controls in absolute terms of 5.1% and 3.7%, respectively.
By 18 months, however, participation by controls rose from 16.2% to 27.1%, and only SSKs sent continued
to show a significant increase in uptake. Although these interventions were aimed at specific barriers,
accessing the interventions did not always directly result in uptake, but appeared to ‘nudge’ women into
action. It seemed that a significant number of women who had not attended promptly for screening, did
understand its importance and got round to it over time. This concept is supported by the DCE in which
women who had not attended promptly indicated that they thought cervical screening was important.
It was clear from the ORs of the interventions that unrequested SSKs sent had the largest effect, followed
by timed appointments, and this was reflected in the cost-effectiveness results. Other phase 2 interventions
were thought to carry lower certainty of cost-effectiveness, and neither of the phase 1 interventions
was effective. Offering timed appointments and unsolicited SSKs to a national cohort of women aged
25 years, and across the entire lifetime of screening would cost £13.4M and £18.37M, respectively, with
cost-effectiveness ratios of £7593 and £8437 and a 94% probability of being below the £20,000 ceiling.
It may be more cost-effective to offer all invited women a timed appointment and reserve SSKs for
non-attenders. The DCE confirmed that the attributes valued by women who had not yet attended are
inherent in the strategy of sending SSKs.
Conclusions
Women receiving their initial invitation to cervical screening do not attend promptly but continue to do so
during the interval prior to the next screening round. Approximately 30% had been screened by 6 months
and another 20% over the following year. Previously vaccinated women had a higher uptake than
unvaccinated women. The pre-invitation leaflet and online booking were not effective in increasing uptake,
but the latter would be convenient for many young women. Among non-attenders at 6 months, both SSKs
sent to women and timed appointments resulted in a 10% increase in uptake. These interventions were
also shown to have a high likelihood of being cost-effective in the NHS. A DCE revealed that women who
had not attended valued privacy and convenience, both of which are inherent in self-sampling. Future work
should focus on optimising self-sampling in terms of age range, timing of offer for non-attenders and the
use of urine testing instead of vaginal samples.
Trial registration
This trial is registered as ISRCTN52303479.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Cervical screening based on exfoliative cytology has provided the means of reducing cervical cancerincidence. It is widely recognised that a high population coverage is necessary for cervical screening to
be effective. A coverage of around 80% in the UK has been associated with a falling death rate for cervical
cancer over the past 25 years.1 The identification and treatment of premalignant lesions through cervical
screening prevents the development of cervical cancer. These lesions are called cervical intraepithelial
neoplasia (CIN) and this strategy is one of secondary prevention. Confirmation in the 1990s that high-risk
human papillomavirus (HPV) was responsible for all cervical cancer led to the successful development of
prophylactic vaccines. These vaccines, composed of virus-like particles, are highly effective in preventing
HPV type-specific infection and, as a result, the UK government initiated a programme of prophylactic HPV
16/18 vaccination among adolescent females in 2008. This strategy of primary prevention will have a very
significant effect on the incidence of high-grade CIN, more so if the nonavalent vaccine covering five
additional high-risk types replaces the currently used quadrivalent vaccine, which covers HPV16/18 as well
as HPV 6 and 11 responsible for genital warts. Cervical screening will, however, continue to be required as
the currently used vaccines directed against type 16/18 will not prevent all cervical cancers.
NHS Cervical Screening Programme
The organised national Cervical Screening Programme was launched in 1988. It has developed into an
internationally renowned programme based on quality assurance throughout and high coverage. The
programme has now been delegated to the devolved nations within the UK and some differences currently
exist. In England, women are screened every 3 years from the age of 25 to 49 years and 5-yearly from
50 to 64 years. In Scotland, women are screened 3-yearly from the age of 20 years, although this about to
change to 25 years, and screening stops at 60 years. Cervical screening currently relies on liquid-based
cytology, but HPV triage is used to determine which women with low-grade changes should be referred
to cytology. The National Screening Committee has recommended a switch to primary HPV screening
(with cytology to triage HPV-positive women for onward referral) on the basis of greater sensitivity and the
opportunity for extended screening intervals.
Coverage
There has been a small drop in population coverage (5 years since last test) in England, from 80.6% to
77.8%, in the decade 2004–14.2 Among 25- to 29-year-olds, however, coverage in 2013/14 (< 3.5 years
since last test) was only 63%. This has been accompanied by a worrying increase in the incidence of
invasive cancer in the 25- to 34-year-old group. Although lifestyle factors such as smoking may be
involved, an increased prevalence of high-risk HPV infection and falling participation in screening are
probably factors.1
Barriers to screening
The reasons for falling participation in cervical screening by young women are incompletely understood,
particularly given a NHS programme that offers free screening to all eligible women. Two recent systematic
reviews3,4 pointed to a lack of randomised trials that address falling screening uptake and the need to look
beyond reminders and instead evaluate new ways to overcome particular barriers. In a qualitative study
from London,5 a number of reasons for non-attendance were highlighted. A younger subset from this
population of non-attenders said they intended to be screened but raised practical barriers to this actually
being achieved.
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Considerations in designing a study to address
non-participation
Strategies to improve uptake of cervical screening in young women are hampered by several factors.
Our incomplete understanding of the reasons for non-attendance has already been mentioned, but for
different women convenience, fear, dislike of gynaecological procedures, anxiety, inertia and not feeling at
risk are all relevant. Effective contact with large numbers of hard-to-reach individuals with whom academic
investigators are unable to contact directly also represents a challenge. Developing novel interventions and
implementing them on a large scale is also challenging. Finally, there is the issue of capturing accurate
uptake data. Encouraging those who would attend and those who have not attended requires different
strategies. Clearly any intervention that looked to be effective would need to be cost-effective too,
requiring detailed work on costs and models of screening outcomes.
Our hypothesis was that different interventions would appeal to different women and, therefore, we
wished to test several to determine which, if any, would prove most effective and cost-effective. We aimed
to recruit a large cohort, and to conduct a randomised trial of interventions over two phases: phase 1 for
all invitees; and phase 2 for those who had not attended, using a different set of interventions to phase 1
because we judged that women who had just been invited would differ from those who had not yet taken
up the invitation.
We made the decision to conduct the study in two sites: Greater Manchester, where prompt uptake of
cervical screening (< 6 months from invitation) is only 25%, and Grampian, Scotland, where it would be
possible to gain insight into the effect of prior HPV vaccination on participation. Selection of interventions
took into account our hypothesis that ‘one size would not fit all’ (i.e. for different women there were
different issues). We considered that for newly invited women, a lack of interest in the lengthy factual
national information sheet, and the inconvenience of booking a test could be disincentives. Therefore,
we used a prior focus group of young women to inform the development of a more concise leaflet that
specifically addressed the key issues highlighted. Indeed, pre-notification for colorectal screening has been
associated with a small but significant increase in uptake in both Scotland6 and Australia.7 Online booking
has become the norm for many activities and we felt that this would help overcome any inconvenience
engendered by the need to book an appointment to attend for cervical screening.
With regard to non-attenders by 6 months, we felt that there were several disincentives that interventions
could address. Dislike of a gynaecological examination could be overcome by self-sampling, which had been
shown to be a feasible and reliable means of testing for high-risk HPV.8,9 Again, the inconvenience of
having to book could be addressed by self-testing and by timed appointments, which have been used
effectively for other purposes in some general practices. The potential fear of what is involved and a poor
understanding of the rationale and potential benefits and harms of cervical screening could be addressed by
use of a nurse navigator (NN), a term coined in the USA, where this role has been evaluated in a number of
areas of health.10 Finally, we considered that offering a choice between two different interventions, NNs
and timed appointments would be attractive to some women who might wish to exert a preference.
The aim of the trial was to increase participation in cervical screening among women receiving their initial
invitation. The objectives were to evaluate the effectiveness and cost-effectiveness of different interventions
in a randomised manner in an adequately powered trial. We also wished to determine the impact of prior
vaccination on screening uptake. Another objective was through a discrete choice experiment (DCE), to
determine what aspects of cervical screening were most highly valued among those who had not yet
attended, in order to improve our understanding.
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Chapter 2 Clinical effectiveness
Objectives
The overall aim of STRATEGIC was to determine whether or not uptake of cervical screening could be
improved among 25-year-old women receiving their initial invitation. The trial was embedded in the NHS
Cervical Screening Programme and conducted in two phases with the following objectives.
Phase 1 objectives
1. To determine, in an English cohort of 24.75-year-old women in Greater Manchester and a Scottish
cohort of 20-year-old women in Grampian, the clinical effectiveness and cost-effectiveness of a pre-first
invitation leaflet (pre-leaflet), which had been designed to increase receptivity of young women to
cervical screening. The development of this leaflet had been completed prior to the trial, and was based
on focus group work with young women, targeting the issues that influence them when thinking about
attending for cervical screening.
2. To determine the feasibility, acceptability, clinical effectiveness and cost-effectiveness of offering online
booking as a convenient alternative to telephoning the general practice as a means of making an
appointment at first invitation. This was available only to the women covered by Manchester Primary
Care Trust (PCT) (now redesignated a Clinical Commissioning Group).
3. To determine, among the 20-year-old women in Grampian, whether prior HPV vaccination in the
catch-up campaign was associated with an increase or decrease in participation.
Phase 2 objectives
To determine, among those women in the cohort who had not attended after 6 months, the feasibility,
acceptability, clinical effectiveness and cost-effectiveness of several novel strategies:
1. the offer of requesting a self-sampling kit (SSK) for HPV status as a determinant of the need for cervical
cytology (HPV-negative women would not require cytology)
2. SSKs sent unsolicited to women
3. a specialist NN to help a woman overcome her barriers to screening
4. timed appointments for cervical screening to encourage women to attend
5. a choice of requesting a HPV SSK or the NN.
In addition, a health economic study (see Chapter 3) would be performed to determine the costs and
cost-effectiveness of these interventions and a DCE (see Chapter 4) would be performed to determine the
importance non-attending women attach to different aspects of the screening experience.
Methods
Phases 1 and 2 both comprised a cluster randomisation of general practices (Figure 1). All women invited
for their first screen were eligible. Concurrent with phase 1, a pilot study tested the feasibility of the
planned interventions to be evaluated during phase 2. A pre-leaflet had been developed prior to the
STRATEGIC trial (see Appendices 1–3), based on focus group work with young women, and addressed
issues that influenced their views.11 These included the relationship between cervical cancer and HPV, the
sexually transmitted nature of HPV and why young women should be screened. The pre-leaflet was sent,
by the screening agency in Greater Manchester and by the research team in Grampian, 6 weeks before
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their standard invitation was sent out. Phase 1 also included the offer of online booking, which provided
women in randomised practices restricted to Manchester PCT the option to choose from a selection of
set appointments online, as an alternative to telephoning the general practitioner (GP). The phase 2
interventions, which were introduced after the pilot study, were sent out only to women without a
cytology test recorded 6 months after their test due date. These included SSKs, either sent unsolicited or
requested, timed appointments to have a cervical sample taken, access to a NN and a choice between the
NN or a SSK. The primary outcomes were uptake of phase 1 interventions 3 months after the routine
invitation and of phase 2 interventions 12 months after the invitation. The cervical screening process within
the STRATEGIC trial can be seen in Figure 2. Data were obtained from the NHS screening agency, which
also facilitated mailings.
Interaction with the screening agency
The STRATEGIC trial procedures were conducted differently in Greater Manchester and Grampian because
of differing amounts of support from the screening agencies.
Phase 1: Parallel studies in Greater Manchester and Grampian
Cluster randomise 180 general practices (83 Grampian) to send pre-cervical
screening leaflet 6 –12 weeks prior to first invitation (24.5 years/20 years)
Pre-leaflet No pre-leaflet
Online
bookingb
No
internetb
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internetbPa
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Phase 2: Greater Manchester and Grampian non-attenders (phase 1) before
second reminder entered phase 2
Pre-leaflet No pre-leaflet
Request HPV SSK
Timed appointments
Unsolicited HPV SSK
NN
Choice (NN or request HPV SSK)
No further action
Request HPV SSK
Timed appointments
Unsolicited HPV SSK
NN
Choice (NN or request HPV SSK)
No further action
Randomised Randomised
Randomised
Randomised Randomised
FIGURE 1 The STRATEGIC study cluster randomisation: Greater Manchester and Grampian. a, Synchronous pilot
studies on known non-attenders (age 25.5 years) to ensure the feasibility of HPV self-sampling, NNs and timed
appointments; b, in Manchester PCT only.
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Produce PNL for GP practice identifying women
due to be screened
Run report to identify women aged 24 (20) years
included for first call (use this report to
create/update spreadsheet for monitoring
purpose)
Send pre-leaflet to women in cohort specified to
receive pre-notification
Is woman included in cohort to receive
details of online booking?
Send standard invitation letter to woman
unless GP practice have advised woman
should be postponed/ceased
Is woman included in cohort to receive
details of online booking?
Send standard reminder letter
Send non-responder notification to GP practice
(card or via Open Exeter)
Run CSSE report to identify non responders to
screening age 25 years – call/recall type
Split into six phase 2 intervention groups
Send standard invitation
with details of online
booking
(Manchester PCT only)
Send details of online
booking
Set next test date as 
3 years from last TDD
(Second reminder sent
in Scotland 100 days
after TDD)
NN Choice
NN or SSK
Unsolicited
HPV SSK
Timed
appointment
Offer of
HPV SSK Control
STRATEGIC trial
process
Standard call/recall
process
5–6 weeks
before
TDD
12 weeks
after
TDD
(50 days)
26 weeks
after
TDD
10 weeks
before
test due
date
(TDD)
(12 weeks)
FIGURE 2 Cervical screening process with STRATEGIC trial processes embedded (Scotland). This excludes pre-leaflet
and includes online booking that was not done in Scotland. PNL, patient notification list.
DOI: 10.3310/hta20680 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 68
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
Greater Manchester
Phase 1
The mailing of the phase 1 pre-leaflet took place weekly, and each week the screening agency recorded
and returned a summary of these data to the trial team in Manchester. This summary included the number
of pre-leaflets sent that week and the number of participants allocated to the control group that week.
This enabled the trial team to keep track of the study numbers for the duration of the trial. It also enabled
the trial team to estimate the number of pre-leaflets and pre-paid envelopes the screening agency would
require in future weeks and months.
In Manchester, for general practices allocated to the online booking arm, the screening agency inserted
extra text into the standard invitation to screening and reminder letters. The extra text invited women to
book a screening appointment at one of the community and sexual health (CaSH) clinics in Manchester.
Phase 2
Phase 2 interventions were sent by the screening agency to women who had no cytology test recorded
6 months after their test due date. The screening agency mailed out offers from the study team for the
different interventions to eligible women. The screening agency provided a summary of interventions sent
weekly to the trial team in Manchester. This was important, as they required the trial team in Manchester
to order and maintain stock and supplies of SSKs and the stamps required to post them. Unusual activity
prompted a query to the screening agency to ensure that the numbers were accurate.
Grampian
Phase 1
Because the screening agency in Grampian did not have the provision to assist the STRATEGIC trial team
in the way the screening agency in Greater Manchester did, the team in Grampian were required to send
the phase 1 interventions directly on a weekly basis. In Grampian, ATOS, the information technology
company that developed and maintains the Scottish Cervical Call/Recall System (SCCRS), provided the trial
team with a data extract of eligible women.
This extract was run weekly by the principal investigator in Grampian and the GP practices were then
randomised to the phase 1 intervention. The pre-leaflets were posted by a member of the research team.
This was subsequently recorded weekly in a Microsoft Excel® 2003 (Microsoft Corporation, Redmond, WA,
USA) format. The data were stored on a secure drive, in line with data protection policy. The vaccination
status was extracted from the SCCRS, along with the screening outcome data transferred to the SCCRS by
linkage with the Scottish Immunisation Record System. Data recorded include type of vaccine, number of
doses and dates of doses administered.
Phase 2
A similar procedure was followed as in phase 1; however, the practicalities were more complicated. ATOS
provided a data extract from the SCCRS of women eligible for phase 2. The data were downloaded using the
extract by the Aberdeen principal investigator and were used during the preparation of data outcomes as a
source document. In order to transform this data extract into a format that could be used by the trial team, a
macro was developed to format the data extract into a tabulated layout. This included all women who were
potentially eligible for phase 2, filtered to exclude those women with a cytology test result. This left a list of
women who were eligible for a phase 2 intervention. A look-up query was added in order to establish which
phase 2 intervention their GP practice had been randomised to, and the interventions were sent out.
All the steps above have been followed and records maintained, again stored on a secure drive,
in line with University of Aberdeen data protection policies. This procedure was monitored by the trial
co-ordinator based in Manchester and visits were made to the centre in Grampian in order for quality checks.
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Interaction with general practices
Phase 1
Initial contact was made with the GPs by the trial team in order to introduce them to the trial. The
research nurse attended the clinical commissioning group meetings prior to the STRATEGIC pilot study
starting and provided a synopsis of the trial. Representatives from general practices were given the
opportunity to make the trial team aware of any potential issues that they could foresee with the trial.
Next, a standard letter was sent to the general practice informing them of their trial arm allocation to a
pre-leaflet or no pre-leaflet.
Phase 2
The next point of contact made to the general practice by the trial team was prior to the phase 2
interventions when the trial team informed them of the intervention to which their practice had been
randomised. The timed appointments required the screening agency to send a standard letter to the
general practice asking them to send eligible women an offer letter, detailing a time and date for them to
attend for a cytology sample. The general practice then returned the letter to the agency with the date
given to the woman. Once the trial team received a list of confirmed timed appointments, the general
practice invoiced the trial team for reimbursement of £5 per letter.
Operationalising the interventions
Phase 1
Pre-leaflet
The development of the pre-leaflet is described in Appendix 1. Once a general practice was randomised,
the research team in Manchester produced a mail merge informing each general practice of the
intervention that they had been randomised to. Included in the letter was the contact details of the trial
team, and the general practice were encouraged to contact the research team with any questions.
Once this initial contact had been made with the general practices, and phase 1 was ready to begin, the
research team arranged a meeting with the screening agency in order to discuss the implementation of
phase 1. The screening agency (as detailed previously), produced a weekly mailing for women eligible to
take part in the STRATEGIC study; the intervention received by each woman depended on the intervention
to which their general practice had been randomised. These figures were reported back to the trial team
in Manchester on a weekly basis.
Online booking
Young women are more accustomed to using online services, so the provision of a web link that enabled
women to book their screening test online could have been popular. It was not possible to offer this in
general practice because of the large number of practices involved, but online booking was implemented
for the CaSH clinics in the Manchester area. Online booking was not available in Salford/Trafford or in
Grampian. A standalone online appointment scheduling system was used (www.supersaas.com/), and
appointments were available throughout the day and at clinics across Manchester.
In order to offer this online booking service consistently and effectively, the trial team in Manchester
implemented and a followed a strict standard operating procedure, and worked closely with the central
CaSH clinic. The offer of booking an appointment for cervical screening online was sent by the screening
agency. If a woman chose to respond, she would access the online system to select an appointment,
with a choice of three clinics and selecting her preferred date and time, then leaving a contact name and
telephone number. Each Friday, a member of the trial team would access the online system in order to
remove the empty slots for the next week and inform the CaSH clinic of any booked appointments for the
next week. Reminders were set for the day before each booked appointment as a reminder text message
was sent by a member of the trial team, via the secure NHS.net system.
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Pilot study
The pilot study was performed in Greater Manchester concurrently with phase 1 involving a slightly older
cohort than the STRATEGIC cohort, and determined the feasibility of HPV self-sampling, both sent and
requested, as well as the NNs and timed appointments being offered to known non-attendees in
Manchester. The piloted interventions were tested in women who were already aged 25.5–27.5 years,
who had previously not taken up their invitation for their first cervical screen, despite reminders.
Although the primary purpose of this pilot was to evaluate the feasibility of the intervention (e.g. arranging
pre-booked appointments), as well as practicability such as arrangements for self-testing, it would also
provide estimates of the likely effect on uptake of screening as a result.
Phase 2
Nurse navigator
Nurses offer support and guidance to patients, and offering a trained cervical screening nurse with whom
women could discuss concerns or raise questions confidentially about screening may help alleviate their
fears and ‘navigate’ women over barriers to attending for screening. The NN would be able to discuss
the woman’s perceived barrier(s) or difficulty accepting her invitation for cervical screening and advise
how these could be overcome. She could also answer questions and assist the woman in booking an
appointment if necessary.
Six months after their test due date, if no test date was recorded, women in general practices randomised
to receive the NN intervention received a letter describing the trial along with a second reminder letter
from the screening agency as per standard procedure. This letter (see Appendix 4) included the ways in
which the women could contact the NN (via e-mail, telephone or text message), and the suggested ways
in which the NN could offer advice or help. Once contact had been made with the NN, the role of the NN
could be far-reaching, providing advice on the importance of cervical screening and how to attend a
cervical screening appointment at their general practice, at a sexual health clinic or by sending them a HPV
SSK. Written consent for any follow-up was sought by the NN at the time the woman made contact,
and with her permission the consent forms and an information sheet were mailed out (see Appendix 5).
The consent enabled the trial team to check for the presence of a cytology test result on the national
screening database, allowing our researchers to monitor compliance with screening after contact. Women
were also offered a follow-up call from the NN to discuss whether or not they had arranged/attended for
screening and to provide further advice or support.
Human papillomavirus self-sampling
Cervicovaginal self-testing for high-risk HPV triaged with cytology for the purpose of colposcopy referral is
as sensitive in the detection of CIN as practitioner-obtained cytology at detecting CIN. This strategy accepts
that a negative self-sample would allow a woman to be considered as having had a negative screen,
whereas a positive result would indicate the need for practitioner-obtained cytology in order to achieve the
required level of specificity for colposcopy referral. Women were offered a self-sample test for HPV to
attract those who preferred not to attend their GP for a cytology sample.
There were two HPV self-sampling interventions; the first was a letter offering the opportunity to request a
SSK, and the second an unrequested SSK was sent directly to the home. The SSK comprised the following:
a SSK [either Delphi lavage (Rovers Medical Devices BV, Oss, the Netherlands) or The Rovers® Evalyn-Brush
(Rovers Medical Devices BV, Oss, the Netherlands)]; and packaging, to return their sample, compliant with
transport regulation UN3373 for category B biological substances.12
An information sheet explained the purposes of the test, how the results would be communicated to the
woman and her GP, the implications of the results and instructions for taking the sample and returning it
to the virology laboratory. A consent form for processing the sample and providing the results was
included, giving her the option of receiving her result by a telephone call, text message, e-mail or letter.
The consent also obtained permission for the research team to check the Exeter screening database
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(SCCRS in Grampian) for subsequent cytology samples in the event of a positive result. After the women
collected the sample it was sent to the virology laboratory at Central Manchester University Hospitals NHS
Foundation Trust for processing. The team at the laboratory sent the results and the consent forms to the
trial team in Manchester University. The trial research nurse provided the HPV result as per the women’s
preference (letter/telephone call/text/e-mail).
Choice between nurse navigator and human papillomavirus self-sampling
The rationale of using an intervention involving choice was to provide some women with a degree of
control over what intervention they may prefer. Access to a nurse to provide advice and access to a SSK
were felt to be sufficiently different to provide a meaningful choice. A letter was sent to women offering
them either having access to a NN or a SSK on request.
Timed appointments
Timed appointments for non-responders have shown promise in other screening settings.13,14 Timed
appointments mean that a woman does not have to contact the practice to book a cervical screening
appointment herself. Agreement to set up timed appointments was achieved through contact with general
practices. As with the implementation of the other STRATEGIC study interventions, the research team in
Manchester sent a sample invitation letter to the screening agency it then sent this onto the general
practices so that they could populate the letters with the time, date and women’s details, in order to offer
them a timed appointment. In these letters, the general practices were asked to send women an invitation
letter detailing a time and date for them to attend for a cervical screening appointment (see Appendix 6).
Only three general practices were unable to facilitate these appointments.
Patient and public involvement
We had planned to convene a panel of young women who had chosen not to attend for screening, in
order to provide insight and advice regarding our interventions and the responses to these. We were not,
however, able to use this proposed panel of users during the study. The principal reason for this was that
we found it very difficult to engage with non-attenders for the DCE (see Chapter 4), which was required
to be conducted at arm’s length in the sense that such women were contacted initially through the
screening agency. We considered that a face-to-face panel or, indeed, a more indirect form of
communication would have been impossible to facilitate.
The DCE can be considered a form of public engagement because it targeted young non-attenders,
as defined by the protocol, but who were completely independent of the study. These individuals were
not involved in the study itself, but did provide relevant views regarding preferences with respect to
cervical screening.
Data
In addition to monitoring the weekly interventions, the trial team requested intermittent previews of
blinded data from the screening agency during the trial to ensure that data outcomes were not being
missed. Three such requests were made during the trial.
Data outcomes in Grampian were collated by the trial team and not by the screening agency, as was the
case in Greater Manchester. In order to prepare the final data outcomes for analysis, we merged the
mailings recorded for phase 1 and phase 2, linking the two mailings on the woman’s Community Health
Index, the unique patient identifier containing date of birth and gender. In order to be assured that the
files had merged successfully, two members of the research team checked 10% of these data and could
be confident that the files had been merged successfully. In addition to this, extensive cleaning was
performed on the data outcomes from Scotland by the research co-ordinator and the trial statistician.
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Statistical methods
Randomisation of general practices
In this trial the interventions were randomised to practices for both the phase 1 and phase 2 interventions.
Because all practices in a PCT entered the trial at the same time it was possible to use a minimisation
procedure for cluster randomised trials, as described by Raab and Butcher.15 In this, allocations of
interventions to practices were generated using a random number generator and implemented accordingly.
For each allocation the imbalance between intervention arms is calculated and the allocations are then
sorted according to the magnitude of the imbalance, before selecting an allocation with good balance.
We controlled for the cervical screening uptake rate and size of this cohort of women in each practice prior
to randomisation based on standard reports of these data provided by the screening agencies involved.
We chose the allocation that was the fifth centile of the distribution of imbalance from 10,000 possible
allocations. This procedure was carried out separately for each PCT with the names and location of the
practices concealed. In phase 2, allocation was also balanced for allocation in phase 1.
Sample size
Phase 1
The pre-leaflet was tested across Manchester, Salford and Trafford PCTs, which had, respectively, 100,
55 and 46 general practices (the total of general practices had altered by July 2013, the current totals
are 97, 47 and 36), with an average practice size of 4900 patients, conservatively suggesting that
approximately 40 women per GP practice would become eligible for the screening programme over a
12-month period. Data from Manchester PCT had suggested that the initial response to the first invitation
was < 30%. A modified pre-leaflet was tested in women who had been offered HPV vaccination as part of
the catch-up component of the Scottish vaccination programme (Grampian cohort). The primary outcome
was the absolute increase in screening uptake by 3 months (phase 1) and 12 months (phase 2) following
standard invitation, compared with controls. Owing to a potential adverse effect of vaccination on
attendance, a larger intervention effect was expected. With an intracluster correlation coefficient (ICC) of
2.6%, and with 38 intervention and 39 control practices (leaflet sent to 1520 women), the trial had a
power > 95% to detect a 10% increase in attendance. The power of a cluster randomised trial designed
depends on the ICC, the number of clusters, the cluster sizes and variation in cluster size. Jensen et al.16
suggest an ICC for a similar outcome of 0.026.
With 92 practices randomised to pre-leaflet (leaflet sent to around 4000 women) and 88 control practices,
the trial had a power of 89% to detect an uplift in attendance, assuming an ICC of 0.026 and an average
cluster size of 40. This calculation assumed that the variance in the cluster size was equal to the mean
cluster size.
The online booking intervention was tested in Manchester PCT only. With 49 practices randomised to
online booking and 48 to control, the trial had a power of 93% to detect a 7.5% improvement in
attendance by 3 months, assuming an ICC of 0.026 and an average cluster size of 40. Given that the
online booking intervention was introduced on a different occasion to the pre-leaflet, any interaction
between the two interventions was considered unlikely, so that a factorial design was justified.
The effect of online booking could be cumulative over the follow-up period, as access to online booking
continued to be available. A total of 63 Greater Manchester practices received no intervention. These had
a power of 94% to detect a 10% increase due to access to online booking. The planned allocation of
practices in phase 1 and 2 is summarised in Tables 1 and 2, respectively.
Pilot study
The interventions in phase 2 were expected to increase attendance among those who had not attended by
between 10% and 20%. In proof-of-concept studies, a larger significance level and increased power is
appropriate so that potential beneficial treatments are not rejected.17 With 120 women in each arm,
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the study had a power of 90% to reject the null hypothesis of no increase in uptake with a one-sided
significance level of 25%.
Phase 2
It was estimated that the standard first reminder might increase response by 5%. At 6 months
(second reminder), we estimated that at least 50% would not attend, that is a mean of 20 women per
practice. In phase 2, the following five interventions were tested: (1) SSK offered, (2) SSK sent, (3) NN,
(4) choice between NN and SSK offered and (5) timed appointments. Statistical analysis compared each
intervention with the control.
In order to improve the power in phase 2 of the study, we planned for a larger control group sample
than with the phase 2 interventions. It has been shown that the optimal method of choosing the size of
the control arm is to multiply the estimated sample size for an intervention arm by the square root of the
number of interventions.18 Our adopted intervention to control group sample size ratio of 1 : 3 was
deemed suitable to compare five interventions.
We assumed that a further 5% would attend without further intervention by the time of next recall, and
that a follow-up intervention would increase uptake by an additional 5%. Among the 50% of women
who we estimated would not have attended by 6 months, this corresponded to a difference of between
TABLE 1 Allocation of practices in phase 1 at study conception
Study site
Intervention
TotalPre-leaflet Control
Manchester
Online booking 24 25 49
Online booking control 24 24 48
Salford 26 21 47
Trafford 18 18 36
Total (north-west of England) 92 88 180
Grampian 38 40 78
TABLE 2 Allocation of practices in phase 2
Study site
Intervention
TotalPre-leaflet
Online
booking
SSK
sent
SSK
offered NN
NN and SSK
offered
Timed
appointment Control
Manchester Yes Yes 3 4 3 4 2 8 24
Yes No 3 3 4 3 2 9 24
No Yes 4 3 3 3 3 9 25
No No 2 3 2 3 4 10 24
Salford Yes – 6 5 6 6 5 16 44
Trafford No – 4 5 4 4 5 17 39
Grampian Yes – 4 5 6 3 5 15 38
No – 5 6 5 5 6 13 40
Total 31 34 33 31 32 97 258
DOI: 10.3310/hta20680 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 68
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
10% and 20%. A study with 30 practices in each of the five intervention arms (SSK sent and offered, NN,
timed appointments, NN or SSK offered) and 100 control practices would have a power of > 80% to
detect this difference, provided that the ICC does not exceed 0.07. This calculation included a Bonferroni
correction of the significance level to allow for five comparisons with the control and an allowance for
additional variation in cluster sizes as a result of the effect of the phase 1 intervention by assuming a
cluster size variance of 40.
Self-sampling kits were sent by the trial centre. It was estimated that about 1200 SSKs would be sent out.
So that the acceptability of the two kits can be compared, women were randomised to receive either kit
type using randomisation stratified by site with a random block size of 4, 6 or 8. In each study site, the
screening centre assigned kits in order according to a pre-prepared list.
Statistical analysis
A detailed statistical analysis plan based on an intention-to-treat (ITT) protocol was prepared and agreed
with the Trial Steering Committee at the end of the pilot study. Because of the nature of the primary
outcome, we envisaged complete data being available on all women in the trial regarding attendance,
via the Exeter system in Greater Manchester and SCCRS in Grampian.
Initially, descriptive analysis tabulated the rate of attendance and rate differences by intervention group
followed by formal inferential statistical analysis accounting for clustering of patients within practices.19
In short, this was accomplished by fitting a generalised estimating equation (GEE) model in the form of a
population average logistic regression,20 with the intervention group adjusted for the covariates, uptake
rate for each practice and location (Manchester/Salford and Trafford/Grampian).
The primary outcome
The primary outcome for phase 1 was uptake of cervical screening 3 months following the standard
invitation, at which time point a reminder would be sent by the screening agency. The primary outcome
for phase 2 was uptake of cervical screening at 12 months following the standard invitation. Uptake rates
were also calculated at 6 and 18 months to assess any long-term effects. Each primary outcome was
calculated using a provided ‘date of test’ variable that related either to cytology test only (phase 1) or
to cytology or HPV test (phase 2). In each case a generated binary variable was defined as ‘completed’
(1) and ‘not completed’ (0) by the allotted follow-up time point (e.g. 3 months). A missing date of first test
indicated if a test had not been completed by the end of the follow-up period. The data can therefore
be considered to be a complete data set for all individuals. Outcome variables were then created by
identifying a test present (yes/no) for 3, 6, 12 and 18 months since the standard call.
Secondary outcomes were (1) differential uptake of screening among vaccinated and unvaccinated women
in Grampian by 6 months after invitation and (2) uptake 12 months following phase 2 interventions.
Data exclusion and data cleaning criteria
Participants were excluded from the phase 1 data and the subsequent analysis if:
1. the cytology test was prior to the allotted pre-leaflet intervention date (approximately 6 weeks prior to
standard invite) assigned to both the intervention and control group participants
2. all intervention dates are missing.
Women were excluded from the phase 2 data and the subsequent analysis if:
1. time in study was > 9 months from when phase 2 interventions started (Greater Manchester)
2. test date was prior to phase 2 interventions start
3. subject had a ‘left trial date’ (i.e. moved home/GP prior to proposed phase 2 intervention sent)
4. subject’s first invitation date was sent outside the recruitment period.
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Baseline cervical uptake screening rates
In Greater Manchester, the phase 1 baseline rate for each practice was determined for a baseline data
cohort consisting of women for 12 months between October 2010 and September 2011 prior to the trial.
The data extraction methodology was the same as that used for the outcome measure. In Grampian, the
equivalent cohort was not available and so routinely reported uptake rates for women aged 20–24 years
at each practice was used instead. The difference between the methods of determination of the baseline
rate is accounted for in the analysis by adding an interaction term between region and baseline rate.
Estimation method
The effect of interventions was estimated using a logistic regression model with covariates for intervention
group, baseline rate, PCT (region) and an interaction between baseline rate and PCT/region to account for
differences in methods of collection of baseline rate. To account for the clustering effect of practice, a GEE
model was used with an exchangeable covariance structure and robust standard errors. This analysis was
performed using the Stata procedure xtgee (version 13, StataCorp LP, College Station, TX, USA).
Phase 1 analysis
Phase 1 determined the effect of a pre-leaflet/no pre-leaflet and online/no online booking on uptake of
any test, either HPV or cytology. The pre-leaflet was run in Salford, Trafford and Grampian, whereas
both the pre-leaflet and online booking was run within a factorial design in the Manchester PCT only.
Both interventions were analysed in an ITT analysis, where response was compared between the two
groups, as offered, irrespective of whether the subject received the pre-leaflet or the method employed
to book the test. A test for evidence of interaction between the pre-leaflet and online booking was
performed. Descriptive statistics and response rates were calculated for each intervention and the GEE
model estimated the treatment effect. Odds ratios (ORs) would indicate if a significant change in response
between the control group and the interventions had occurred (p < 0.05). An OR is expressed on the
logarithmic scale meaning a value of 1 indicated no change in response rate, a value > 1 showed an
increase in response and a value of 0–1 indicated a decrease in response. Analyses are presented for the
uptake at 3 and 6 months post invitation, with the 3-month analysis being the primary end point.
Moderator analyses
Moderator analyses were carried out to test for:
(a) an interaction effect between treatment group and the location, with respect to the screening age
differential between Scotland and the north-west of England
(b) the influence of HPV vaccination status (Grampian PCT only).
Pilot study among non-responders
The pilot study in Manchester was running concurrently with phase 1 in women who had already not
taken up their invitation despite reminders. The pilot determined the response rate and effectiveness for
the planned interventions for phase 2: HPV self-sampling, choice of two SSKs, NN, choice of SSK or NN, or
timed appointments. Each intervention was compared with the control group using the GEE model. Any
intervention found to be significant at a one-tailed 25% significance level (i.e. with an OR of an uptake
between the intervention and the control larger than 1 with a p-value of < 0.25) would be taken forward
into phase 2 of the main study.
Phase 2 analysis
As in phase 1, descriptive statistics in the form of incidence rates described the response to each
intervention. Response rates for each intervention were compared with the control response rate, again
using a GEE model under an ITT framework. As well as an overall Wald chi-squared test, pairwise tests
were carried between each intervention and control. Consistent with the power calculation, a Bonferroni
correction of significance levels is used to adjust for multiple testing, with a significant level of 1% in place
of 5%. Baseline rates for each general practice used as covariates for the phase 2 analyses were calculated
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from the uptake rates observed in phase 1. The improved consistency and the direct relationship within
general practice of baseline uptake rate in phase 2 compared with phase 1, means an interaction between
site and baseline rate should no longer be required.
As the only date available for all women was the standard invitation date, follow-up assessments were
timed relative to this. Analyses of phase 2 were carried out at 12 and 18 months after this date, with
12 months post call being the primary end point.
Phase 2 moderator analysis
Moderator analyses were carried out to test for:
(a) An interaction effect between the intervention groups and the study location (Greater Manchester vs.
Grampian), to investigate the differential screening age and socioeconomic differences between
Scotland and the three north-west of England sites.
(b) An interaction effect between phase 2 intervention groups and phase 1 intervention groups
(pre-leaflet vs. control and online booking vs. control), to determine if a cumulative effect was
occurring. The interaction analysis including online booking was performed in the Manchester PCT only.
(c) The effect of vaccination status and subsequent interaction effects with phase 2 interventions
(Grampian only).
(d) Test result was modelled as a binary result (positive equals low or high dyskaryosis) to determine the
impact any improved screening may have had on identifying cases.
Table 3 shows the intended comparisons of interventions for each cohort, including any suitable
interactions (in bold). The table also outlines the follow-up time points for each comparison to be made.
These refer to months since participants’ 25th (20th in Grampian) birthday, and hence allows for a further
6–8 weeks for pre-leaflet intervention.
TABLE 3 A list of comparisons to be made within each cohort at follow-up time points
Comparisons (interaction)a
Comparison time points (since standard invitation)
3 months 6 months 12 months 18 monthsb
Phase 1
Pre-leaflet vs. control ✗ ✗ ✗
Online booking vs. control ✗ ✗ ✗
Vaccinated vs. control (Grampian only) ✗ ✗ ✗
Pre-leaflet (Greater Manchester vs. Grampian) ✗ ✗ ✗
Pre-leaflet (vaccinated vs. control) ✗ ✗ ✗
Online booking (pre-leaflet vs. control) ✗ ✗ ✗
Pilot
HPV SSK offer vs. control ✗c
NN vs. control ✗c
Choice vs. control ✗c
Timed appointments vs. control ✗c
HPV SSK sent vs. control ✗c
CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Results
The participant flow diagram is shown in Figure 3. This shows both the number of practices and invited women
for phase 1 and the number of practices and non-attenders for phase 2, by intervention. It should be noted
that online booking involved just under half of the phase 1 cohort, as it was available only in Manchester.
Phase 1
Table 4 shows the number of practices and corresponding number of participants randomised to each
phase 1 intervention group. The screening uptake curves over time for the pre-leaflet and online booking,
and those of the control practices, are shown in Figures 4 and 5, respectively. The actual percentage
uptake at the 3- and 6-month time points following the standard invitation is shown in Table 5. The
benefit of pre-leaflet is negligible. Although there was a slight benefit immediately after the standard
invite, by 3 months there was no difference. In fact, up until 3 months, both interventions almost overlay
the uptake in the controls. At 3 months, a routine reminder was sent out. Between 3 and 6 months the
pre-leaflet arm continued to follow the controls, but there was a small increase in the online booking
group. Also striking was the steady gradual increase in participation following the invitation and the
intervention continuing following the standard reminder at 3 months.
Considering the percentage uptake (see Table 8), the first observation to be made is that by 3 months
19.2% of the control group had attended, and by 6 months this had increased to 30.6%. Uptake by
women sent a pre-leaflet was almost identical at both time points (3 months, OR 0.967; 6 months, OR
1.014). Among the Manchester cohort, uptake by the control group was marginally lower, at 17.2% and
26.6% at 3 and 6 months, respectively. This is not surprising, as Manchester has poorer coverage than the
country as a whole. The online booking group showed a very similar uptake by 3 months. Although
uptake at 6 months was 2.2% higher, at 28.8%, in the online booking group, this difference was not
statistically significant (p = 0.242). It should be noted that 199 women booked an appointment online, but
only 127 (63.8%) actually attended that appointment. The absence of data linkage means that it is not
possible to determine the precise proportion of women who attended an online-booked appointment
before 3 or 6 months, as some of the online-booked appointments may have occurred after 6 months.
TABLE 3 A list of comparisons to be made within each cohort at follow-up time points (continued )
Comparisons (interaction)a
Comparison time points (since standard invitation)
3 months 6 months 12 months 18 monthsb
Phase 2
HPV SSK offer vs. control ✗ ✗
HPV SSK sent vs. control ✗ ✗
NN vs. control ✗ ✗
Choice vs. control ✗ ✗
Timed appointments vs. control ✗ ✗
Phase 2 intervention vs. site ✗ ✗
Phase 2 intervention vs. phase 1 pre-leaflet ✗ ✗
Phase 2 intervention vs. phase 1 online book ✗ ✗
Phase 2 vs. vaccination status ✗ ✗
a Bold text indicates suitable interactions.
b Note that this refers to 6 months post phase 2 intervention (the minimum that everyone was followed up for Greater
Manchester or Grampian), which relates to approximately 18 months post phase 1 intervention.
c Comparison at 5 months within the pilot study.
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Phase 1 parallel studies in Greater Manchester and Grampian
Cluster randomise 20,879 participants in 276 practices (83 Grampian)
entered phase 1
Pre-leaflet
138 (41)
(n = 10,461)
No pre-leaflet
138 (41)
(n = 10,418)
26 online
bookinga
(n = 2641)
25 no
onlinea
(n = 2352)
26 online
bookinga
(n = 2115)
26 no
onlinea
(n = 2626)
Phase 2 parallel studies in Greater Manchester and Grampian
Non-attenders before second reminder
Entered phase 2 (n = 10,126)
Pre-leaflet
134 (41)
(n = 5051)
No pre-leaflet
133 (41)
(n = 5075)
• SSK offered, n = 570, 17 (5)
• Timed appointments, n = 439, 14 (5)
• SSK sent, n = 620, 16 (4)
• NN, n = 633, 20 (7)
• Choice, n = 773, 18 (5)
• Control, n = 2016, 49 (15)
• SSK offered, n = 720, 16 (5)
• Timed appointments, n = 1190, 19 (6)
• SSK sent, n = 521, 16 (5)
• NN, n = 374, 14 (5)
• Choice, n = 504, 16 (5)
• Control, n = 1766, 52 (15)
Randomised Randomised
Excluded
• As screened in phase 1, n = 6454
• Due to a 3-month delay in commencing phase 2, n = 2330
• Due to change of address, n = 1969Delay
b
FIGURE 3 The Consolidated Standards of Reporting Trials (CONSORT) diagram for the STRATEGIC trial. Note that
values in green refer to the number of women invited and numbers in black in brackets refer to the number of
general practices. a, In Manchester PCT only; b, delay in starting phase 2 because of a delay in operationalising
the interventions.
TABLE 4 Distribution of GP practices (study participants) entered into phase 1 of the study
Study site
Intervention
TotalPre-leaflet Control
Manchester
Online booking 26 (2641) 26 (2626) 52 (5267)
Online booking control 25 (2352) 25 (2115) 50 (4467)
Salford 26 (1767) 26 (1972) 52 (3739)
Trafford 20 (1303) 19 (1097) 39 (2400)
Total (north-west of England) 97 (8063) 96 (7810) 193 (15,873)
Grampian 41 (2398) 42 (2608) 83 (5006)
Total combined 138 (10,461) 138 (10,418) 276 (20,879)
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FIGURE 4 Kaplan–Meier plot showing time to test from standard invitation by pre-leaflet groups (7-month follow-up).
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FIGURE 5 Kaplan–Meier plot showing time to test since standard invitation by online booking groups: Manchester
PCT only (7-month follow-up).
TABLE 5 Cervical screening uptake rates and analyses for pre-leaflet intervention (all sites) and online booking
intervention (Manchester PCT only)
Time No, % (n/N) Yes, % (n/N) Total, % (n/N) ORa (95% CI) p-value ICCb
Pre-leaflet (all sites)
Time from standard invitation
3 months 19.2
(2002/10,418)
18.8
(1970/10,461)
19.0
(3972/20,879)
0.967
(0.879 to 1.062)
0.485 0.0099
6 months 30.6
(3191/10,418)
31.1
(3256/10,461)
30.9
(6447/20,879)
1.014
(0.928 to 1.109)
0.747 0.0157
Online booking group: Manchester PCT only
Time between intervention and test
3 months 17.2
(770/4467)
17.8
(936/5267)
17.5
(1706/9734)
1.021
(0.869 to 1.200)
0.802 0.0090
6 months 26.6
(1190/4467)
28.8
(1518/5267)
27.8
(2708/9734)
1.097
(0.939 to 1.282)
0.242 0.0194
CI, confidence interval.
a Adjusted OR for intervention compared with control, adjusted for baseline rate and PCT region.
b ICC for GP practice.
DOI: 10.3310/hta20680 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 68
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
It follows, therefore, that < 2.4% (127/5267) of women in this arm attended an appointment booked
online by 6 months. The interaction between pre-leaflet and online booking at both 3 and 6 months was
not significant (p-value is 0.604 at 3 months and 0.912 at 6 months), indicating no synergistic effect of
pre-leaflet and online booking.
Table 6 compares, at 3 and 6 months, the overall uptake in Grampian and Greater Manchester. Both the
proportion who attended at each location and the proportion attending at each vaccination level were
calculated for subjects within the pre-leaflet group, the control group and in total. The OR relates to the
baseline group: vaccination none and location Greater Manchester.
Absolute attendance was similar over time in Greater Manchester and Grampian, although with a slightly
greater absolute percentage uptake in Grampian, by 1% and 3.4% at 3 and 6 months, respectively.
The ORs of a test for Grampian compared with Greater Manchester were 1.169 [95% confidence interval
(CI) 1.030 to 1.326; p = 0.016], and 1.275 (95% CI 1.133 to 1.435; p < 0.001) at 3 and 6 months,
respectively. Interaction effects between pre-leaflet and location were found to be not statistically
significant, indicating that the effect of location was consistent across intervention groups (a p-value of
0.591 at 3 months and of 0.542 at 6 months).
TABLE 6 Cervical screening uptake rates and analyses by location (Greater Manchester/Grampian) and vaccination
status (Grampian only)
Follow-up
Screening uptake,
% (n screened/n invited)
Total rate, %
(n screened/n invited) ORa (95% CI) p-value ICCbControl Pre-leaflet
Location (all women)
3 months
Greater Manchester 19.3
(1503/7810)
18.3
(1478/8063)
18.8 (2981/15,873) – – 0.043
Grampian 19.1
(499/2608)
20.5
(492/2398)
19.8 (991/5006) 1.169
(1.030 to 1.326)
0.016
Total 19.2
(2002/10,418)
18.8
(1970/10,461)
19.0 (3972/20,879) – –
6 months
Greater Manchester 30.1
(2351/7810)
30.1
(2423/8063)
30.1 (4774/15,873) – – 0.066
Grampian 32.2
(840/2608)
34.8
(833/2398)
33.5 (1673/5006) 1.275
(1.133 to 1.435)
< 0.001
Total 30.6
(3191/10,418)
31.1
(3256/10,461)
30.9 (6447/20,879) – –
Vaccination status (Grampian only)
3 months
None 9.8 (69/708) 12.5 (76/607) 11.0 (145/1315) – – 0.015
Incomplete 20.1 (30/149) 16.7 (29/174) 18.3 (59/323) 1.404
(0.1030 to 1.914)
0.032
Full 23.1
(398/1724)
24.2
(383/1583)
23.7 (781/3308) 2.074
(1.698 to 2.534)
< 0.001
Missing 7.4 (2/27) 11.8 (4/34) 9.8 (6/61) 0.760
(0.402 to 1.438)
0.399
Total 19.1
(499/2608)
20.5
(492/2398)
19.8 (991/5007) – –
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Table 6 also gives the uptake of screening associated with the level of completeness of vaccination in
Grampian. Estimated ORs are given comparing those with ‘full’, ‘incomplete’ or ‘missing’ vaccination status
compared with ‘none’. The absolute increase in attendance between ‘none’ and ‘complete’ was 12.62%
(23.65 – 11.03%) and 21.96% at 3 and 6 months, respectively. With an approximate doubling of the
attendance rate, the ORs for ‘complete’ compared with ‘none’ were 2.074 and 2.571, with both being
statistically significant (p < 0.001). Those who were partially vaccinated, that is, with fewer than the
three doses, had a smaller but still significant increase in uptake. The three degrees of freedom chi-squared
interaction test again indicated that no interaction effect was present between the pre-leaflet group and
vaccination status (χ23 p = 0.828 at 3 months and χ
2
3 p = 0.870 at 6 months).
The pilot study of proposed phase 2 interventions
A total of 720 women were targeted, with 120 being offered each of the intervention options, and there
was a control group. The piloting required 2–3 months to offer the interventions, 3–4 months of follow-up,
and 2 months for analysis.
The piloting interventions were offered as of April 2012 for 3 months; follow-up began in July 2012 for
4 months, ending in November 2012.
The analysis replicated the main study, with the outcome being the performance of a test within 6 months
following sent date, compared across interventions. If the cytology date was prior to the intervention,
those women were removed from the analysis, as they were duplicates. The following analysis is based on
714 women out of the original 720. The sample sizes per intervention across the north-west of England
are summarised in Table 7.
The pilot demonstrated that each of the interventions could be delivered successfully. The uptake of
screening following the different interventions is shown in Table 8. Of the 119 control subjects, 14 (11.8%)
attended screening. The greatest rates of uptake were achieved by offering timed appointments (22.5%)
and a choice of interventions (18.3%), with the NN intervention actually resulting in a decrease in uptake
(7.7%) compared with controls. The effect was striking even in this small sample of women, with 21 out of
22 participants offered a choice actually attending for a routine cytology sample, as did 8 out of 20 women
who were sent a SSK. This suggests a ‘nudge’ effect being exerted by these interventions, whereby the
intervention indirectly influences the woman to attend for screening.
TABLE 6 Cervical screening uptake rates and analyses by location (Greater Manchester/Grampian) and vaccination
status (Grampian only) (continued )
Follow-up
Screening uptake,
% (n screened/n invited)
Total rate, %
(n screened/n invited) ORa (95% CI) p-value ICCbControl Pre-leaflet
6 months
None 16.4
(116/708)
20.3
(123/607)
18.2 (239/1315) – – 0.007
Incomplete 30.9 (46/149) 29.3 (51/174) 30.0 (97/323) 1.555
(1.213 to 1.992)
0.001
Full 39.1
(674/1724)
41.2
(651/1583)
40.9 (1325/3308) 2.571
(2.205 to 2.999)
< 0.001
Missing 14.8 (4/27) 23.5 (8/34) 19.7 (12/61) 0.974
(0.541 to 1.754)
0.93
Total 32.2
(840/2608)
34.8
(833/2398)
33.5 (1673/5006) – –
CI, confidence interval.
a Adjusted OR for intervention compared with control, adjusted for baseline rate and PCT region.
b ICC for GP clusters estimated from GEE model.
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Table 9 reports the OR for each intervention compared with the control group, along with both the 95%
and 50% CIs. The 50% CIs are given as the lower limit corresponding to one-tailed 25% significance level
test. Timed appointments resulted in a significant increase in uptake, with the odds of any test being
administered being almost 2.5 times that of the control group. Choice (1.75) and SSK sent also resulted an
increase in uptake, which in both cases was significant at the 25% level. As suggested in Table 8, the NN
and offer of a SSK showed a decrease in test uptake, with the NN intervention showing a significant
decrease at the 25% level.
TABLE 7 Numbers of women (%) by intervention and PCT
Intervention
Study site
Total number of womenSalford Trafford Manchester
Control 42 (35.3) 14 (11.8) 63 (52.9) 119
Choice 17 (14.2) 40 (33.3) 63 (52.5) 120
NN 49 (41.9) 16 (13.7) 52 (44.4) 117
SSK offered 33 (28) 17 (14.4) 68 (57.6) 118
SSK sent 22 (18.3) 34 (28.3) 64 (53.3) 120
Timed appointments 38 (31.7) 20 (16.7) 62 (51.7) 120
Total 201 (28.2) 141 (19.8) 372 (52.1) 714
TABLE 8 Pilot study: test uptake by intervention
Intervention
Test, n (%)
Total number of participants
in interventionCytology HPV Any
Control 14 (11.8) – 14 (11.8) 119
Choice 21 (17.5) 2 (1.7) 22 (18.3) 120
NN 9 (7.7) – 9 (7.7) 117
SSK offer 11 (9.3) 2 (1.7) 13 (11) 118
SSK sent 8 (6.7) 13 (10.8) 20 (16.7) 120
Timed appointments 27 (22.5) – 27 (22.5) 120
Total 90 (12.6) 17 (2.4) 105 (14.7) 714
TABLE 9 Pilot study comparison of intervention group on any test occurring
Intervention OR p-value (two-tailed) p-value (one-tailed) 95% CI 50% CI
Control – – – – –
Choice 1.75 0.177 0.089 0.78 to 3.95 1.32 to 2.31
NN 0.66 0.403 0.800 0.25 to 1.73 0.48 to 0.92
SSK offer 0.87 0.774 0.614 0.35 to 2.16 0.64 to 1.20
SSK sent 1.67 0.231 0.115 0.72 to 3.87 1.25 to 2.23
Timed appointments 2.37 0.034 0.017 1.07 to 5.29 1.80 to 3.13
ICC = 0.037 (95% CI 0.005 to 0.2136).
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Even among the small sample in this pilot study, timed appointments appeared to result in a significant
increase in attendance, along with SSK sent and being offered a choice. The combined effect of both SSK
offer and NN appeared to result in a strong increase in attendance, even though each individual intervention
resulted in a decrease in attendance. Because choice required both NN and an offer of a SSK, the independent
Trial Steering Committee advised that all of the piloted interventions should be offered in phase 2.
Phase 2
Each practice was randomly allocated to one of the five phase 2 interventions or to the control group,
again using a cluster randomisation that employed a minimisation algorithm to balance each intervention
arm. Study participants were excluded from receiving a phase 2 intervention if they had attended
screening or moved practices prior to the phase 2 intervention.
Figure 6 repeats the lower half of the STRATEGIC Consolidated Standards of Reporting Trials (CONSORT)
diagram. Of the 20,879 participants who entered the study and participated in phase 1, 2330 were not
eligible for phase 2 because of a 3-month delay in implementing the phase 2 interventions. A further 6454
attended for cytology screening within 7.5 months of their standard invitation and a further 1969 moved
house or GP also within 7.5 months since their standard invitation was sent. This left 10,126 eligible to
participate in phase 2.
Phase 1 parallel studies in Greater Manchester and Grampian
Cluster randomise 20,879 participants in 276 practices (83 Grampian)
entered phase 1
Phase 2 parallel studies in Greater Manchester and Grampian
Non-attenders before second reminder
Entered phase 2 (n = 10,126)
Pre-leaflet (phase 1)
134 (41)
(n = 5051)
No pre-leaflet (phase 1)
133 (41)
(n = 5075)
• SSK offered, n = 570, 17 (5)
• Timed appointments, n = 439, 14 (5)
• SSK sent, n = 620, 16 (4)
• NN, n = 633, 20 (7)
• Choice, n = 773, 18 (5)
• Control, n = 2016, 49 (15)
• SSK offered, n = 720, 16 (5)
• Timed appointments, n = 1190, 19 (6)
• SSK sent, n = 521, 16 (5)
• NN, n = 374, 14 (5)
• Choice, n = 504, 16 (5)
• Control, n = 1766, 52 (15)
Randomised Randomised
Excluded
• As screened in phase 1, n = 6454
• Owing to a 3-month delay in commencing phase 2, n = 2330
• Owing to change of address, n = 1969Delaya
FIGURE 6 The CONSORT diagram for phase 2. Note: black numbers in brackets refer to the number of general
practices invited during phase 1. a, Delay in starting phase 2 because of a delay in operationalising the interventions.
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Phase 2 results
Table 10 shows the number of practices randomised to each phase 2 intervention. Nine practices were
not randomised to phase 2 (leaving 269 practices) because all eligible participants in these practices had
been screened, and a further two were effectively lost from phase 2 as all remaining eligible women
had moved. This left the 267 practices shown in Table 10, which was still enough for 30 practices for each
intervention and 100 control practices, as required to achieve adequate statistical power. It should also be
noted that the original power calculation had estimated that 50% of the phase 1 participants would
be available as ‘non-attenders’ in phase 2, and, despite the loss of almost 10% of the STRATEGIC study
cohort because of a delay in initiating phase 2, 10,126 out of 20,879 (48.5%) participants were available
for phase 2. Of those entering phase 2, the median [interquartile range (IQR)] follow-up without attendance
was 727 days (IQR 630–860 days) [i.e. 24.2 months (IQR 21–28.6 months)]. Note that the minimum
follow-up without attendance was 17.8 months, indicating all but 62 (who were within a few days) were
followed for a minimum of 18 months. Those 62 were assumed to have not attended during the last few
days and were included in the 18-month follow-up outcome. Of those who did attend screening, the
median time to attendance was 358 days (IQR 267–500 days) [i.e. 11.9 months (IQR 8.9–16.7 months)]
since standard invitation or 4.4 months (IQR 1.9–9.4 months) since phase 2 interventions were sent.
The type of screening test performed in phase 2 participants (i.e. HPV test only, cytology only or both, in
which case in which order) is shown in Table 11. The result of the HPV test and whether or not the
participant went on to have a cytology test, is shown in the lower part of Table 11. Of the 122 women
tested for HPV, 33 tested positive, of whom 20 (60%) then went on to have a cytology test. It is interesting
that a large proportion of those screened following self-sampling interventions (i.e. sent or offered as part
of a choice) did, in fact, have a practitioner-obtained cytology sample. For example, of the 1149 women
who were sent a HPV SSK, 292 (21.3%) were screened in phase 2, although 198 of these women (67%)
TABLE 10 Distribution of GP practices (subjects) eligible for phase 2 of the study
PCT
Phase and intervention
Total, n
practices
(n subjects)
1 2, n practices (n subjects)
Pre-
leaflet
group
Online
booking
group SSK sent
SSK
offered NN
Timed
appointment Choice Control
Greater
Manchester
Yes Yes 3 (120) 4 (109) 3 (98) 2 (57) 4 (294) 8 (474) 24 (1152)
Yes No 3 (196) 3 (151) 4 (95) 2 (72) 3 (143) 9 (385) 24 (1042)
No Yes 4 (164) 3 (135) 3 (88) 3 (134) 4 (175) 9 (476) 26 (1172)
No No 2 (89) 3 (204) 2 (57) 4 (104) 3 (139) 10 (388) 24 (981)
Manchester total 12 (569) 13 (599) 12 (338) 11 (367) 14 (751) 36 (1723) 98 (4347)
Salford No – 3 (51) 3 (111) 2 (64) 4 (283) 2 (63) 9 (313) 23 (885)
Yes – 3 (132) 3 (84) 4 (139) 3 (62) 4 (198) 9 (239) 26 (854)
Salford total 6 (183) 6 (195) 6 (203) 7 (345) 6 (261) 18 (552) 49 (1739)
Trafford No – 2 (53) 2 (29) 2 (46) 2 (80) 2 (26) 9 (221) 19 (455)
Yes – 3 (58) 2 (43) 2 (35) 2 (77) 2 (42) 8 (331) 19 (586)
Trafford total 5 (111) 4 (72) 4 (81) 4 (157) 4 (68) 17 (552) 38 (1041)
Greater Manchester total 23 (863) 23 (866) 22 (622) 22 (869) 24 (1080) 71 (2827) 185 (7127)
Grampian No – 5 (164) 5 (241) 5 (119) 6 (589) 5 (101) 15 (368) 41 (1582)
Yes – 4 (114) 5 (183) 7 (266) 5 (171) 5 (96) 15 (587) 41 (1417)
Grampian total 9 (278) 10 (424) 12 (385) 11 (760) 10 (197) 30 (955) 82 (2999)
Overall total 32 (1141) 33 (1290) 34 (1007) 33 (1629) 34 (1277) 101 (3782) 267 (10,126)
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underwent only a cytology test. Of the 279 women who were screened after being offered a SSK, only 21
had a HPV test, the rest having cytology only. Only 7 of the 314 participants screened after being offered a
choice, which included SSK, actually had a HPV test.
Figure 7 and Table 12 illustrate the proportion of non-attenders in phase 2 who had any screening test
(cytology or HPV) associated with each intervention at 12 and 18 months since the standard invitation.
Figure 7, a Kaplan–Meier plot, indicates a differential rate of uptake over time since the standard invite for
each of the intervention groups. As this cohort did not attend before the first reminder, all curves are flat
for the first 6 months. By 12 months post standard invitation (approximately 6 months of phase 2)
between 14.5% and 21% of non-attenders had been screened; 6 months later the proportion had
reached between 22.8% and 30.1%. The control group demonstrated a similar trend with 16% and 27%
of non-attenders in the control group screened at the same time points.
TABLE 11 Type of test utilised by the participant, split by intervention and HPV result at 12 and 18 months and
end of study
Follow-up
Phase 2
intervention No test
Type of test
Total number
of participants
tested
Overall total
number of
participants
in intervention
Single Both
HPV
only
Cytology
only
HPV
first
Cytology
first
12 months Control 3169 1 612 – – 613 3782
SSK sent 898 52 158 32 1 243 1141
SSK offered 1081 12 190 7 – 209 1290
NN 861 – 145 1 – 146 1007
Timed
appointment
1306 – 323 – – 323 1629
Choice 1037 5 233 2 – 240 1277
Total 8352 70 1661 42 1 1774 10,126
18 months Control 2756 1 1025 – – 1026 3782
SSK sent 799 59 248 34 1 342 1141
SSK offered 957 12 314 7 – 333 1290
NN 777 – 229 1 – 230 1007
Timed
appointment
1157 1 471 – – 472 1629
Choice 892 5 378 2 – 385 1277
Total 7338 78 2665 44 1 2788 10,126
HPV result
12 months 8352 – 1661 – – 1661 10,013
Invalid – 1 – – – 1 1
Negative – 63 – 19 1 83 83
Positive – 6 – 23 – 29 29
Total 8352 70 1661 42 1 1774 10,126
18 months 7338 2 2665 – – 2667 10,005
Invalid – 1 – – – 1 1
Negative – 67 – 19 1 87 87
Positive – 8 – 25 – 33 33
Total 7338 78 2665 44 1 2788 10,126
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Table 12 provides the cumulative uptake following each phase 2 intervention at each time point as a
proportion along with their corresponding OR (95% CI) and p-value with respect to the control group.
A chi-squared test with 5 degrees of freedom suggests that there was a difference between the six study
arms at 12 (p < 0.001) and 18 months (p = 0.008) following the standard invitation. Owing to the
multi-intervention study design, the study protocol and power calculation specified a Bonferroni correction
of significance levels to adjust for multiple testing with a significant level of 1% in place of 5%. The odds
of attending increased significantly (p-value = 0.001) for SSK sent (OR 1.512) and timed appointments
(OR 1.408) compared with control at 12 months post standard invitation. Although both continued to
suggest an increase, only SSK sent (OR 1.286) was statistically significant (p = 0.012) at 18 months. Of the
TABLE 12 Phase 2 attendance (%) of tests occurring within 12 and 18 months since standard invitation
Phase 2 intervention Attendance, % (n screened/n invited) ORa 95% CI p-value ICCb
12 months (4.5 months since the start of phase 2 intervention)
Control 16.2 (613/3782) – – – 0.0083
SSK sent 21.3 (243/1141) 1.512 1.197 to 1.910 0.001
SSK offered 16.2 (209/1290) 1.074 0.871 to 1.325 0.505
NN 14.5 (146/1007) 0.887 0.670 to 1.174 0.401
Timed appointment 19.8 (323/1629) 1.408 1.141 to 1.738 0.001
Choice 18.8 (240/1277) 1.091 0.864 to 1.378 0.466
Total (χ25) 17.5 (1774/10,126) – – < 0.001
c
–
18 months (10.5 months since the start of phase 2 intervention)
Control 27.1 (1026/3782) – – – 0.0211
SSK sent 30.0 (342/1141) 1.286 1.056 to 1.567 0.012
SSK offered 25.8 (333/1290) 1.056 0.884 to 1.262 0.548
NN 22.8 (230/1007) 0.799 0.642 to 0.994 0.044
Timed appointment 29.0 (472/1629) 1.191 0.975 to 1.456 0.087
Choice 30.2 (385/1277) 1.058 0.869 to 1.289 0.573
Total (χ25) 27.5 (2788/10,126) – – 0.008
c
–
a Adjusted OR associated with the change in odds of attendance occurring within intervention compared with control,
adjusted for practice attendance rate and PCT region.
b ICC indicating level of agreement between GP clusters as defined by the population average model with robust
standard errors.
c Comparison test (5 degrees of freedom) of the five intervention effects, significance (p< 0.01) indicates that
interventions are significantly different from each other.
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remaining interventions, SSK offered and choice both resulted in a slight, but non-significant, increase in
uptake of any test. The NN intervention actually resulted in a non-significant reduction in uptake at
12 months (OR 0.887), which became a statistically significant reduction at 5% significance but not at the
Bonferroni-corrected 1% level at 18 months (OR 0.799; p = 0.044). Table 12 also gives the result of a
comparison test of the five interventions. The null hypothesis states that there is no difference between the
five intervention effects, here p < 0.01 indicates that the null hypothesis is rejected and that there are
significant differences between the five interventions at both 12 and 18 months.
Phase 2 planned moderator and predictor analyses
A series of moderator analyses were specified in the statistical analysis plan. By adding a factor by phase 2
treatment interaction, we examined the moderating effect of phase 1 intervention (intervention pre-leaflet
vs. control and online booking vs. control), location (Greater Manchester vs. Grampian) and, in Grampian
only, prior vaccination status (none, incomplete and complete). The predictive effect of these factors was
considered using a main-effects model without interaction terms. There was no evidence that the pre-leaflet
intervention moderated the effect of phase 2 interventions at either 12 (χ25 p = 0.740) or 18 months
(χ25 p = 0.216) since the standard invitation (see Appendix 7, Table 43). There was no effect of the pre-leaflet
during the phase 2 intervention period at either 12 (p = 0.760) or 18 months (p = 0.875) post call, see
Appendix 7, Table 43). Similarly, there was no evidence that the online booking intervention moderated
the effect of phase 2 interventions at either 12 (χ25 p = 0.594) or 18 months (χ
2
5 p = 0.321) post call
(see Appendix 7, Table 44), nor was there any effect of online booking at 12 (p = 0812) or 18 months
(p = 0.263). When the effect of location was considered (Greater Manchester vs. Grampian), there was no
effect on phase 2 interventions at 12 months post call (χ25 p = 0. 141), but this was significant at a 5% level
at 18 months (χ25 p = 0.020) (Table 13). Inspection of the pairwise interaction of each phase 2 intervention
against control suggests that the effect of the NN intervention differed between Grampian and Greater
TABLE 13 Influence of location (Grampian vs. Greater Manchester) on attendance at 12 and 18 months post
standard call
Variable Comparison
Time point
12 months 18 months
ORa 95% CI p-value ORa 95% CI p-value
Interaction model
Phase 2 (Greater
Manchester only)
SSK sent vs. control 1.52 1.163 to 1.986 0.002 1.247 0.988 to 1.574 0.064
SSK offered vs. control 1.103 0.854 to 1.424 0.454 1.111 0.895 to 1.378 0.34
NN vs. control 0.779 0.548 to 1.107 0.164 0.684 0.523 to 0.894 0.006
Timed appointment
vs. control
1.420 1.099 to 1.835 0.007 1.108 0.892 to 1.376 0.355
Choice vs. control 1.184 0.914 to 1.535 0.201 1.085 0.876 to 1.343 0.456
Location Grampian vs. Greater
Manchester
0.711 0.560 to 0.902 0.005 0.59 0.470 to 0.740 < 0.001
Interaction Location × SSK sent 0.977 0.583 to 1.637 0.928 1.097 0.721 to 1.670 0.664
Location × SSK offered 0.910 0.568 to 1.460 0.697 0.796 0.538 to 1.180 0.256
Location × NN 1.473 0.859 to 2.524 0.159 1.636 1.104 to 2.425 0.014
Location × timed
appointment
1.000 0.649 to 1.541 0.999 1.310 0.866 to 1.980 0.201
Location × choice 0.573 0.347 to 0.946 0.029 0.791 0.491 to 1.276 0.337
Interaction test 0.141 0.02
6-month rate 1.028 1.021 to 1.035 < 0.001 1.031 1.024 to 1.037 < 0.001
ICCb 0.0082 0.0158
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Manchester compared with other interventions. The negative effect of this intervention at 18 months
(see Table 12) appeared to be moderated in Grampian. Figures 8 and 9 show the uptake rate at 12 and
18 months post call by intervention and location. With the exception of the NN intervention, we see that
the uptake rate is higher in Greater Manchester than in Grampian, whereas the NN intervention attendance
was higher in Grampian than in Greater Manchester. When a model was fitted without the interaction
terms (see Table 13), there was evidence of an overall higher uptake in Greater Manchester than Grampian
during phase 2 at both 12 (p < 0.001) and 18 months (p < 0.001) post call. This contrasts with the
equivalent analysis during phase 1, which found that uptake in Grampian was higher than in Greater
Manchester (see Table 6).
TABLE 13 Influence of location (Grampian vs. Greater Manchester) on attendance at 12 and 18 months post
standard call (continued )
Variable Comparison
Time point
12 months 18 months
ORa 95% CI p-value ORa 95% CI p-value
Main-effects model
Phase 2 SSK sent vs. control 1.460 1.116 to 1.909 0.006 1.222 0.957 to 1.559 0.107
SSK offered vs. control 1.036 0.803 to 1.336 0.787 1.003 0.795 to 1.266 0.979
NN vs. control 0.868 0.647 to 1.163 0.343 0.772 0.613 to 0.973 0.028
Timed appointment
vs. control
1.425 1.120 to 1.812 0.004 1.231 0.988 to 1.535 0.065
Choice vs. control 1.103 0.831 to 1.466 0.497 1.069 0.841 to 1.360 0.585
Location Grampian vs. Greater
Manchester
0.723 0.611 to 0.855 < 0.001 0.665 0.578 to 0.765 < 0.001
ICCb 0.021 0.027
a Adjusted OR for the covariates displayed in the table.
b ICC for GP clusters estimated from GEE model.
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Finally, we considered the relation of vaccination to uptake during phase 2. There was no evidence that
intervention effects were moderated at either 12 (χ25 p = 0.147) or 18 months (χ
2
10 p = 0.122) post call
(see Appendix 7, Table 45). As with the analysis of phase 2, both ‘incomplete’ and ‘complete’ vaccination
status were associated with improved uptake at 12 and 18 months (see Appendix 7, Table 45). As with
phase 1, those participants who had experienced some form of vaccination compared with those with
none were approximately twice as likely to attend screening in phase 2, with ORs of 2.109 and 2.169 for
incomplete and complete, respectively, at 12 months post call, with both effects being statistically
significant (p < 0.001).
Adherence with randomisation during phase 2
In both phase 1 and 2, interventions were randomised to practices. The analyses presented above have
been by ITT, irrespective of whether or not the intended intervention was actually delivered. The data
available do not allow us to determine if a participant could receive or actually received the intended
intervention. For example, some women may have changed address, but this information could not be
provided. However, the date at which a phase 2 intervention was sent was recorded by the screening
agencies for each type of intervention for each woman. These data are summarised in Table 14, by
intervention. The column Correct date refers to the number of women recorded as having been sent the
randomly allocated intervention for the practice with which they were registered. The column Incorrect
date gives the number recorded as having been sent the incorrect intervention for their practice.
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FIGURE 9 Percentage attendance at 18 months for phase 2 interventions split by location. GM, Greater
Manchester; GR, Grampian.
TABLE 14 Description of the phase 2 intervention dates
Phase 2 intervention
Status of phase 2 intervention date, n (%) Overall total
number of
participants
in interventionNo date Correct date Incorrect date
Control 3734 (98.7) 0 (0) 48 (1.3) 3782
SSK sent 152 (13.3) 954 (83.6) 35 (3.1) 1141
SSK offered 169 (13.1) 1072 (83.1) 49 (3.8) 1290
NN 144 (14.3) 861 (85.5) 2 (0.2) 1007
Timed appointments 449 (27.6) 1174 (72.1) 6 (0.4) 1629
Choice 136 (10.6) 1137 (89) 4 (0.3) 1277
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The percentage of women sent the incorrect intervention ranged from 0.2% for NN to 3.8% for SSK sent.
Among the control group, 1.3% received a phase 2 intervention in error. For the timed appointments
intervention, 27.6% (449/1629) had no date recorded, largely because one large practice was unable to
implement timed appointments. For the other four interventions, between 83% and 89% of women
appear to have been sent the correct intervention.
Impact of phase 1 and phase 2 interventions on detection of low- and
high-grade cytology
The cervical screening result was available for women who attended for a test. Table 15 gives the rates of
women invited by the standard invitation who were tested and found to have low- or high-grade cytology
overall, and broken down by phase 1 intervention group and follow-up assessment point. Note that the
rates are based on numbers of women randomised and not numbers tested. After 3 months’ follow-up
the percentage of women invited for screening and found to have cytology of ‘low grade or above’ or
‘high grade’ was 4.24% and 0.44%, respectively. By 6 months’ follow-up the percentage of women
invited for screening and found to have cytology of ‘low grade or above’ or ‘high grade’ cytology was
7.82% and 0.64%, respectively. Rates are given broken down according to intervention. Adjusted ORs
were estimated using the same methods and covariates as the analysis of screening uptake. Neither
pre-leaflet nor online booking had a significant effect on a low grade or above outcome, or high grade,
which is to be expected, as neither intervention had an effect on uptake. The largest, although still
non-significant, effect (p = 0.130) occurred for online booking at 6 months (OR 1.57, 95% CI 0.88 to
2.80) for high-grade cytology. It should also be noted that the CIs are now rather wider, which is an
indication that the trial is underpowered for plausible effect sizes for these outcomes.
Table 16 gives the corresponding result by phase 2 interventions. Of this cohort, 5.1% and 7.6% were
detected as having low grade or above at 12 and 18 months post call, with 0.3% and 0.5% of the cohort
being high grade. At 12 months post call the intervention groups differed in the proportion of low-grade
cytology detected (p = 0.043). Of the phase 2 interventions, timed appointments showed a significant
increase (p = 0.001) in low grade or above (OR 1.57, 95% CI 1.21 to 2.03) at 12 months that persisted
with a borderline significant increase at 18 months (OR 1.24, 95% CI 0.98 to 1.57; p = 0.074). SSKs sent
showed a borderline increase at 12 months (p = 0.065). Inference from these data should be viewed with
caution because of the possibility of multiple testing artefacts. The significant increase because of timed
appointment, and to a lesser extent for SSK sent, nevertheless reflects the increased uptake rates of these
interventions (see Table 12).
Conclusions
Compared with control, no evidence was found to suggest a statistically significant effect for either of the
phase 1 interventions: pre-leaflet or online booking. With pre-leaflet only a slight increase in attendance
was observed 6 months after the standard invitation. Online booking did indicate an increase in
attendance from 3 months that continued out to 6 months. Vaccination status appears to have the largest
(and most significant) influence on screening attendance, with fully vaccinated subjects approximately
twice as likely to attend screening as unvaccinated women, who had very low participation.
The results indicated that the phase 2 interventions SSK sent and timed appointments exerted a statistically
significant effect on attendance compared with the control practices in both Greater Manchester and
Grampian. In an underpowered analysis this appeared to lead to increased detection of low-grade
cytology. Women in Grampian appeared to be significantly less likely overall to attend in phase 2, yet
showed mostly no differences in behaviour with respect to the influence of the phase 2 interventions with
the exception of NN and choice. As seen previously in phase 1 vaccination status, in Grampian participants,
appears to indicate an increase in the likelihood of attendance and phase 1 interventions failed to have an
effect in these non-responders. We can be sure that of those randomised to an intervention, on average,
81% of women were at least sent the correct intervention, 17.6% were sent no intervention and only
1.4% were recorded as being sent the incorrect intervention.
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Chapter 3 Cost-effectiveness
Objectives
The economic analysis had three components.
1. Calculating the costs of each intervention. For the leaflet, this included development, printing and
distribution costs. For online booking the costs included programming and information technology
changes required to implement the system. For the requested and unrequested HPV SSK, the costs
included SSKs, staff time to prepare them and distribution. For the specialist NN, the calculated
costs included all letters, telephone calls and publicity material, as well as the average time involved in
providing advice and facilitating access.
2. Calculating other health-care costs. These included attendances at screening clinics, consultations,
screening-related tests and diagnostic procedures. These were obtained from a combination of trial
sources and literature.
3. Calculating cost-effectiveness. This was expressed in two ways: (1) the incremental lifetime cost per
screened woman for each of the strategies being examined compared with standard practice and
(2) lifetime cost utility. Lifetime results were obtained by combining the cost and attendance results of
the study with published estimates of the lifetime costs and effects of participating in cervical cancer
screening programmes.
Methods
The economic analysis complied with the methodological guidelines issued by the National Institute for
Health and Care Excellence (NICE)21 and followed the reporting standards of the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) statement.22
Measurement and valuation of costs
Intervention costs
Full details of the STRATEGIC study interventions have been described in Chapter 2, Operationalising the
interventions, but specific details of the interventions that are relevant to the cost analysis are given in
Appendix 8.
All resources required to develop and implement each intervention were identified and recorded by two
researchers at the University of Manchester, and providers of the interventions then cross-checked the list
to ensure completeness and accuracy. The list included items such as labour time, printing and distribution
of information materials, laboratory kits, rent for meeting rooms, training of professionals, information
and communications, and programming. Labour time costs were based on gross monthly income
corresponding to the salary grade of the staff involved in an activity. A detailed list of the items for each
intervention, and associated costs, is presented in Appendix 9. For each intervention, the intervention costs
per attendee were calculated by dividing the total intervention costs by the number of women who
attended cervical screening.
Other screening-related costs
Data on cytology tests and HPV SSKs were collected from the screening agencies in Greater Manchester
and Grampian. The number of colposcopies was estimated by using information about the colposcopy
referral rate for the relevant age group, the attendance rate and the different types of colposcopy derived
from the national Cervical Screening Programme, categorised into outpatient diagnostic procedures,
outpatient diagnostic procedures with biopsy and therapeutic colposcopy.
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Unit costs of screening tests
Unit costs of HPV tests and cytology tests were obtained from previous studies23,24 and included staff time
in screening centres and laboratories, equipment and consumables. Any costs arising from non-attendance
are not included, in line with previous studies. Unit costs of different types of colposcopic procedures were
obtained from the NHS Reference Costs 2013–2014.25 All unit costs were inflated to 2014 prices using the
Hospital and Community Health Services inflation index.
Measures of effects and follow-up
The primary within-trial outcome measure for all interventions was attendance for cervical screening. This
outcome was measured at 3 and 6 months post invitation for phase 1 interventions (i.e. pre-leaflet and online
booking) and at 12 and 18 months post invitation for the interventions provided in phase 2. The primary
end point for phase 1 interventions was uptake of screening at 3 months and for phase 2 interventions at
12 months post invitation. These end points were used in the main economic evaluation and the secondary
end points (6 months for phase 1 interventions, 18 months for phase 2) in a secondary economic analysis.
Lifetime costs and quality-adjusted life-years of screening attendance
A systematic literature review was performed to obtain information about the lifetime costs and
quality-adjusted life-years (QALYs) of women who attended cervical cancer screening and those who did
not. We developed the literature search strategy based on the PICOS (population, intervention, comparator,
outcomes, study design) framework, in order to retrieve economic evaluations of screening strategies.
These included no screening as a comparator and reported lifetime costs and outcomes in the form of
life-years and/or QALYs for women eligible for cervical cancer screening. Following the recommendations
of the Centre for Reviews and Dissemination26 and Cochrane Central Register of Controlled Trials,
the following computerised bibliographic databases were searched on 15 May 2016: MEDLINE, MEDLINE
In-Process, EMBASE, EconLit and the NHS Economic Evaluation Database. Letters, editorials, historical
articles, animal studies, studies published before 1995 and studies published in languages other than
English were excluded from the search.
A two-stage selection process was followed. The title and abstract of the retrieved studies were scanned for
relevance and the full text was then accessed if a paper was judged to be an economic evaluation related to
cervical cancer screening and had employed a disease progression model with a lifetime time horizon. Where
exclusion based on the titles/abstracts was not possible, the full publication was retrieved and evaluated. When
all relevant full texts were obtained, they were assessed for eligibility against the PICOS criteria (Table 17).
The reviewing process was documented in Microsoft Excel, and reasons for inclusion and exclusion
detailed to facilitate updates of the review. The websites of agencies including NICE, the Medical Research
Council and National Cancer Screening Programmes were also scanned for relevant reports. A template
was developed and used to extract the information from the most relevant studies to the STRATEGIC trial.
The review was performed in May 2015.
TABLE 17 The PICOS criteria to select relevant studies
PICOS criterion Inclusion criteria
Patient population l Females eligible for cervical cancer screening, in high-income settings
Intervention l Cervical cancer screening strategies
Comparators l No cervical cancer screening strategy
Outcomes l Life expectancy
l Mortality
l QALYs
Study design l Economic evaluations reporting at least one outcome of interest and costs
l Lifetime horizon
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The quality of the selected studies from the literature review was assessed using a checklist of good
practice in decision-analytic modelling studies developed by Philips et al.27 and the CHEERS statement for
reporting economic evaluation.22 In this way, the selected studies were assessed both on specific modelling
and on broader evaluation grounds. In case of disagreement between the assessors, the mean assessment
score was assigned. In studies where more than one cancer screening strategy was compared with
no-screening strategy, we used a selection process to retrieve lifetime costs and outcomes of screening
compared with no screening. In this process, the next more-costly strategies to no screening as well as
strategies that had similar population (i.e. age groups), interval of screening and discount rates (i.e. 3.5%)
to the UK were preferred. Where results from cancer screening in different countries were reported, we
selected the UK-based estimates.
A meta-analysis was performed to pool the lifetime costs and outcomes reported in the selected studies.
A random-effects model was specified to pool the estimates assuming real differences in treatment effects
because of heterogeneity in screening strategies, population and other factors.28 The study quality score
was used in this model to weight each study’s contributed information to the pooled estimate. The NICE
appraisal studies were assigned the highest possible weight on the grounds that they were of high
relevance to our study and of high methodological quality.
Costs and quality-adjusted life-years
Costs were inflated from each study’s price reference year to 2014 using consumer price inflation rates
for each study’s country of origin, as reported by the Organisation for Economic Co-operation and
Development (OECD)29 and were converted to UK sterling using average exchange rates for the year 2014
as suggested by the UK Government.30 QALYs retrieved from the selected studies were adjusted to make
them comparable and relevant to the UK context. To do this, the risk rate of life expectancy between the
screening and control cohorts in the selected studies was applied to the mean age of women in the trial.
For example, if the reported life expectancy of screening was 28.71 years and the reported life expectancy
of no screening was 28.69 years, the risk rate of life expectancy would be 1.001. This was then applied
to the mean remaining life expectancy of women in the trial (62.29 years) to derive a remaining life
expectancy for screened women of 62.35 years (62.29 × 1.001). Quality-adjusted life expectancy and QALY
differences were then calculated by weighting these 62.29 and 62.35 years by the utility of women in
each age band in the general population from the mean age of women in the trial up to 85 years of life.
Cost-effectiveness and cost–utility analyses
A decision model was constructed in Microsoft Excel to calculate the lifetime costs and outcomes of each
intervention. Each of the six interventions was compared with the control group. The probabilities of
attendance in each intervention and control group were informed by the trial results. Costs in this model
included the intervention costs, screening costs during the study, and lifetime screening and disease-specific
costs (which were informed by the meta-analysis described in Lifetime costs and quality-adjusted life-years of
screening attendance).The incremental cost-effectiveness ratios (ICERs) were expressed as incremental costs
per women attending a screening test and incremental costs per QALY gained taking the NHS perspective.
Uncertainty and scenario analysis
Probabilistic sensitivity analysis was performed to address the uncertainty in the ICERs by performing 5000
draws of all cost and effect parameters using pre-specified distributions, and recording incremental costs
and incremental QALYs from each draw. These results were then plotted on cost-effectiveness planes.
Mean costs and outcomes, as well as their standard errors as reported by the trial’s statistical analysis, were
used to define distributions for the attendance rate. The reported mean estimated and standard errors of
lifetime costs and QALYs from the meta-analysis were used to estimate the distribution of these parameters.
The intervention costs per attendee, unit costs and probabilities of having a HPV test, cytology test and
colposcopy were also included in the probabilistic sensitivity analysis. Cost-effectiveness acceptability curves
were derived from these results, to express the uncertainty in these cost-effectiveness estimates in graphical
form. This was done by displaying the probability that each intervention is cost-effective as the ceiling ratio
for the maximum acceptable ICER varies from £0 to £75,000 per QALY gained.
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Two univariate sensitivity analyses were also performed. First, the impact of using secondary end points
(6 months instead of 3 months for phase 1 and 18 months instead of 12 months in phase 2) on the results
of the economic evaluation was tested. In another univariate analysis, the study quality scores based on
Phillips et al.27 that were used to weight the pooled estimates in the meta-analysis were replaced with the
study quality scores based on the CHEERS statement.
A scenario analysis was also performed to explore the adoption of these interventions for a population of
365,087 women in phase 1 interventions, which is approximately the total number of women annually
invited for cervical screening for the first time in England, Scotland and Wales. A similar scenario analysis
was performed for phase 2 interventions applied to a population of 255,561 women, that is, assuming that
70% of women do not attend phase 1 interventions. In these analyses, intervention costs were categorised
into fixed one-off costs, semifixed scalable costs, which are incurred in steps as the scale increases, and
variable costs. It was assumed that large-scale purchasing of materials and equipment would allow a cost
discount to be obtained; this is set at 20% in the sensitivity analysis. In these scenario analyses, therefore,
only the components of total cost that are not variable will affect the cost per woman and the ICERs.
Results
Figure 10 shows that 3766 studies were screened based on title and abstract and 30 studies were
screened based on full text. A total of eight studies24,31–37 met the inclusion criteria and were therefore
included in the final review. The papers were fully evaluated and relevant information was extracted.
An overview of the papers included and the summary results extracted from these papers showing that
quality scores were variable across the identified studies can be seen in Appendix 10.
Table 18 shows summary results from the meta-analysis, indicating that participation in a screening
programme increased lifetime quality-adjusted life expectancy by 0.0947 QALYs, at an additional lifetime
cost of £566.30. More details of the meta-analysis are reported in Appendix 10.
Potentially relevant
references were identified
(n = 3766)
References excluded
based on title and abstact
(n = 3737)
References excluded
based on full text
(n = 22)
Full texts retrieved and
assessed for eligibility
(n = 30)
References were included
(n = 8)
FIGURE 10 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart.
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Parameters used in the decision model
Table 19 summarises all main probability parameters used in the analysis and Table 20 summarises the cost
parameters used.
Further details of the interventions and their costs are provided in Appendices 8 and 9. It can be seen that
the intervention costs per woman attending varied from < £1 for the NN intervention, to > £52 for the
unrequested SSK. The relatively high cost of the latter is because those attending are bearing the costs of
sending SSKs to all women in GP practices.
TABLE 18 Pooled estimates of lifetime costs and outcomes for screened and unscreened populations
Variable Coefficient Standard error p-value 95% CI
Lifetime costs no screening 304.6262 96.60469 0.002 115.2845 to 493.9679
Lifetime costs screening 870.9233 247.2858 0.000 386.252 to 1355.595
Lifetime QALYs no screening 57.39219 0.0166141 0.000 57.37411 to 57.429219
Lifetime QALYs screening 57.48689 0.0354359 0.000 57.41744 to 57.55635
TABLE 19 Parameter values used in primary analysis: mean, standard error, distribution and source: probabilities
(at the 3-month follow-up for phase 1 and at the 12-month follow-up for phase 2)
Parameter Deterministic
Standard
error Distribution Alpha Beta Source
Treatment
% screened women
Pre-leaflet 0.190 0.005 Beta 1106.31 4719.09 Trial
Booking 0.179 0.007 Beta 495.64 2282.54 Trial
Requested SSK 0.168 0.013 Beta 143.74 718.86 Trial
Unrequested SSK 0.220 0.018 Beta 119.68 428.12 Trial
NN 0.143 0.016 Beta 67.71 412.45 Trial
Timed appointment 0.208 0.015 Beta 152.64 584.67 Trial
Choice SSK or NN 0.170 0.015 Beta 109.80 542.14 Trial
Control
% screened women
Pre-leaflet 0.196 0.006 Beta 987.33 4064.74 Trial
Booking 0.176 0.009 Beta 296.71 1395.73 Trial
Requested SSK 0.158 0.007 Beta 405.13 2165.97 Trial
Unrequested SSK 0.158 0.007 Beta 405.13 2165.97 Trial
NN 0.158 0.007 Beta 405.13 2165.97 Trial
Timed appointment 0.158 0.007 Beta 405.13 2165.97 Trial
Choice SSK or NN 0.158 0.007 Beta 405.13 2165.97 Trial
continued
DOI: 10.3310/hta20680 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 68
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
TABLE 19 Parameter values used in primary analysis: mean, standard error, distribution and source: probabilities
(at the 3-month follow-up for phase 1 and at the 12-month follow-up for phase 2) (continued )
Parameter Deterministic
Standard
error Distribution Alpha Beta Source
Probability of having a test by phase 2 trial arm
Requested SSK:
HPV test
0.091 Beta 19.00 190.00 Trial
Requested SSK:
cytology
0.943 Beta 197.00 12.00 Trial
Unrequested SSK:
HPV test
0.350 Beta 85.00 158.00 Trial
Unrequested SSK:
cytology
0.786 Beta 191.00 52.00 Trial
NN: HPV test 0.007 Beta 1.00 145.00 Trial
NN: cytology 1.000 Beta 146.00 0.00 Trial
Timed appointment:
HPV test
0.000 Beta 0.00 323.00 Trial
Timed appointment:
cytology
1.000 Beta 323.00 0.00 Trial
Choice SSK or NN:
HPV test
0.029 Beta 7.00 233.00 Trial
Choice SSK or NN:
cytology
0.979 Beta 235.00 5.00 Trial
Control: HPV test 0.002 Beta 1.00 612.00 Trial
Control: cytology 0.998 Beta 612.00 1.00 Trial
Follow-up tests
Proportion of HPV
triage after cytology
(age 20–24 years)
0.096 Beta 1231.00 11,561.00 PHE’s Health
Economics Report for
Primary HPV Pilot38
Colposcopy referral
rate (cytology only and
after HPV triage;
age 20–24 years)
0.117 Beta 1503.00 11,289.00 PHE’s Health
Economics Report for
Primary HPV Pilot38
Colposcopy attendance
rate
0.767 Beta 188,775.57 57,346.43 Table W. Cervical
Screening Programme,
England. Statistics
for 2013–201439
Colposcopy, outpatient
procedure
0.387 Beta 73,072.18 115,744.82 Table X. Cervical
Screening Programme,
England. Statistics
for 2013–201439
Colposcopy with
biopsy, outpatient
procedure
0.482 Beta 91,009.79 97,807.21 Table X. Cervical
Screening Programme,
England. Statistics
for 2013–201439
Therapeutic colposcopy,
outpatient
0.131 Beta 24,735.03 164,081.97 Table X. Cervical
Screening Programme,
England. Statistics
for 2013–201439
PHE, Public Health England.
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Cost-effectiveness analysis
Table 21 shows the results of the analysis pertaining to the pre-leaflet intervention. The probability of
attending was slightly higher in the control group than in the intervention group. Intervention costs
totalled £8496, but screening costs were slightly higher in the control group because of the higher
attendance, resulting in an additional cost for intervention and screening of £0.51 per woman in the
intervention group. Lifetime costs were also slightly higher in the control group because of increased
participation in screening, and so the lifetime cost per woman invited was £2.46 higher in the control
group. Lifetime QALYs were slightly higher in the control group as a higher proportion of women received
the benefits of being screened. In consequence, the pre-leaflet intervention was less costly but also less
effective than control, and the ICER of £4953 can be interpreted as indicating that opting for the
pre-leaflet intervention would result in a loss of 1 QALY for every £4953 saved.
TABLE 20 Parameter values used in analysis: mean, standard error, distribution and source: costs (£)
Parameter Deterministic
Standard
error Distribution Alpha Beta Source
Treatment
Intervention costs per
woman attending
Pre-leaflet 4.27 0.01 Gamma 428,748 0.00 Trial
Booking 2.80 0.01 Gamma 121,682.18 0.00 Trial
Requested SSK 1.71 0.01 Gamma 93,762.18 0.00 Trial
Unrequested SSK 52.20 0.18 Gamma 83,310.51 0.00 Trial
NN 0.99 0.00 Gamma 51,411.28 0.00 Trial
Timed appointment 23.94 0.08 Gamma 93,601.84 0.00 Trial
Choice SSK or NN 5.73 0.02 Gamma 82,240.54 0.00 Trial
Lifetime costs 870.92 247.29 Gamma 12.40 70.21 Meta-analysis
Lifetime QALYs 57.49 0.04 Normal Meta-analysis
Control
Lifetime costs 304.63 96.60 Gamma 9.94 30.64 Meta-analysis
Lifetime QALYs 57.39 0.02 Normal Meta-analysis
Unit costs, all women
attending
Cytology test 36.37 1.66 Gamma 478.97 0.08 Kim (2010)40 based
on Sherlaw-Johnson
and Philips (2004)
HPV test 29.01 8.56 Gamma 11.48 2.53 Kim (2010)40 based
on Sherlaw-Johnson
and Philips (2004)
HPV (only laboratory
costs)
8.00 NHS Reference
Costs 2013–1425
Colposcopy, outpatient
procedure
169.56 NHS Reference
Costs 2013–1425
Colposcopy with
biopsy, outpatient
procedure
219.51 NHS Reference
Costs 2013–1425
Therapeutic colposcopy,
outpatient
229.86 NHS Reference
Costs 2013–1425
DOI: 10.3310/hta20680 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 68
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
Online booking
The results of the analysis pertaining to the online booking intervention are shown in Table 22. The
probability of attending was slightly higher in the intervention group than in the control group. Intervention
costs totalled £2382 and screening costs were slightly higher in the intervention group because of higher
attendance, resulting in an additional cost for intervention and screening of £0.67 per woman in the
intervention group. Lifetime costs were also slightly higher in the intervention group resulting from
increased participation in screening, and so the lifetime cost per woman invited was £2.38 higher in the
TABLE 21 Costs, outcomes and cost-effectiveness of the pre-leaflet intervention (at 3 months)
Variable
Intervention
DifferenceTreatment (n= 10,461) Control (n= 10,418)
n attending 1991 2038
Total intervention costs (£) 8496 0 8496
Total screening costs (£) 114,142 116,810 –2668
Total intervention and screening costs (£) 122,638 116,810 5828
Total intervention and screening costs per woman (£) 11.72 11.21 0.51
Lifetime costs (£) 4,314,254 4,327,515 –13,261
Total costs (£) 4,436,892 4,444,325 –7433
Total cost per woman (£) 424.14 426.60 –2.46
Total cost per woman attending (£) 2228.35 2181.10 47
Lifetime QALYs 600,568 598,105 2463
Lifetime QALYs per woman 57.4102 57.4107 –0.00050
Cost per QALY gained (£) 4953
TABLE 22 Costs, outcomes and cost-effectiveness of the online booking intervention (at 3 months)
Variable
Intervention
DifferenceTreatment (n= 4756) Control (n= 4978)
n attending 850 875
Total intervention costs (£) 2382 0 2382
Total screening costs (£) 48,750 50,168 –1417
Total intervention and screening costs (£) 51,133 50,168 965
Total intervention and screening costs per woman (£) 10.75 10.08 0.67
Lifetime costs (£) 1,930,385 2,012,014 –81,629
Total costs (£) 1,981,518 2,062,182 –80,664
Total cost per woman (£) 416.64 414.26 2.38
Total cost per woman attending (£) 2330.08 2356.42 –26
Lifetime QALYs 273,038 285,781 –12,743
Lifetime QALYs per woman 57.4091 57.4088 0.00028
Cost per QALY gained (£) 8344
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intervention group than the control group. Lifetime QALYs were slightly higher in the intervention group as
a higher proportion of women received the benefits of being screened. In consequence, the online booking
intervention was more costly but also more effective than the control group, with an ICER of £8344 per
QALY gained.
Human papillomavirus self-sampling kit offered
The results of the analysis pertaining to the HPV SSK on request intervention are shown in Table 23.
The probability of attending was higher in the intervention group than the control group. Intervention
costs totalled £369, and screening costs per woman were higher in the intervention group because of
higher attendance, resulting in an additional cost of £0.42 for intervention and screening per woman in
the intervention group. Lifetime costs were also slightly higher in the intervention group resulting from
increased participation in screening, and so the lifetime cost per woman invited was £5.93 higher in the
intervention group than the control group. Lifetime QALYs were higher in the intervention group as a
higher proportion of women received the benefits of being screened. In consequence, the HPV SSK on
request intervention was more costly but also more effective than the control group, at an ICER of £6436
per QALY gained.
Human papillomavirus self-sampling kit sent
The results of the analysis pertaining to the unrequested HPV SSK intervention are shown in Table 24.
The probability of attending was higher in the intervention group than in the control group. Intervention
costs totalled £13,157 and screening costs per woman were higher in the intervention group because of
higher attendance, resulting in an additional cost of £13.01 for intervention and screening per woman in
the intervention group. Lifetime costs were also slightly higher in the intervention group, resulting from
increased participation in screening, and so the lifetime cost per woman invited was £48.68 higher in the
intervention group. Lifetime QALYs were higher in the intervention group as a higher proportion of
women received the benefits of being screened. In consequence, the unrequested HPV SSK intervention
was more costly but also more effective than the control group, at an ICER of £8161 per QALY gained.
TABLE 23 Costs, outcomes and cost-effectiveness of the HPV SSK on request intervention (at 12 months)
Variable
Intervention
DifferenceTreatment (n= 1290) Control (n= 3782)
n attending 216 597
Total intervention costs (£) 369 0 369
Total screening costs (£) 11,273 32,542 –21,269
Total intervention and screening costs (£) 11,642 32,542 –20,900
Total intervention and screening costs per woman (£) 9.02 8.60 0.42
Lifetime costs (£) 515,422 1,490,276 –974,854
Total costs (£) 527,064 1,522,818 –995,755
Total cost per woman (£) 408.58 402.65 5.93
Total cost per woman attending (£) 2437.44 2550.02 –113
Lifetime QALYs 74,056 217,114 –143,057
Lifetime QALYs per woman 57.4081 57.4071 0.00092
Cost per QALY gained (£) 6436
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Nurse navigator
Table 25 shows the results of the analysis pertaining to the NN intervention. The probability of attending
was higher in the control group than in the intervention group. Intervention costs totalled £142 and
screening costs per woman were higher in the control group because of higher attendance, resulting in an
additional cost of £0.66 for intervention and screening per woman in the control group. Lifetime costs
were also slightly higher in the control group, resulting from increased participation in screening, and
so the lifetime cost per woman invited was £9.34 higher in the control group. Lifetime QALYs were
TABLE 24 Costs, outcomes and cost-effectiveness of the unrequested HPV SSK intervention (at 12 months)
Variable
Intervention
DifferenceTreatment (n= 1141) Control (n= 3782)
n attending 252 597
Total intervention costs (£) 13,157 0 13,157
Total screening costs (£) 11,509 32,542 –21,033
Total intervention and screening costs (£) 24,665 32,542 –7877
Total intervention and screening costs per woman (£) 21.62 8.60 13.01
Lifetime costs (£) 490,304 1,490,276 –999,973
Total costs (£) 514,969 1,522,818 –1,007,849
Total cost per woman (£) 451.33 402.65 48.68
Total cost per woman attending (£) 2043.27 2550.02 –507
Lifetime QALYs 65,508 217,114 –151,605
Lifetime QALYs per woman 57.4131 57.4071 0.00596
Cost per QALY gained (£) 8161
TABLE 25 Costs, outcomes and cost-effectiveness of the NN intervention (at 12 months)
Variable
Intervention
DifferenceTreatment (n= 1007) Control (n= 3782)
n attending 144 597
Total intervention costs (£) 142 0 142
Total screening costs (£) 7838 32,542 –24,704
Total intervention and screening costs (£) 7979 32,542 –24,563
Total intervention and screening costs per woman (£) 7.92 8.60 –0.68
Lifetime costs (£) 388,063 1,490,276 –1,102,213
Total costs (£) 396,042 1,522,818 –1,126,776
Total cost per woman (£) 393.29 402.65 –9.36
Total cost per woman attending (£) 2758.48 2550.02 208
Lifetime QALYs 57,808 217,114 –159,306
Lifetime QALYs per woman 57.4057 57.4071 –0.00145
Cost per QALY gained (£) 6449
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higher in the control group as a higher proportion of women received the benefits of being screened.
In consequence, the NN intervention was less costly but also less effective than the control, and the ICER
of £6435 can be interpreted as indicating that opting for the NN intervention would result in a loss of
1 QALY for every £6449 saved.
Timed appointments
Table 26 shows the results of the analysis pertaining to the timed appointments intervention. The
probability of attending was higher in the intervention group than in the control group. Intervention costs
totalled £18,145 and screening costs per woman were higher in the intervention group because of higher
attendance, resulting in an additional cost of £7.79 for intervention and screening per woman in the
intervention group. Lifetime costs were also higher in the intervention group, resulting from increased
participation in screening, and so the lifetime cost per woman invited was £36.66 higher in the intervention
group than in the control. Lifetime QALYs were higher in the intervention group as a higher proportion of
women received the benefits of being screened. In consequence, the timed appointments intervention was
more costly but also more effective than the control, at an ICER of £7593 per QALY gained.
Choice of nurse navigator or human papillomavirus
self-sampling kit offered
Table 27 shows the results of the analysis pertaining to the combination intervention offering a choice of
NN or HPV SSK. The number and probability of attending was higher in the intervention group than
the control group. Intervention costs totalled £1243 and screening costs per woman were higher in the
intervention group because of higher attendance, resulting in an additional cost of £1.47 for intervention
and screening per woman in the intervention group. Lifetime costs were also slightly higher in the
intervention group, resulting from increased participation in screening, and so the lifetime cost per woman
invited was £8.21 higher in the intervention group than in the control group. Lifetime QALYs were higher
in the intervention group as a higher proportion of women received the benefits of being screened. In
consequence, this combination intervention was more costly but also more effective than the control, at an
ICER of £7290 per QALY gained.
TABLE 26 Costs, outcomes and cost-effectiveness of the timed appointments intervention (at 12 months)
Variable
Intervention
DifferenceTreatment (n= 1629) Control (n= 3782)
n attending 340 597
Total intervention costs (£) 8145 0 8145
Total screening costs (£) 18,557 32,542 –13,985
Total intervention and screening costs (£) 26,702 32,542 –5840
Total intervention and screening costs per woman (£) 16.39 8.60 7.79
Lifetime costs (£) 688,936 1,490,276 –801,340
Total costs (£) 715,638 1,522,818 –807,180
Total cost per woman (£) 439.31 402.65 36.66
Total cost per woman attending (£) 2103.08 2550.02 –447
Lifetime QALYs 93,524 217,114 –123,590
Lifetime QALYs per woman 57.4120 57.4071 0.00483
Cost per QALY gained (£) 7593
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Uncertainty concerning cost-effectiveness results
Tables 21–27 report only the point estimates for all results. To capture the full uncertainty around
the parameter values, probabilistic sensitivity analysis was performed (seeMethods for details), and
Figures 11–17 show cost-effectiveness planes for each intervention, in which 5000 cost–effect pairs
derived with all parameters varying are displayed. It is immediately evident from the cost-effectiveness
planes that timed appointments and unrequested SSK are the two interventions that are clearly more
effective than the control intervention, with virtually all cost–effect pairs to the right of the y-axis. Both are
also almost certain to cost more than control.
The probability of each intervention being cost-effective at different willingness-to-pay values for 1 QALY
is presented in Figure 18. The pre-leaflet intervention is characterised by uncertainty in costs and
effectiveness, and so the probability of this intervention being cost-effective is very low. A similar pattern
is displayed by the NN intervention. Similarly, there is no clear evidence that online booking is effective,
TABLE 27 Costs, outcomes and cost-effectiveness of the combination intervention (at 12 months)
Variable
Intervention
DifferenceTreatment (n= 1277) Control (n= 3782)
n attending 217 597
Total intervention costs (£) 1243 0 1243
Total screening costs (£) 11,628 32,542 –20,914
Total intervention and screening costs (£) 12,871 32,542 –19,671
Total intervention and screening costs per woman (£) 10.08 8.60 1.47
Lifetime costs (£) 511,791 1,490,276 –978,486
Total costs (£) 524,662 1,522,818 –998,156
Total cost per woman (£) 410.86 402.65 8.21
Total cost per woman attending (£) 2419.83 2550.02 –130
Lifetime QALYs 73,310 217,114 –143,803
Lifetime QALYs per woman 57.4083 57.4071 0.00113
Cost per QALY gained (£) 7290
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FIGURE 11 Cost-effectiveness planes for pre-leaflet compared with control (lifetime difference in costs and QALYs,
outcomes assessed at 3 months for phase 1 interventions).
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FIGURE 12 Cost-effectiveness planes for online booking compared with control (lifetime difference in costs and
QALYs, outcomes assessed at 3 months for phase 1 interventions).
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FIGURE 13 Cost-effectiveness planes for SSKs on request compared with control (lifetime difference in costs and
QALYs, outcomes assessed at 12 months for phase 2 interventions).
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FIGURE 14 Cost-effectiveness planes for SSKs sent unrequested compared with control (lifetime difference in costs
and QALYs, outcomes assessed at 12 months for phase 2 interventions).
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FIGURE 15 Cost-effectiveness planes for NNs compared with control (lifetime difference in costs and QALYs,
outcomes assessed at 12 months for phase 2 interventions).
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FIGURE 16 Cost-effectiveness planes for timed appointment compared with control (lifetime difference in costs
and QALYs, outcomes assessed at 12 months for phase 2 interventions).
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FIGURE 17 Cost-effectiveness planes for choice of a NN or requested SSK compared with control (lifetime
difference in costs and QALYs, outcomes assessed at 12 months for phase 2 interventions).
COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
and so the probability that this intervention is cost-effective never rises above 60%. The SSK on request
intervention has a slightly higher probability of being cost-effective, but this is still no higher than 71%
at conventional ceiling ratios of willingness to pay for 1 QALY; a similar pattern is displayed by the
combination intervention, which includes SSK on request. For timed appointments the probability that
the intervention is cost-effective at a ceiling ratio of £20,000 per QALY gained is 94%, and for
unrequested SSK is 93% (see Figure 18).
Results from the univariate sensitivity and scenario analyses
The results from the sensitivity analysis, in which the results are based on the secondary end points (outcomes
assessed at 6 months for phase 1 interventions and at 18 months for phase 2), are presented in Table 28.
The ICERs for each intervention from the main analysis are shown in the final column to facilitate comparison.
For most interventions the differences are small, but the cost per QALY gained of the pre-leaflet intervention
has risen from < £5000 to > £9000, primarily because the adjusted OR for this intervention has changed from
0.967 at 3 months to 1.014 at 6 months, suggesting that the intervention may have a small effect in increasing
attendance, which results in better health outcomes but increased lifetime costs per woman.
Figure 19 reports the cost-effectiveness acceptability curves for all interventions using the secondary end
points, and it can be seen that, for example, the probability that timed appointments are cost-effective
at a £20,000 ceiling has fallen to 87% from 94% in the primary analysis, while the probability that
the pre-leaflet or online booking interventions are cost-effective has increased. Appendix 11 shows the
accompanying cost-effectiveness planes for each intervention.
Table 29 reports the results for each intervention when the studies used to derive estimates of lifetime
benefits and costs of screening are given quality weights using the CHEERS study criteria. This change has
relatively little effect on the cost-effectiveness results.
Finally, Table 30 reports the results of a scenario analysis in which it is assumed that the relevant
population is all women eligible for cervical screening in England (365,087 in 2014). In all cases the
incremental costs were lower or savings were higher than in the main analysis because of the economies
of scale and amortisation compared with the incremental costs in the main analysis, but the impact of
these on the ICERs is not large.
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FIGURE 18 Cost-effectiveness acceptability curves for all interventions (outcomes assessed at 3 months for phase 1
interventions and at 12 months for phase 2).
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TABLE 28 Cost-effectiveness results when using secondary end points (outcomes assessed at 6 months for phase 1
interventions and at 18 months for phase 2 interventions)
Intervention
Incremental cost
per woman (£)
Incremental cost
per woman
(main analysis) (£)
Incremental
QALYs
per woman
Incremental
cost per QALY
gained (£)
Incremental cost
per QALY gained
(main analysis) (£)
Pre-leaflet 2.77 –2.46 0.00030 9311 4953
Online booking 12.22 2.38 0.00178 6867 8344
Requested SSK 6.49 5.93 0.00101 6440 6436
Unrequested SSK 41.18 48.68 0.00486 8465 8161
NN –25.25 –9.36 –0.00387 6516 6449
Timed appointment 26.78 36.66 0.00333 8052 7593
Combination 7.70 8.21 0.00105 7344 7290
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FIGURE 19 Cost-effectiveness acceptability curves for all interventions (outcomes assessed at 6 months for phase 1
interventions and at 18 months for phase 2 interventions).
TABLE 29 Cost-effectiveness results when using the CHEERS study quality weights
Intervention
Incremental cost
per woman (£)
Incremental cost
per woman
(main analysis) (£)
Incremental
QALYs
per woman
Incremental
cost per QALY
gained (£)
Incremental cost
per QALY gained
(main analysis) (£)
Pre-leaflet –2.71 –2.46 –0.00061 4481 4953
Online booking 2.52 2.38 0.00035 7267 8344
Requested SSK 6.39 5.93 0.00112 5699 6436
Unrequested SSK 51.67 48.68 0.00726 7117 8161
NN –10.09 –9.36 –0.00177 5710 6449
Timed appointment 39.09 36.66 0.00588 6649 7593
Combination 8.77 8.21 0.00137 6401 7290
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Conclusion
In this economic analysis we have assessed the costs and cost-effectiveness of each of the interventions
considered in the STRATEGIC trial, in each case making comparisons with the relevant control group to
estimate the incremental costs and effects. Incremental cost-effectiveness has been calculated in terms of
the additional cost per additional woman attending for cervical screening, and the incremental cost per
QALY gained over a lifetime. In addition, we have estimated the total lifetime costs and effects of adopting
each of the interventions for the entire population of women entering the screening programme each year
in England on their 25th birthday.
A full discussion of the economic analysis, results and limitations is presented in Chapter 5. In summary,
we find that timed appointments and unrequested SSK have the most compelling cost-effectiveness
evidence in favour of adoption: in both cases the incremental cost per QALY gained is well below the
generally accepted ceiling values, at £7593 and £8161, respectively, and there is a 94% probability these
interventions are < £20,000 per QALY. The uncertainty around the cost-effectiveness of the timed
appointments intervention increases slightly if the effectiveness of the intervention is assessed at the
18-month outcome point rather than the primary end point of 12 months, but there is still an 87%
probability that it is cost-effective.
The cost-effectiveness results depend heavily on the trial results and on the estimated lifetime costs and
benefits of screening, which were estimated from a meta-analysis of published studies. We find that our
results are not particularly sensitive to changes in the way evidence from the meta-analysis was synthesised,
for example using different checklists to attach quality weights to the studies made little difference overall.
TABLE 30 Cost-effectiveness results of the scenario analysis: interventions offered to entire eligible population of
England at first screening invitation
Intervention
Incremental cost
per woman (£)
Incremental cost
per woman
(main analysis) (£)
Incremental
QALYs
per woman
Incremental
cost per QALY
gained (£)
Incremental cost
per QALY gained
(main analysis) (£)
Pre-leaflet –2.69 –2.46 –0.00050 5412 4953
Online booking 2.18 2.38 0.00028 7654 8344
Requested SSK 5.97 5.93 0.00092 6480 6436
Unrequested SSK 50.33 48.68 0.00596 8438 8161
NN –9.40 –9.36 –0.00145 6474 6449
Timed appointment 37.38 36.66 0.00483 7741 7593
Combination 8.26 8.21 0.00113 7335 7290
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Chapter 4 Evaluating preferences of
non-responders to the UK Cervical Screening
Programme at first invitation: a stated preference
discrete choice experiment
Introduction
The success of any health-care programme depends on acceptability to, and engagement by, its intended
users. Understanding the views and preferences of potential users of a new health-care policy is vital for
assessing the potential future consequences of the programme. As a means of assessing preferences
for policies or programmes on the basis of their inherent factors or characteristics, DCEs offer a credible
approach and are increasingly being used in the health-care setting.41
Discrete choice experiments have been successfully conducted in the area of screening. Watson et al.,42
for example, used a DCE to examine women’s preferences for characteristics of chlamydia screening,
including the location of the test, the type of test and the support available when receiving results.
In the field of prostate cancer, de Bekker-Grob et al.43 used the approach to explore men’s preferences
for screening and to quantify the trade-offs between the benefits and costs of screening, including the
reduced risk of cancer-related death versus the increased risk of unnecessary biopsy in the event of a
false-positive screening test. DCEs have also been used to examine women’s preferences in cervical cancer
screening. In 2006, Wordsworth et al.44 conducted a DCE to explore women’s preferences for process
changes to the existing Cervical Screening Programme resulting from the introduction of new guidelines
and policies.
An important and upfront aspect of the STRATEGIC study was to evaluate young women’s preferences
for the hypothetical interventions to be trialled within phase 2 of the study to increase uptake at first
invitation within the context of the existing Cervical Screening Programme. These interventions included
pre-specified timed appointments, solicited and unsolicited SSKs, and a NN. For this purpose, a DCE was
designed to elicit the preferences of young women in Greater Manchester and Grampian who had not
responded to their first invitation to screening.
Methods
Using discrete choice experiments to explore individual preferences
Human beings consciously or subconsciously make choices in their everyday lives. Researchers interested in
exploring how individuals make choices between alternatives face methodological, theoretical and practical
challenges. It is very complex to find a theoretical model that explains exactly an individual’s decision-making
process, as this is highly variable among individuals.45 Researchers cannot get into people’s minds and
observe exactly what happens when a decision is made. Therefore, analysts need to find a strategy for
identifying, capturing and using as much as possible the information that an individual considers when
processing a scenario that leads to a choice. Because the analyst will never be able to identify all data and
information processed by an individual, there is always a margin for error. This error of measurement is an
important component of any choice model. There are two main alternatives that have been used to elicit
people’s preferences in the economic literature: revealed preferences (we observe the choices made by
people) and stated preferences (we directly ask people about their preferences).46 Revealed preferences can
be used only when an individual has made a real decision, and thus far in the context of novel and new
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therapies its use in health care has been very limited. Stated preferences have so far been found to be a
more appropriate strategy to obtain preferences for alternatives that individuals may or may not have
experienced in real life. To obtain preferences for different strategies to increase cervical screening uptake by
non-responders, we used a stated preference method called a DCE.47
A DCE is an elicitation technique to obtain individual preferences using a series of hypothetical choices.
DCEs are implemented using surveys that require a series of choices to be made between alternatives where
each alternative, although described using a set of common attributes (i.e. characteristics or traits), has
different values or levels for these attributes. Alternatives are usually presented in pairs known as choice
sets. For each choice set, individuals are asked to select which profile they prefer based on the information
presented. The response data from a DCE are analysed within a random-utility model using statistical
modelling for choice data, such as logit or probit models. A technical summary of the random-utility model
and the theoretical framework employed in this DCE study is presented in Appendix 12.
Development of discrete choice experiment attributes
A number of different methods can be used to obtain and develop attributes for DCEs including literature
reviews,48 expert reviews49 and focus groups or interviews.50 Experts in the field do, however, recommend
that qualitative work is conducted in order to develop such attributes47 and interviews are considered by
Coast et al.51 as providing the greatest ‘richness’ of attributes. A small qualitative study complemented
with the views from the qualitative and quantitative research teams was undertaken to identify the
attributes for this DCE exploring young women’s preferences for cervical screening programmes.
Participants and recruitment
A sample of women invited to take part in phase 1 of STRATEGIC was sent a participant information sheet
and consent form for this additional qualitative component alongside the main study documentation
(see Appendix 14). Those interested in being interviewed were asked to contact the STRATEGIC research
team or return a reply slip and consent form directly to the qualitative researchers. The intention was to
recruit a subsample of 20–30 women. We planned to use purposive sampling52 to ensure that we included
a mix of women who were being offered the three novel interventions (NN, SSK, timed appointments).
We also hoped to interview a mix of women who had taken up the offer of the intervention in the pilot
study and those who had declined. Over a period of 2 months (August–September 2012), only four women
(of approximately 600) responded to the invitation to be interviewed. All had been randomly allocated to
receive the unsolicited SSK through the post, although it was unknown prior to interviewing whether or not
they had used the kits. A second batch of invitations (to approximately 500 women) was sent out early in
2013, which resulted in one more woman (also allocated to unsolicited SSK) being interviewed.
Data collection
Semistructured telephone interviews were conducted and digitally recorded where consent was given.
The first part of the interview explored women’s views on the intervention they had received. For example,
whether or not they had used the intervention and, if yes, how had it gone and what did they like/dislike
about it. If they had not used the intervention we enquired why that was. The second part focused
on what the women felt about important features of a cervical screening programme to encourage
attendance, for example, timing, access, cost and who does the screening. These two sets of questions
were not considered to be mutually exclusive. It was expected that women’s views on a novel intervention
might usefully inform the identification of the attributes for the DCE. The topic guide followed during the
interview is provided in Appendix 13.
Data analysis
The audio-recordings were transcribed verbatim, with all personal data anonymised to ensure
confidentiality. The interview data were then analysed using deductive content analysis.53 First, a
categorisation matrix was developed in which the interview data were coded to (1) the views of the
intervention (initial reaction, understanding the instructions, likes and dislikes, what would encourage use)
and (2) features of a cervical screening programme (booking, screening, receiving results, cost). The coded
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data were then reviewed by the qualitative research team to identify key categories that captured women’s
views on the important features of a cervical cancer screening programme. ATLAS-ti software version 6
(Scientific Software Development GmbH, Berlin, Germany) facilitated data management.
Findings
Four key categories emerged, which are presented in Table 31. For the five women interviewed, issues of
flexibility, expertise, emotion and normalisation were important issues in encouraging/discouraging them to
attend for cervical cancer screening.
Using the qualitative study findings to inform the development of attributes
and levels
Consideration was then given to developing the identified categories and subcategories into attributes for
the DCE. Given the small number of interviews conducted, and from only one intervention group, it was
considered prudent to use these qualitative findings as the starting point of a series of discussions between
the qualitative and quantitative teams to determine the final number of attributes and levels for the DCE.
During initial attempts, we considered up to seven attributes: booking, convenience, flexibility, privacy,
expertise, personalised information and cost. Attempting to assign very descriptive labels to the levels of
each these attributes to remove any potential ambiguity proved problematic. Seven attributes, each with
three or four levels, was felt to be excessive, and in attempting to be so inclusive we found there were
some attributes that were inter-related. An example is privacy and expertise – an indication that the test
would be performed by a woman herself in private on the privacy attribute would automatically imply that
the test would be carried out by the woman herself on the expertise attribute. In addition, using detailed
labels for the level meant that the interventions themselves were identified as levels for each attribute,
rather than, as DCE methodology dictates, more generic attributes or characteristics that can apply across
all study interventions. As a result, the attributes and levels were simplified.
As the rationale for the study interventions was to make the process of screening more acceptable to
women, we looked at the way in which the intervention could achieve this. First, there were a variety
of approaches for arranging a screen. Simply, these could be classified as those interventions that required
some action on the part of the woman to arrange the test (e.g. calling to request a SSK) and those that
did not (e.g. a timed appointment is given). It was thought that some women may consider it important
whether or not action/effort is required to engage with the screening service. Second, all the interventions
offered the potential for the test to be conducted in different locations, namely at a health-care facility,
such as a GP practice or some other clinic (routine clinic smear), or in the woman’s own home (SSK).
Having just one attribute on location of the test would cover all potential aspects of privacy and expertise
that had been shown to be important to women during the interviews.
TABLE 31 Key categories and subcategories from the interviews with women
Category Subcategory
Flexibility l Of booking (online vs. telephone)
l Of the screening itself (fitting it into busy lives)
l Of accessing information (about the screening method as well as the results)
Expertise l Of the woman herself using a SSK vs. the health professional administering the test
l Of the health professional (experience in administering the test)
Emotion l Discomfort of doing the test (using a SSK or administered by a health professional)
l Embarrassment of having the test administered by a health professional
Normalisation/routine l Of providing information about cervical screening (to improve women’s knowledge)
l Of reminders for attending (using texting)
DOI: 10.3310/hta20680 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 68
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
51
In addition to these two characteristics that were relevant to all the study interventions, the role of the NN
also had to be considered. This role involved discussing screening with women and, if required, facilitating
access to a test (whether this be at a clinic or at home). It was felt that the NN could potentially be an
adjunctive option with any of the interventions and, therefore, it would be useful to include it as a
separate attribute.
Table 32 presents the proposed list of attributes and levels used in the DCE. Each attribute had two levels,
with the exception of the attribute relating to the cost of the test, which had four possible values reflecting
the approximate costs to the NHS of integrating each of the interventions under investigation into the
Cervical Screening Programme. This list was first tested during the pilot phase of the DCE and, where
necessary, based on the feedback received, amended for the main DCE study. Details of the pilot and main
DCE study phases are provided in First phase (pilot discrete choice experiment data collection) and second
phase (main discrete choice experiment data collection).
The combination of attributes and levels in Table 32 described potential interventions to increase uptake
to the screening programme. The aim of the DCE analysis was, hence, to identify which combination
of attributes and associated levels women prefer. The specific combinations of attributes and levels
presented in Table 33 identified the interventions under evaluation in the STRATEGIC study. We used
these combinations to identify the intervention with a higher probability of being selected after model
estimation. For example:
For a solicited SSK:
l The woman must take some action to request the test.
l The test is carried out at home.
l A nurse will not have been available for discussion or help prior to appointment.
l The cost of this option is approximately £8.00.
For the timed appointment:
l No action is required on the part of the woman to arrange the screen.
l The test is carried out at the GP surgery or clinic.
l A nurse will not have been available for discussion or help prior to appointment.
l The cost of this option is approximately £20.00.
Experimental design
A full factorial design using the attributes and levels in Table 32 resulted in 2 × 2 × 2 × 4 = 32 possible
profiles and 1024 (322) possible pairwise choice sets to select from. Given that it was impossible to ask a
respondent all the choice sets from the full factorial design, a selection of choice sets was generated using
a D-optimal method in Ngene 1.1.2 software (ChoiceMetrics, Sydney, NSW, Australia).54 This method is
designed to provide stated choice experiments with optimal statistical properties and to elicit the maximum
information from respondents to inform the estimation of model parameters.55–57 We based the choice of
TABLE 32 Proposed attributes and levels for a DCE design to obtain preferences for interventions to improve
screening uptake in non-responders
Main attributes Attribute levels
Action required by you personally to arrange a test Yes/no
Location of the test GP clinic or surgery/home
Nurse available for discussion or help prior to appointment Yes/no
Cost of your test to the NHS £8/£20/£25/£40
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the D-optimal approach on recent guidance about constructing experimental designs for DCEs.58 Only
main effects were considered, with non-linearities and interactions assumed negligible. Table 34 shows the
D-optimality levels for DCE designs with different numbers of choices. The figures indicated that the
marginal benefit of increasing the number of choices above 16 choice sets was minimal. We found little
guidance about the maximum number of choice sets that a person could endure in a single DCE survey,
but a recent study suggested that the number of choice sets depends on the complexity of the DCE study
and the context of the research questions.59 In our case, 16 choices might have been a large number to
ask our population as they are not taking up the offer of cervical screening. In addition, the qualitative
team already had struggled to recruit participants for their interviews and it was felt that non-responders
(the target population for this DCE) were a ‘hard-to-recruit’ sample. Therefore, a trade-off between
number of choices and D-optimality levels was made and 12 choice sets were selected for the DCE survey.
This provided a D-optimality level of 90.86%, which was still considered high. This would ensure that the
survey would be quicker to complete and likely to encourage participation and reduce missing responses.
The final 12 choice sets used in the DCE are presented in Table 35, with an example actual choice set
(in this case set number 1 in Table 33) presented to participants shown in Table 36.
Questionnaire design and data collection
Participants were given the option of completing a paper-based or online version of the DCE survey.
A copy of the paper-based version and the patient information leaflet prepared to accompany the survey
are presented in Appendices 14 and 15, respectively. Prior to the piloting phase, and to assess acceptability
and ease of completion, the questionnaire was given to female members of staff at the Health Economics
Research Centre within the University of Oxford to complete. Minimal changes to the questionnaire
wording were made as a result of this exercise. The DCE questionnaire comprised a section containing a
TABLE 33 Identification of interventions trialled in phase 2 of STRATEGIC, through combinations of attributes
and levels
Attribute and level
Intervention
Timed
appointment
Solicited
SSK
Unsolicited
SSK NN
Action required by you personally to arrange a test
Yes? ✓ ✓
No? ✓ ✓
Location of the test
GP surgery/clinic ✓ ✓a
Home ✓ ✓ ✓b
Nurse available for discussion or help prior
to appointment
Yes? ✓
No? ✓ ✓ ✓
Cost of your test to the NHS
£8 ✓ ✓
£20 ✓b
£25 ✓
£40 ✓a
a NN+ clinic test.
b NN+ SSK.
DOI: 10.3310/hta20680 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 68
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
TABLE 34 D-optimal designs
Number of choices D-optimality levels (%)
8 0.17
12 90.86
16 97.21
20 95.16
40 97.21
52 96.12
60 96.40
80 97.21
Bold value indicates lowest number of choices with highest optimal level.
TABLE 35 D-optimal design with the 12 final choice sets used in the DCE
Choice set
Choice
1 2
Action Location Nurse Cost (£) Action Location Nurse Cost (£)
1 No Home No 40 Yes GP Yes 8
2 Yes GP Yes 20 No Home No 25
3 No GP No 8 Yes Home Yes 20
4 No Home Yes 20 Yes GP No 25
5 No Home Yes 25 Yes GP No 40
6 Yes Home Yes 25 No GP No 40
7 No GP No 40 Yes Home Yes 8
8 Yes Home No 8 No GP Yes 20
9 Yes GP No 25 No Home Yes 40
10 No GP Yes 8 Yes Home Yes 20
11 Yes Home No 20 No GP Yes 25
12 Yes GP Yes 40 No Home No 8
TABLE 36 Example of choice set
Feature
Choice
1 2
Action required by you to personally arrange a test No Yes
Location of your test Home GP surgery/clinic
Nurse available for discussion or help prior to appointment No Yes
Cost of your test to the NHS £40 £8
Which choice do you prefer?
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number of choice scenarios that incorporate the attributes and levels developed from the qualitative analysis
presented above, a section on women’s general views about the value of the current Cervical Screening
Programme and a section where women ranked each of the four attributes in order, from most important
to least important. The questionnaire also included questions on basic demographic information such as
age, education and employment status. Women were also asked about any difficulties encountered when
completing the DCE questionnaire and were given the opportunity to feed back any additional comments.
The English and Scottish screening agencies, in conjunction with the STRATEGIC research study team,
identified non-responding women who were eligible to participate in the DCE study and sent a participant
information leaflet, the paper-based version of the survey and a Freepost return envelope. As women
had the choice of whether to complete the paper-based version or the DCE online, the web link for
the online version was provided in the patient information leaflet and the paper-based version.
A custom-made online survey was developed using the open source application LimeSurvey
(www.limesurvey.org). The online version was an exact replica of the paper-based version. The online
version was tested thoroughly before, and during, the pilot study phase to minimise any potential
problems during the main data collection. The web version complied with the required information
governance standards of the University of Manchester and University of Oxford to ensure anonymity
of responders and compliance with data protection. To ensure anonymity, a token number was created in
LimeSurvey for each potential participant. Participants had to use this token number to access and
complete the online survey. When the system recognised that a token had been introduced, it recorded
only that the number had been used and not any other information about the participant. The token
number was also included in the paper-based version. Once a token was used and a survey was
completed, participants were not able to access the survey again.
To encourage participation in the survey, women were offered a £10 high-street voucher as an incentive.
In order to claim the voucher, an online form was created and the web address to access the form was
included in the patient information leaflet and paper-based survey.
First phase (pilot discrete choice experiment data collection) and second phase
(main discrete choice experiment data collection)
In a first phase, a pilot study was conducted from July 2014 to September 2014 to assess the working
interface between the English and Scottish screening agencies, and the STRATEGIC study research team.
During this period, we also assessed the robustness of the online survey and the likely response rate for
the second phase (main data collection). A total of 1000 questionnaires were sent to women in Greater
Manchester (n = 650) and Grampian (n = 350) during this period.
The feedback from the pilot suggested that communications between the parties was clear and that the
same arrangement could be used with no modifications in the main study. The online survey also worked
well and no major issues were identified. The response rate was low (as described in detail in Results) but,
overall, women felt that they completed the questionnaire without difficulties. Some women reported that
it was not clear when the nurse would be available to help, so the words ‘prior to appointment’ were
added to the description of the attribute for the second phase. We consulted a colleague with extensive
experience in population surveys about possible additional ideas to improve the response rate during the
main data collection. It was clear that there were difficulties in reaching the population of interest and
it was recommended that the look of the questionnaire could be improved, ideally with the assistance
of a graphic designer. This was undertaken and the final questionnaire is presented in Appendix 14.
The research team also decided to maintain the £10 voucher during the main DCE data collection.
No other changes to the questionnaire were made between study phases. The data from the pilot were
entered once and subsequently checked by the quantitative STRATEGIC study research team.
The main DCE data collection (second phase) was carried out between mid-July 2015 and mid-September
2015, and 3000 questionnaires were circulated to women in Greater Manchester (n = 2000) and Grampian
(n = 1000) during this period. Double data entry of paper responses received was used during this phase.
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Sample size
Sample size calculations in statistics are traditionally used to minimise biases and ensure generalisability to
the population of interest. There are approximately 300,000 women in England and 30,000 women in
Scotland who are eligible to be screened for the first time every year. The STRATEGIC study cohort
suggested that around 70% of women do not respond to the first invitation, resulting in 210,000 and
21,000 non-responder women in England and Scotland, respectively. With these figures, obtaining a
representative sample size of the preferences of women to the Cervical Screening Programme would be
very expensive using traditional sampling theories. Therefore, sample size calculations in stated choice
experiments take a different angle: to identify the minimum number of choice observations needed to
obtain reliable parameter estimates for discrete choice models using stated choice data. The latter approach
is described in a recent paper60 and was used in this study. Briefly, the method suggests that, if prior
information on the coefficients of a discrete choice model is available, it is possible to identify the theoretical
minimum sample size (called S-error) required for a design. This is achieved combining the asymptotic
variance-covariance matrix from the experimental design with the available prior information and specifying
a significance level that normally corresponds to 5% and a t-ratio of 1.96. We used the information from
the pilot phase to estimate the prior coefficients associated to each attribute using a conditional logit
without a constant, as suggested by Rose and Bliemer.60 The S-error was estimated to be 1154, but we also
evaluated the minimum sample size requirements for each parameter separately. Figure 20 shows the
asymptotic t-ratios for different sample sizes associated with each of the attribute coefficients, with the
dashed line indicating a t-ratio of 1.96 (e.g. a coefficient significantly different from 0 at 5% level).
The figure suggested that, with sample sizes > 150, we were able to estimate significant parameters in the
action, nurse and cost attributes but not on location. To obtain a significant parameter in the location
attribute using our prior information we needed to obtain the sample identified as S-error = 1151. This
information was very useful for the team to understand; given the response rate in the pilot study, it still
appeared possible to obtain significant coefficients using the data from the second phase. As the prior
information was based on a small sample of women, the results from this analysis were used for guidance,
but did point out that a minimum sample size of 150 was needed to reliably estimate three attribute
parameters. It was uncertain at that time whether or not the parameter for the attribute location was
going to be significant with that sample size.
Statistical analysis
Descriptive statistical analyses were used to present participant demographic information, women’s views
of cervical screening in general and any feedback about the stated choice questions. Choice data were
analysed first using a conditional logit, and the reader is referred to Appendix 12 for its theoretical and
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FIGURE 20 Asymptotic t-ratios for different sample sizes for each parameter in the discrete choice model.
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formal derivation to analyse DCE data. One of the main criticisms of this model is the assumption of
independence of irrelevant alternatives, which states that the ratio of the probabilities of choosing one
alternative over another does not change with the introduction of a new alternative or the removal of an
existing one.47 We therefore also estimated a multinomial conditional probit that relaxed the independence
of irrelevant alternatives assumption. Conditional logit and probit models are analysed using maximum
likelihood estimation methods, but the former assumes a standard logistic distribution of errors, whereas
the latter assumes a normal distribution. In addition, the multinomial conditional probit allows for a general
covariance structure in the errors and hence does not impose the independence of irrelevant alternatives
property present in conditional logistic models. The coefficients from logit and probit models are difficult to
interpret directly, but the signs associated to each coefficient have a more straightforward interpretation.
A positive coefficient means that an increase in the attribute leads to an increase in the predicted probability
of selecting a particular scenario. A negative coefficient means that an increase in the attribute leads to a
decrease in the predicted probability. The aim of the choice model was to identify the effect of each
attribute level on women’s preferences for potential interventions to increase the uptake to the Cervical
Screening Programme. The levels for action, location and nurse were defined using dummies, whereas the
cost variable was included as a continuous variable. The ‘no’ level was used as the reference level for the
action and nurse attributes and ‘home’ was used as the reference level in the location attribute. Costs were
expressed in 2013/2014 UK pounds. A main-effects specification, using attribute levels only and main
effects plus women characteristics, was evaluated in the models. The latter model was used to determine
any propensity to select a particular scenario in the choice set given the characteristics of the participants.
In our unlabelled DCE, it was expected that all these covariates would be non-significant and that the final
model would be either the main-effects conditional logit or probit. Characteristics were included as binary
dummies (0/1) in the model (i.e. employed vs. other current main activities or higher education vs. other
highest level of education). Robust standard errors associated with attribute coefficients were estimated
in recognition that each participant completed 12 choice scenarios. The final selected model was based on
the model specification that yielded best goodness-of-fit measures (lowest value) based on the Akaike
information criterion (AIC) and the Bayesian information criterion (BIC). The coefficients of the final selected
model were employed to predict the probability of selecting each of the STRATEGIC study interventions,
identified in Table 33, as potential strategies to increase screening uptake. All analyses were carried out in
StataMP version 13 (StataCorp, College Station, TX, USA).
Results
Response rate and final sample size
Figure 21 describes the flow of women through the study. The left-hand side presents figures for the pilot
DCE data collection and the right-hand side for the main DCE data collection. In total, 4000 questionnaires
were sent out. Figure 21 shows that response rates were similar for both phases at around 5.5%, as were
the proportion of respondents from Greater Manchester and Grampian. In both phases, the majority of
respondents also chose to complete and return the paper-based version of the questionnaire. There was a
general concern that using only data from the second phase would risk obtaining a reasonable sample size
to estimate the models as indicated in Sample size. Changes made to the DCE from the first to second
phase were minor and the same experimental design was used in both phases with the only amendment
of adding the words ‘prior to appointment’ to the nurse attribute. Therefore, data from the first and
second phases were combined to obtain a final sample size of 222 responses.
Characteristics of the sample
Table 37 describes the characteristics of the 222 participants in the stated choice questionnaire study.
Almost three-fifths were from England and two-fifths from Scotland, and the mean overall age was
24.6 years. Women from Scotland were, on average, 4 years younger than women from England,
reflecting the lower age at which women are first invited for cervical screening in Scotland (20 years vs.
24.5 years). The majority of women (86.4%) were of white ethnicity, with women of Pakistani, Indian and
African descent making up a further 9%. Almost half of the respondents had been educated up to a
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Questionnaires
circulated in the pilot
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(n = 1000)
Questionnaires
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(n = 946)
Questionnaires
received
(n = 54)
Response rate = 5.4%
Questionnaires
received
(n = 168)
Response rate = 5.6%
Questionnaires
not received
(n = 2832)
Questionnaires
circulated in the main
DCE
(n = 3000)
Full responses
(n = 222)
Final response rate = 5.5%
Study site
Elicitation method
• Postal, n = 43 (80%)
• Online booking, n = 11 (20%)
• Greater Manchester, n = 29 (54%)
• Grampian, n = 24 (44%)
• Rather not say, n = 1 (2%)
Study site
Elicitation method
• Postal, n = 121 (72%)
• Online booking, n = 47 (28%)
• Greater Manchester, n = 98 (58%)
• Grampian, n = 68 (40%)
• Rather not say, n = 2 (1%)
FIGURE 21 Flow diagram of women’s participation through the study.
TABLE 37 Description of the sample (n= 222)
Variable Frequency
Country, n (%)
England 127 (57.2)
Scotland 92 (41.4)
I’d rather not say 3 (1.4)
Age (years), mean (SD) 24.6 (2.5)
England 26.4 (0.9)
Scotland 22.1 (1.8)
Missing 6
Ethnicity, n (%)
White British/Irish 174 (79.5)
Any other white background 15 (6.9)
Pakistani 11 (5.0)
Other 9 (4.1)
Indian 4 (1.8)
African 4 (1.8)
Bangladeshi 1 (0.5)
I’d rather not say 1 (0.5)
Missing 3
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university level, and a further 40% had either studied to the age of 18 years or undertaken vocational
qualifications. Just 6% of women had left school aged 16 years and 5% chose not to disclose information
on their education levels. In response to the question on main activity, 57% of women reported being in
employment, just over one-quarter were undertaking full- or part-time studies, and 8% were homemakers
looking after their families. The percentage of women who were unemployed, undertaking voluntary
work, or who were long-term sick or disabled was 3.2%, 1.8% and 1.8%, respectively.
Women’s views of cervical screening
To gauge women’s views of cervical screening in general, respondents were presented with the statement
‘screening for cervical cancer is important’, and were asked to select one of the following responses:
strongly agree, agree, neither agree nor disagree, disagree or strongly disagree. Figure 22 shows that,
despite not attending for their screen, almost two-thirds of responding women strongly agreed with the
statement that screening for cervical cancer is important, and a further 30% agreed. A total of 4.5% of
women appeared indifferent, and just 1.8% disagreed that screening for cervical cancer is important.
Ranking of attributes
When asked to rank each of the four attributes included in the DCE in order from most important (rank 1)
to least important (rank 4). Figure 23 shows that most women identified the location of the test as being
most important (93/204, 46%), whereas others were most concerned about whether or not they personally
needed to take any action to arrange a test (63/204, 31%) or whether or not a nurse was available as part of
the screening process (34/204, 17%). Although a small number of women (14/204, 7%) considered the cost
to the NHS to be most important, for most women (91/204, 45%) cost was the least important attribute.
Stated choice data analysis
Table 38 provides a summary of the proportion of participants selecting choice 1 across the 12 choice sets
as presented in Table 35. There was a clear trend to select choice 1 in scenarios 4–6 and 10, and a trend
to select choice 2 in scenarios 1 and 7. These results provided some insight about the interpretation of the
constant in the modelling results in the next table.
TABLE 37 Description of the sample (n= 222) (continued )
Variable Frequency
Highest level of education, n (%)
University 108 (48.7)
Further education to age 18 years 47 (21.2)
Vocational qualifications 44 (19.8)
School leaver at age 16 years 13 (5.9)
I’d rather not say 10 (4.5)
Main activity
Employed 127 (57.2)
Student (full- or part-time) 57 (25.7)
Homemaker looking after the family 18 (8.1)
Unemployed and seeking work 7 (3.2)
I’d rather not say 5 (2.3)
Unpaid voluntary work 4 (1.8)
Long-term sick or disabled 4 (1.8)
SD, standard deviaton.
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FIGURE 22 Responses to the statement ‘screening for cervical cancer is important’.
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FIGURE 23 Ranking of four attributes (action required to arrange a test, location of test, nurse available for help
and advice, and cost of test) from most (1) to least (4) important. Denominator is 204, as 18 participants did not
complete this question in the survey.
TABLE 38 Number of participants completing the choice scenario and proportion of participants selecting choice 1
across the 12 choice scenarios
Choice set Number of participants completing the choice scenario Proportion selecting choice 1
1 221 0.276
2 219 0.553
3 221 0.498
4 220 0.8
5 220 0.855
6 220 0.791
7 222 0.176
8 221 0.561
9 219 0.516
10 222 0.712
11 221 0.466
12 221 0.371
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The results of the conditional logit and multinomial probit models using main effects and main effects plus
selected women characteristics are presented in Table 39. The table reports the coefficients, associated
standard error and p-values for each attribute or women characteristic. It also reports information about
the goodness of fit to assist in the identification of the final selected model. For both types of models
there were marginal improvements in terms of the AIC and BIC using the probit model, although model
coefficients were similar between both model types. As expected, including women’s characteristics in the
main-effects models did not add any significant information as all demographic coefficients were not
significant in both models. Given the lower AIC and BIC, our final selected model for our stated choice
data was the multinomial probit model with main effects. The coefficients in the selected model indicate
the contribution of each attribute to the probability of selecting a particular scenario (described by a
combination of levels for the four attributes). Negative coefficients indicate that women preferred these
attributes to take lower values for continuous variables (costs) or preferred the reference attribute for
qualitative attributes (action, location and nurse). For example, the signs for the main-effects attributes
were significant (p < 0.001), suggesting that women preferred scenarios where minimal personal action
was required to arrange a test, the test was done at home, there was a nurse available for discussion or
help, and the test was cheaper to the NHS. The constant was statistically significantly different from
0 indicating that potential sources of utility were not captured by the information in the DCE or a potential
bias towards selecting always choice 1 in the choice set.
The coefficients from the main-effects probit model were employed to estimate the probability of selecting
each of the interventions assessed in the STRATEGIC study based on our choice data and are presented in
Table 40. The intervention with a higher probability was the unsolicited SSK, with an estimated figure of
0.263. Although no intervention clearly dominated, strategies involving SSKs accumulated > 75% of the
total joined probability across all interventions. This seemed to indicate that women had a clear preference
for interventions that include the SSK.
Feedback discrete choice experiment survey
Discrete choice experiments have previously been criticised by respondents for being difficult to understand
and to complete. To explore if this was the case within the context of the STRATEGIC study DCE, women
were presented with each of the three statements shown in the first row of Table 41 and were asked to
indicate whether or not they were in agreement, using the same five categories given in the preceding
question on the importance of screening.
Table 41 shows that 86% of respondents agreed or strongly agreed with the statement that the questions
were easy to understand, and just 5% disagreed or strongly disagreed. Over three-quarters of women
agreed or strongly agreed that the difference between the choices on each question was clear, although
around one-fifth of women appeared unsure, reporting that they neither agreed nor disagreed. In response
to the statement about it being easy to make a choice on each question, two-thirds of women agreed or
strongly agreed, and around one-fifth again appeared unsure. Almost 15% of women disagreed or strongly
disagreed with the statement that it was easy to make a choice on each question.
Women were also given the possibility of writing any comment about the stated choice questions or any
other aspect of the questionnaire using a free-text box. The literal qualitative comments received during
phases 1 and 2 are presented using themes in Appendix 16.
Discussion
This chapter has described the design, conduct and reporting of a DCE undertaken to elicit women’s
preferences for interventions with the potential to be embedded in the current NHS Cervical Screening
Programme to increase the uptake of screening among young, non-responding women.
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The stated choice experiment aimed to generate information on women’s preferences for each of the
interventions under evaluation in phase 2 of the STRATEGIC study, with a view to providing some insight
into if they might be effective at improving uptake among non-responders. The results from the modelling
exercise suggested that women preferred scenarios where minimal personal action was required to
arrange a test, the test was done in the privacy of their own homes, there was a nurse available for
discussion or help and that involved less cost to the NHS. The selected probit model predicted that
interventions with a SSK were preferred and could potentially result in a higher probability of increasing
uptake of screening than with interventions without the SSK. These results were in line with the
information obtained in the qualitative phase of the study about potential aspects of privacy and expertise
and are briefly considered in light of the trial results in Chapter 5. Comparing stated and revealed
preferences is a very interesting issue that has received little attention in the literature.
Despite not attending for their screening test, around 94% of women agreed or strongly agreed with the
statement that screening for cervical cancer is important. This finding can be interpreted as meaning that
they consider it important to women personally or a more general view that screening is a worthwhile
activity for the NHS and the UK population. Although we cannot determine which interpretation is the
correct one, either view highlights that screening for cervical cancer from a personal or a societal
perspective was highly valued by the participants.
To our knowledge, this is the first attempt to elicit preferences from non-responding women in the
Cervical Screening Programme in the UK. Although DCEs in general are becoming increasingly common,
few have been conducted in the area of cervical cancer screening.41 One previous stated choice exercise in
the area elicited women’s preferences for changes to the screening programme, which resulted in
reduced recall rates and waiting times for results and varying screening intervals by age.44 That study,
however, primarily included women who had previously attended for screening, and consequently the
results obtained in the STRATEGIC trial and this stated preference study should be considered as
providing the most current evidence about preferences of non-responding women in the Cervical
Screening Programme in the UK.
TABLE 40 Probability of selecting each of the STRATEGIC study interventionsa
Timed appointment Solicited SSK Unsolicited SSK NN and SSK NN and clinic test
0.130 0.234 0.263 0.256 0.117
a The sum of all probabilities adds to 1.
TABLE 41 Opinions on understanding of questionnaire and ease of completion
Levels of opinions
The questions were easy
to understand, n (%)
The difference between
the choices on each
question was clear, n (%)
It was easy to make
a choice on each
question, n (%)
Strongly agree 70 (31.5) 66 (29.7) 47 (21.2)
Agree 121 (54.5) 103 (46.4) 100 (45.0)
Neither agree nor disagree 20 (9.0) 42 (18.9) 43 (19.4)
Disagree 9 (4.1) 7 (3.2) 30 (13.5)
Strongly disagree 2 (0.9) 4 (1.8) 2 (0.9)
Total 222 (100) 222 (100) 222 (100)
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This study attempted to adhere at all times to good practice guidelines for conducting DCEs for both its
qualitative and quantitative components, supporting the robustness of the results obtained,47,51,53,58
but there are several limitations worth noting.
During initial discussions about the inclusion of the DCE within the STRATEGIC study, the challenges around
attempting to elicit responses from a cohort characterised by their very non-responsiveness, was well
recognised. This was solidly verified during the qualitative and quantitative data collection phases.
Identifying these women was challenging and could only be facilitated by the English and Scottish Cervical
Screening Programmes who also managed the questionnaire mail-out for reasons of patient confidentiality.
The study team, therefore, had no access to any individuals’ information at any time. Prior to committing to
the main survey, a pilot survey was conducted to test the feasibility of this approach, and showed the
screening programme mail-out to work well. Without access to patient information, this approach precluded
the use of reminders by the research team, which might have been capable of increasing response rates.
The issue of poor response rate was also highlighted in the study by Wordsworth et al.,44 which targeted a
cohort of women of screening age who had or had not previously attended for screening. In that study,
although the response rate among women who had previously been screened was 44%, the rate for those
who had never been screened was just 8%, despite two reminders being sent. This again highlights the
difficulties involved in reaching and engaging with women who choose not to attend for screening.
Other attempts were also made to maximise response rates. A professional design team was involved to
improve the look and the attractiveness of the questionnaire, which was also offered to women in both
paper and online formats (the thinking being that young women might prefer online submission). In
addition, women were also offered an incentive in the form of a £10 shopping voucher. Despite these
attempts, the number of respondents was still low, at around 5.5% of the 4000 women mailed. It is
therefore necessary to acknowledge that the findings presented in this chapter may not necessarily be
generalisable to the population of young, non-responding women as a whole. For example, the educational
attainment and social class may be higher than the general population of non-attenders. The findings are,
however, intuitive, in line with prior expectations and show clear preferences for the attributes of
interventions designed to overcome the well-documented reasons for non-attendance at screening.4,61–64
An ‘opt-out’ question with the choice ‘not to screen’ was not included as part of the experimental design
in the DCE survey. Cervical screening is an area where women can choose not to be screened, as was the
case with the target population in this study. Including an ‘opt-out’ question would have made sense if
the aim of the study had been to evaluate whether or not cervical screening was a worthwhile activity
for the NHS. In this case, women had already stated a preference; they had decided not to attend. The
objective of our study was to obtain information about the trade-offs between attributes so that we could
gain insight into the most likely combination of attributes that would encourage women to participate,
and not if the Cervical Screening Programme itself was a worthwhile activity. Although an opt-out version
could have been a realistic alternative in our study design, if selected we would not have known why
women had chosen that option. Therefore, in our DCE we excluded an opt-out option forcing a choice but
included a question in the survey about views on the Cervical Screening Programme and whether or not
interventions such as those described in the survey would encourage personal participation.
The final selected choice model estimated a significant constant indicating the possibility that potential
sources of utility were not captured by the information of attributes and levels included in the DCE or a
propensity to select choice 1 in the stated choice survey. It is possible that we have excluded additional key
attributes for these women but, as described in the qualitative component of this report, a trade-off
between an extensive list of attributes and minimising missing responses had to be made. Given the results
of the STRATEGIC trial, and those reported here, we are confident that at least the attributes included in
our DCE have captured an important proportion of the information processed by women when selecting a
particular choice scenario. Related to a potential propensity to select choice 1, it is true that the descriptive
analysis showed that women, on average, selected choice 1 in more scenarios than choice 2. Most of
these scenarios, however, identified interventions for the SSK and hence this was not surprising. It has
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been previously recognised that D-optimal designs may result in an experiment with a particular attribute
level dominating the exercise.54 It is therefore possible that our experimental design was not optimal in
terms of utility balance (i.e. equally attractive options within choice sets) but optimal in terms of level
balance, orthogonality and minimal overlap.65 In addition, all the estimated models with main effects and
women characteristics suggested that none of the covariates (including the constant) was statistically
significant. This indicated that, when controlling for respondent’s characteristics, no potential propensity to
choose a particular scenario in the choice set was observed.
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Chapter 5 Discussion
The STRATEGIC trial has shown that a variety of interventions designed to increase uptake of cervicalscreening in young women receiving their first invitation exerted little impact when compared with
controls. With the exception of sending unrequested SSKs and being given timed appointments, women in
practices who were offered these interventions had similar participation in screening when compared with
control practices. This applied both to women at the time of their first standard invitation and to those
designated as non-attenders 6 months after the invitation.
The pre-leaflet designed to increase preparedness to be screened was ineffective. Online booking, SSK and
timed appointments were adopted by a number of women who might otherwise not have been screened.
The finding that the control group demonstrated an unexpectedly persistent uptake over time, as well as
the data on the type of SSK preferred, were helpful in interpreting the significance of participation
following phase 1 and phase 2 interventions.
This was a challenging study in several respects. It relied heavily on a third party (i.e. the NHS screening
agency) to provide access to the trial interventions, to women invited for screening in some cases by direct
mailing of samplers and in others by mailing additional information. This arm’s-length approach did
achieve a realistic operational setting for this type of research and utilised routine data in a large complex
clinical trial. The disadvantage was the indirect nature of contact, which resulted in dependence on the
goodwill of the screening agency and the inherent interest of women in facilitating the research. Further
challenges were that we were trying to reach women in phase 2 who had shown an initial lack of
enthusiasm for screening, and operationalising new interventions that had not been fully implemented
prior to the study.
Strengths and weakness
The strengths of this study included the following: (1) it was a large study in a real-world context;
(2) it tackled a hard-to-reach group and attempted several novel interventions; and (3) it had control
practices for comparison.
The weaknesses of the study included the following: (1) the interventions had to be administered at arm’s
length by the investigators – administration by primary care staff may have exerted more influence;
(2) online booking was not professionally set up and was not as widely accessible as we would have
wished; and (3) as acknowledged earlier, the DCE relied on too few survey responders.
A further limitation of the design was that precisely interpreting the effect of the interventions among a
broader age range is not possible.
Phase 1: pre-leaflet and online booking
Our expectation from historical screening data was that only 25–30% of invited women of this age would
have been screened 6 months following the initial standard invitation. This was indeed what occurred in
the STRATEGIC study, with the pre-leaflet control group demonstrating 30.6% uptake at 6 months.
The rate of uptake over time shown in Figure 4 shows that women appear to attend for screening over a
protracted period, which continued beyond phase 1 and throughout the duration of the study. The lack of
impact of the pre-leaflet is striking with the Kaplan–Meier curves for the pre-leaflet and no pre-leaflet
group virtually overlying each other (see Figure 4). Pre-leaflets have been shown to be of some benefit in
bowel cancer screening. In a randomised study reported from Scotland, a pre-leaflet was associated with
increased uptake among both high- and low-uptake groups,7 the authors attributing this effect at least in
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part to the health belief model,66 with the letter acting as a cue and increasing preparedness to participate
in screening. In an Australian study,6 a so-called advanced notification letter ahead of the standard
invitation for bowel cancer screening was associated with a 25% greater uptake than the standard
invitation alone. These authors cited the transtheoretical model in suggesting that simply increasing
awareness may move people from contemplating (screening) to action. Direct comparisons with bowel
screening may not be appropriate, however, as the latter involves a much older age group, and the
process is a private one. The reason for lack of impact by our pre-leaflet is not clear, despite its content
being based on views expressed to us by young women at focus groups on cervical screening.
It may be that for a substantial proportion of young women cervical screening is not a priority, while
others may appreciate the rationale for screening, and those who intend going for a screen will go
eventually. For some, they are at a pre-contemplation stage and proceeding to action depends on a
decisional balance.67 For the woman who does not feel at risk of cancer, the perceived effect size of
attending for cervical screening may be insufficient to push them into taking action.
Online booking
We had considered that the facility to book online would appeal to young women who are used to this
process in other areas of life. It might have been expected that this would prompt a more rapid response,
but it had no such effect. The Kaplan–Meier curve indicates a similar rate of uptake until 3 months, when
a routine reminder is sent from the screening agency, and at which point there did appear to be a net
uplift in screening among those offered online booking, although only 2.4% actually booked online. The
actual absolute difference was 0.53% at 3 months, rising to 2.18% at 6 months. Although this does not
achieve statistical significance, it should be borne in mind that this offer through just three family planning
clinics was tested only in the Manchester cohort, where the control uptake was actually less than the
STRATEGIC study cohort as a whole (26.3% vs. 30.6%). It may also be that some women would feel
negatively about attending at a sexual health clinic. It seems possible, therefore, that wider access and
more professional presentation could prove a more popular means of booking a screening appointment,
but it would not seem an effective way of achieving increased uptake. A number of general practices do
offer online booking of appointments, although not necessarily for cervical screening. Aside from the
appeal of online booking, it does have the potential to make booking more efficient and avoid the
disincentive of booking a practice appointment by telephone, which can be frustrating. Of course, even if
online booking cuts out hassle, it does need to offer times that are convenient to women. Bookings were
made throughout the day, but only two-thirds of women who made an appointment online actually
attended. The one-third non-attendance rate represents a waste of resources.
Effect of prior human papillomavirus vaccination
One of the concerns expressed by professional groups when the HPV vaccination policy was being
implemented was that young women may overestimate the degree of protection provided by vaccination
and may disregard the benefit of cervical screening, with the effect that fewer women would attend.
Although the age of starting cervical screening in Scotland is planned to rise to 25 years, it remains at
present 20 years, which provided an opportunity to study uptake among young women in Grampian
according to their vaccination status. The vaccinated women in the STRATEGIC study were from the
catch-up campaign, which is reflected in the fact that 27.2% had not been vaccinated, a higher proportion
than in the schools-based programme for 12- to 13-year-olds. There was, in fact, a very striking difference
among those who had no vaccination and those who had been fully vaccinated. Of course, lack of
vaccination in this setting could be associated with social deprivation because the catch-up campaign did
carry a greater risk of not accessing disadvantaged children than was the case with the schools-based
programme for 12- to 13-year-olds. A similar finding68 of greater uptake of cervical screening among
vaccinated women was recently reported from Sweden among women aged 25–35 years. A recently
published Scottish study69 found that the rate of uptake among unvaccinated women was only 65% of that
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among vaccinated women. Furthermore, the decline in screening seen between the 1988 and 1993 birth
cohorts was compensated for by the increase in screening among vaccinees. Whether or not this observed
screening uptake among vaccinees and non-vaccinees will be seen in England, where cervical screening
begins 5 years later, remains to be seen. If the pattern is mainly associated with social class, it may well
follow the same trend. If it were associated more with increased awareness, this may diminish with longer
passage of time. Although the OR was smaller in Sweden, it remained significant after adjusting for
socioeconomic status. These data suggest that, rather than making young women complacent about
protection from cervical cancer, screening has increased their awareness of the need to be protected.
Another recent study in the UK has reported a significant rise in return to screening among mothers of
vaccinated daughters, underscoring the positive impact of HPV vaccination on cervical screening uptake.70
This provides reassurance that uptake among women may increase throughout the UK population, an
effect that may be seen in England as early as 2016/17. The increased odds of being screened by 6 months
that was noted in Grampian compared with Greater Manchester could be related to a vaccination effect,
or it may be related to other factors, such as a higher overall uptake of screening in Grampian than in
Greater Manchester.
Phase 1 interactions and moderators
The lack of interaction between pre-leaflet and online booking in phase 1 was not surprising not only
because the pre-leaflet appeared to be ineffective, but also because the two interventions are unrelated.
The pre-leaflet intervention showed no significant interaction effect with either the location (Grampian vs.
Greater Manchester) or the vaccination status, indicating no differential pre-leaflet effect in locations or
cumulative effect with vaccination status. It is interesting, however, that the Grampian cohort uptake was
significantly greater overall during phase 1 (33.5% vs. 30.1%; OR 1.275, 95% CI 1.33 to 1.44; p ≤ 0.001),
suggesting that awareness from the vaccination programme or lifestyle factors of the differing age groups
may play a part. The differing location effect should be interpreted with caution, the differing method
of acquiring practice baseline attendance rates for Greater Manchester and Grampian meant that the
covariate had to be removed from the model. Here, failure to adjust for differential baseline rates may bias
the effects.
Phase 2
The phase 2 cohort constituted the non-attenders from the phase 1 cohort, and it might have been
expected that they would have been more ‘resistant’ to screening. In fact, 27.5% (2788/10126) of
non-attendees in phase 1 had undertaken a screening test by 18 months in phase 2, a proportion very
similar to the 30.9% at 6 months post phase 1. This can be seen in the phase 2 Kaplan–Meier curve,
which shows a steady and continuous uptake (see Figure 7), almost half of which was achieved in the first
6 months following the interventions, and half subsequently. It is true that the duration of follow-up in
phase 2 was longer; nonetheless, it demonstrates that attendance at screening, at least for these young
women, is more of a continuous process and less of a prompt response to an invitation. This has not been
as clear before, at least following routine invitations. Women who required early recall for mildly abnormal
cytology prior to HPV triage were known to respond very variably, often requiring several reminders. It
would seem that women do not feel the need to attend promptly, but that they do eventually feel that they
should attend. The ‘nudging’ effect of the interventions in phase 2 may have some effect, but does not
appear to explain this phenomenon fully because, although some practices in the control group will send
their own communication to women, others may not. Additional ‘nudging’ may be provided by GPs who
notice when women consult them for unrelated issues that cervical screening is overdue. Other potential
nudges are intermittent campaigns run locally. The screening agency does inform GPs of non-attenders, but
it is not mandatory for practices to send further reminders after 6 months. We do not have comprehensive
data on what general practices do after 6 months’ non-attendance.
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As far as the individual phase 2 interventions are concerned, the odds of being screened were significantly
greater at both 12 and 18 months with SSKs being sent out unsolicited. SSKs being offered was ineffective
either as a stand-alone offer or as part of a choice between it and a NN. The NN intervention performed
most poorly and at 18 months was actually detrimental. Timed appointments were associated with
increased uptake at 12 and 18 months’ follow-up. SSKs sent and timed appointments appear to emerge
as the only interventions that were associated with an increase in uptake, and that uplift was only 5% and
3.6%, respectively, at 12 months and about half of that by 18 months compared with the control group.
In terms of the entire population invited for screening this would represent around 1.5% uplift in absolute
terms as phase 2 included only 70% of the entire invited cohort.
Another insight into uptake of screening in the STRATEGIC study is that women did not react directly to
interventions, in the sense of specifically choosing what was offered. For example, the majority of those
who were screened following a SSK being sent, did not actually send in a sample for HPV testing, but
simply attended for a cytology sample to be taken. This is a significant finding and does suggest a
‘nudging’ effect.
With regard to timed appointments, although we have data on the actual number of timed appointment
requests sent to GPs, we do not know the number that were actually offered to women by GPs, or the
number of these that women attended. It is, therefore, not possible to assess what proportion of women
who were screened after receiving a timed appointment actually attended that appointment, which is
relevant to their cost-effectiveness. Evidence supporting timed appointments comes from a recently
published study of breast screening that reported a second timed appointment sent to women who had not
attended by 4 months after their invitation timed appointment was taken up by 20% overall. Among those
who had received their initial invitation, the uptake was 24%. This translated to a 6% uplift among this age
group (< 53 years) overall, and a 1.5% uplift in the overall uptake of the Breast Screening Programme.71
There is no doubt that the cluster randomised control group in the STRATEGIC study in both phases 1
and 2 has greatly increased the reliability of the findings. Without this, the unexpectedly high uplift in
attendance after 6 months could have been attributed directly to the interventions, whereas the control
group participants suggest that this is not the case.
Although the STRATEGIC trial was aimed at women receiving their initial invitation, the applicability of
these findings to a broader age range is unclear. The large majority of older women will have been
screened previously, some not only for cervical disease, but also for breast and bowel cancer. The
convenience of timed appointments would apply to women across the full age range as indeed would
SSKs for non-attenders. There is no reason, however, to believe that either pre-notification or online
booking would be viewed differently.
Cost-effectiveness
The effectiveness of the interventions is driven entirely by two things in our analysis: (1) the observed
impact in the trial of the interventions on screening attendance and (2) the lifetime benefits of screening,
derived from the meta-analysis, which indicated a lifetime quality-adjusted life expectancy increase of
0.0947 QALYs per woman attending. It was clear from the ORs of the different interventions that
the unrequested SSK intervention had the largest statistically significant effect, followed by timed
appointment intervention, and this is reflected in the cost-effectiveness results. The total cost of the timed
appointments intervention is higher than the control because of the intervention costs and the additional
lifetime screening and other health costs arising from participation in the screening programme, and this
would amount to just over £37 per woman offered the intervention, or £9.5M over the entire lifetime of a
national cohort aged 25 years. The health benefits would be 0.0048 QALYs averaged over a woman
offered the intervention, or 1234 for the national cohort aged 25 years. Therefore, the cost per QALY
gained of a national programme would be £7741, which is well within the usual cost-effectiveness ceiling
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of £20,000 per QALY gained used by NICE. As the cost-effectiveness planes and the cost-effectiveness
acceptability curves showed, there is a high probability that this intervention is more effective and more
costly, and the likelihood that it falls below the £20,000 per QALY ceiling is around 94% (measuring
outcome at the primary end point of 12 months). The unrequested SSK intervention was even more
effective, but also more costly. Extended to the whole cohort of 25-year-old women in England, the
lifetime cost would be £12.9M with 1524 QALYs gained, and a cost-effectiveness ratio of £8438 per QALY
gained for a national programme. As with the time appointments, there is a 94% probability that this
intervention is below the £20,000 ceiling.
The results for the other interventions were much less favourable. The requested SSK is more likely than
not to be effective, as shown in the OR, but this was not statistically significant and when combined with
likely costs the probability that this intervention is cost-effective is no more than 70% at conventional
cost-effectiveness ceiling ratios. The combination intervention is very similar to requested SSK alone, due
almost entirely to the requested SSK component. There is no certainty at all that online booking would be
clinically effective or cost-effective. The pre-leaflet and NN interventions might be associated with lower
lifetime costs, but only because the OR of attendance for both was < 1, and so both interventions had
lower costs but also lower lifetime QALYs than their control groups. In these circumstances, it is possible
that decision-makers may wish to consider whether or not a small reduction in health benefits is a price
worth paying for a large saving in health-care costs, for example if savings are > £20,000 for every QALY
sacrificed. However, here that is not the case; savings would be modest in relation to the loss of health.
The costs of the interventions were based on the costs of delivering them to women participating in the
trial. These varied from just £0.14 per woman enrolled in the NN arm of the study to £11.53 per woman
enrolled in the unrequested SSK arm. If offered to the entire population there would be some saving on
the fixed costs of these interventions (such as development of materials and training of staff), as these
could be spread over a larger population and would not have to be incurred each year. In addition, we
have assumed that variable costs for things such as printing and posting letters could be reduced if these
interventions were scaled up to the national level, and have assumed a reduction of 20% could be
obtained. On that basis, the most expensive interventions to provide would be the unrequested SSK, at an
annual cost of £3.37M for each new cohort entering the screening programme, and timed appointments
at £1.46M.
The health-care costs incurred if women do attend for screening vary between arms only insofar as there
was minor variation in the recorded numbers having HPV or cytology tests or both; no information was
available on actual colposcopies or other items of health-care use and so the same assumptions were applied
to all women. As a result, the cost per woman attending did not vary widely, ranging from £46 for
unrequested SSK to £57 for the phase 1 interventions. To estimate the lifetime costs and benefits of
attending screening we relied on a meta-analysis of published studies, which reported lifetime costs and
outcomes; these suggested that the additional lifetime cost of a screened woman was £566. This is
approximately 10 times the within-trial figures quoted above, and so is roughly in line with a woman with
a full lifetime attendance record in the English programme and no recalls who would attend 12 times
(every 3 years aged 25–49 years, every 5 years aged 50–64 years). The introduction of primary HPV screening
could reduce this to seven or eight visits, depending on the duration of extended screening intervals.
If both timed appointments and unrequested SSK were to be independently introduced nationally, the
total additional cost would be approximately £22.3M, this would be the intervention and lifetime
screening and treatment costs for a 25-year-old cohort, but would approximate to the annual national cost
for the entire screened population once a steady-state had been reached. It seems unlikely in the current
programme based on cytology that these would be offered simultaneously, and more plausible to think
that timed appointments might be offered to all and unrequested SSK to those who did not attend. There
is a range of such scenarios in which costs and effects might vary depending on a number of assumptions,
these have not been fully explored here, and would require further attention. In the event of primary HPV
screening, routine self-sampling for HPV could be feasible and indeed popular with women, and the added
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expense of sending SSKs would be compensated for by avoiding the need for timed appointments and
achieving considerable cost saving in primary care by not requiring practitioner-obtained samples in the
large majority.
Among the limitations of the economic analysis was that lifetime costs and effects had to be estimated
using average cost and effect results from a meta-analysis; some uncertainty was captured, reflecting
variations between studies, but this does not reflect the full uncertainty that might be captured if
patient-level simulation had been possible. However, the lack of such data was a consequence of a
streamlined and simplified trial design, which otherwise might not have been possible to perform.
The implementation costs could also be estimated with more precision, for example by examining the
economies of scale obtained in other screening programmes. However, these do not have a major impact
on the cost-effectiveness results, which are heavily influenced by the observed effects of the interventions
on attendance. Neither has the economic analysis replicated the subgroup analyses performed in the main
trial results, comparing vaccinated and unvaccinated women, and comparing the two screening centres
in Aberdeen and Manchester; it is unclear how any cost-effectiveness differences arising from these
comparisons could be interpreted or used by decision-makers.
The economic analysis used estimates of the costs associated with screening attendance that were
derived from previous published studies. These do not explicitly take account of any costs arising from
non-attendance or ‘no-shows’. In some health-care settings this may be a significant problem, but in this
context it is likely that a no-show rate at a busy general practice or clinic is fairly predictable and does not
result in substantial periods of idle staff time; however, further evidence on this issue would be useful.
In conclusion, the economic analysis indicates that the evidence from the STRATEGIC trial strongly supports
the conclusion that timed appointments and unrequested SSKs are both highly likely to be cost-effective
interventions to improve uptake in first invitees who have failed to attend. Further work is required
to establish the optimal way of combining them (e.g. offering them sequentially), as well as the
cost-effectiveness of extending them more generally to all women across the screened age range.
Discrete choice experiment
The DCE suggests that, despite being non-attenders, women still clearly understand and agree with the
importance of screening for cervical cancer from a personal or societal perspective. This result conflicts
with previous evidence from systematic reviews that identified indifference as one of the main barriers to
screening uptake. It is possible, nevertheless, that the difference was driven by the social class and
education levels of our sample, which indicated that our sample may not be representative for the
population of non-attenders. The DCE also demonstrates preferences for screening scenarios where
minimal personal action is required to arrange a test, the test is done in the privacy of the home, there is a
nurse available for discussion or help, and which are cheaper to the NHS. As these are characteristics of the
SSK interventions trialled within phase 2 of the STRATEGIC study, the results from our stated preference
exercise provides an important first step in confirming that these interventions are valued by women; a
prerequisite for such interventions to be clinically effective and cost-effective. The evidence from the DCE
provides an additional layer of information in addition to the clinical effectiveness and cost-effectiveness
that should be considered when evaluating which strategy to implement to improve uptake to the Cervical
Screening Programme in young women.
Conclusions
Many young women do not respond rapidly to an invitation to cervical screening and uptake appears not
to plateau until 18–24 months. Interventions designed to increase uptake should probably be deferred
well beyond the 6 months used in the STRATEGIC study. A pre-invitation leaflet was ineffective. Online
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booking, although not particularly effective, may be more appealing if available through general practices.
Two interventions, timed appointments and sending SSKs, showed a statistically significant effect among
non-attenders and although the increased uptake was modest, they were shown to have a high likelihood
of being cost-effective within accepted thresholds. Self-sampling to test for HPV could be implemented
either in the current NHS pilot of HPV primary screening or more widely when the national programme
converts to primary HPV testing. There would be a number of operational issues to address. Timed
appointments should be more straightforward to implement provided GPs are supportive. Cervical
screening is increasingly being viewed as a choice women make, but until the expected herd protection
of HPV vaccination exerts its impact over the next 10–20 years, high coverage of cervical screening will
remain a necessary measure if cervical cancer incidence is to remain under control.
Implications for health care
Overall, we found that efforts to increase uptake showed either no effect or a modest effect. Evidence
from the STRATEGIC trial supports data from other studies that have used broader age ranges, for SSKs
being sent to women who have not responded to their initial invitation for cervical screening. The same
applies to timed appointments. Six months is probably too soon following the invitation, rather an interval
of 18–24 months may achieve a larger effect.
Recommendations for research
We feel that further research should focus on self-sampling:
1. Expanding the potential use to non-attenders throughout the screening age range.
2. Exploring the optimal time to offer a self-sample, as it appears that women chose to attend for
screening over a 18–24 month period following their invitation. This is also relevant because
self-sampling involves HPV testing and the prevalence of high-risk HPV infection falls significantly in
the years between the ages of 25 and 30 years.
3. Exploring the use of urine testing in place of a vaginal samples as a convenient means of obtaining
a sample.
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Appendix 1 Pre-leaflet (development)
The pre-leaflet aimed to motivate women who had not considered taking part in screening to do so,based on the transtheoretical model.
The first step in development was to try and establish or identify what would motivate women to take part
and what the barriers to screening were. Focus groups were held in order to achieve this, in total five
focus group discussions (FGDs), the groups consisted of a range of ages and demographics, four focus
groups were with women aged 17–25 years and one group consisted of practice nurses.
The questions and areas for discussion in the FGDs can be summarised as:
l What is known about the cervical screening process?
l What do you know about the screening invitation?
l What is the purpose of screening?
l What do you know about the details of the (screening) procedure?
l Do you feel at risk of cervical cancer?
l Is screening important?
l Could a pre-leaflet motivate you to attend?
l What are the views of cervical screening nurses? (In the practice nurse group only.)
The FGDs were recorded and transcribed verbatim. The main themes that arose in the responses to the
above questions were compiled and led to the development of the pre-leaflet used in the STRATEGIC study.
For further details on the development of the STRATEGIC study pre-leaflet, please see Health
Education Research.11
Once the content had been decided, a selection of pre-leaflets were designed and presented to two more
focus groups. The proposed leaflets were folded like a card, with various formats, in addition to the final
choice of a card with a birthday cake on the front cover – owing to the fact that the women were first
called to screening just prior to 25 years of age and 20 years of age in Greater Manchester and Aberdeen,
respectively. We also proposed a six-page, folded leaflet with mobile phone text and ‘to-do’ list, an A4
information sheet with coloured border and a six-page, folded leaflet featuring a picture of a bin with the
slogan, ‘Don’t throw this away, it might just save your life . . .‘.
The focus groups were asked for their views on design and it was decided that the pre-leaflet should take
the form of a birthday card.
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Appendix 2 Pre-leaflet (Manchester)
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Appendix 3 Pre-leaflet (Aberdeen)
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Appendix 4 Nurse navigator intervention letter
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Appendix 5 Nurse navigator patient information
and consent form
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Appendix 6 General practitioner timed
appointments letter
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Appendix 7 Additional statistical tables
TABLE 42 Full analysis model of phase 1 including covariates for pre-leaflet and online booking
Time since intervention
Time point
3 months 6 months
ORa p-value 95% CI ORa p-value 95% CI
Pre-leaflet: all data
Pre-leaflet (control) 0.967 0.485 0.879 to 1.063 1.015 0.747 0.928 to 1.109
PCT – Trafford (Salford) 1.332 0.713 0.29 to 6.122 1.095 0.913 0.215 to 5.57
PCT – Manchester (Salford) 1.301 0.653 0.412 to 4.107 0.724 0.631 0.193 to 2.709
PCT – Grampian (Salford) 0.886 0.881 0.179 to 4.37 0.653 0.587 0.14 to 3.036
Baseline rate 1.039 < 0.001 1.022 to 1.056 1.033 0.001 1.013 to 1.053
PCT(Trafford) × baseline rate 0.994 0.598 0.971 to 1.017 0.997 0.801 0.972 to 1.022
PCT(Manchester) × baseline rate 0.993 0.443 0.975 to 1.011 1.001 0.922 0.98 to 1.022
PCT(Grampian) × baseline rate 0.996 0.717 0.973 to 1.019 1.001 0.91 0.978 to 1.025
ICCb 0.010 0.016
Online booking: Manchester PCT only
Online booking (control) 1.021 0.802 0.869 to 1.200 1.097 0.242 0.939 to 1.282
Baseline rate 1.032 < 0.001 1.023 to 1.041 1.033 < 0.001 1.025 to 1.041
ICCb 0.009 0.019
a OR adjusted for covariates displayed in table.
b ICC for GP clusters estimated from GEE model.
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Appendix 8 Details of interventions
Pre-leaflet
A pre-leaflet was developed by Sadler et al.11 and aimed to move women about to be invited for first
screening from the ‘pre-contemplation’ to ‘contemplation’ stage based on the transtheoretical model.
In Manchester, the screening agency, as part of the standard NHS Cervical Screening Programme, sent
the pre-leaflets to women 6 weeks before they were due to receive their first invite to cervical screening.
As the screening agency in Scotland did not have the provision to assist the research, in Grampian the
Aberdeen-based research team sent the pre-leaflets in weekly batches 4–6 weeks before the women were
due to receive their first invite to cervical screening. The team spent a great deal of time working on this
and so the costs were somewhat higher than in Manchester; however, if the service was operationalised
nationwide, the costs would be more comparable to the process in Greater Manchester.
Online booking
Women in surgeries randomised to receive the online booking intervention received a letter providing
them with information on how to make an online booking and a list of participating clinics. This
information was sent with their first invitation letter, 6 weeks before the women were due to receive their
first invitation to cervical screening, and with the first reminder letter from the screening agency, which
was sent to women without a test recorded 3 months after their test due date. The team in Manchester
set up an online appointment scheduling system via a free service, SuperSaaS (www.supersaas.com). The
team then spent time contacting a range of sexual health clinics across Greater Manchester and agreed on
a block of set appointments for women to attend. Women who accessed the service were asked to input
only their name and a contact number online, and were not able to see appointments that had been
booked by other users. An administrator account was held for the system by the research team, who
forwarded on details of booked appointment to an administrator at the clinics using the NHS.net e-mail
system at the start of each week. In addition, each woman received a text message confirming the
appointment the day before. Family planning staff were subsequently asked to indicate if a woman who
had booked online had attended. From the 215 women who accessed the service, 128 attended:
20 cancelled beforehand, 60 did not attend and data were missing on seven.
Human papillomavirus self-sampling
There were two HPV self-sampling intervention arms: the first was a letter sent to the women, offering
them to chance to request a SSK; and the second was an unsolicited SSK being sent directly to their home.
The kits included a consent form that came back with the sample to the laboratory at Central Manchester
Health Care Trust. Once the test had been processed, the team at the laboratory sent the results and
the consent form to the research team in Manchester who fed back the results as per the request in the
consent form.
Nurse navigator
The offer of the NN service came in the form of a letter sent by the screening agency; it provided contact
details for the NN and explained how they may be able to offer help and advice in order to allay any
anxieties that they might have regarding attending for a cervical screening test. Women were encouraged
to contact the NN via telephone to speak to her directly during daytime hours or to contact the trial office
via telephone, e-mail or text messaging to request that the NN calls them at a convenient time. The NN
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discussed the woman’s perceived barrier(s) to accepting the invitation for cervical screening and assisted
the woman in booking an appointment where necessary. If the NN felt online booking or a HPV SSK was
appropriate to the woman’s needs, she facilitated access to these interventions. Women were also asked
if they would like to receive a follow-up call from the NN to discuss whether or not they had arranged/
attended for screening.
Timed appointments
General practitioners were asked to send women an invite letter detailing a time and date for them to
attend for a cytology appointment. In this invite letter women were given the option to rearrange for a
more convenient time if needed. The service proved difficult to operationalise and some practices were
unable to ring-fence enough appointments, these figures have been recorded.
Choice of nurse navigator or request human papillomavirus sample
Choice between NN and SSK offered.
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Appendix 9 Intervention unit costs
Intervention Cost item Unit
Unit
cost (£) Units Costs (£) Cost type
Pre-leaflet Researcher time Hour 17.22 20 344.40 Fixed, one-off
Refreshments Item 15.00 15 225.00 Fixed, one-off
Consumables Item 100.00 1 100.00 Fixed, one-off
Design 200.00 1 200.00 Fixed, one-off
Pre-leaflets Item 0.16 10,461 1673.76 Variable
Postage Item 0.39 10,461 4079.79 Variable
Envelopes Item 0.03 10,461 334.75 Variable
Labels Item 18.29 6 109.74 Variable
Staff time to produce and post Hour 16.42 87 1428.54 Variable
Total 8495.98
Online booking Staff time to set-up online
booking system
Hour 16.42 35 574.70 Fixed, one-off
Staff time for weekly duties Hour 16.42 104 1707.68 Variable
Consumables (telephone) Item 100.00 1 100.00 Variable
Total 2382.38
HPV SSK Delphi Item 2.85 603.5 1719.98 Variable
Evalyn (variable charge) Item 1.25 603.5 754.38 Variable
Evalyn (freight charge) Item 125.00 1 125.00 Variable
Consumables (clinical) Item 1.00 1207 1207.00 Variable
Postage Evalyn Item 0.70 603.5 422.45 Variable
Postage Delphi Item 2.60 603.5 1569.10 Variable
Staff time (set-up) Hour 16.42 14 229.88 Variable
Staff time (weekly) Hour 20.00 315 6300.00 Variable
Staff time (lab) Hour 11.72 18 211.00 Variable
Laboratory kits [Cobas (Roche
Diagnostics, Pleasanton, CA, USA)]
Item 7.00 197 1379.00 Variable
Total 13,917.78
Total cost per kit 11.53
Requested SSK Total costs 368.99
Unrequested SSK Total costs 13,156.74
NN Nurse training Item 150.00 1 50.00 Variable
Nurse time Hour 20.00 4 80.00 Variable
Requested HPV kit Item 11.53 1 11.53 Variable
Total 141.53
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Intervention Cost item Unit
Unit
cost (£) Units Costs (£) Cost type
Timed appointments Appointment letter Item 5.00 1629 8145.00 Variable
Total 8145.00
Combination Information letter Item 0.16 1277 204.32 Variable
Envelops Item 0.03 1277 38.31 Variable
Postage Item 0.39 1277 498.03 Variable
Requested HPV kit Item 11.53 21 242.15 Variable
Nurse training Item 150.00 1 100.00 Fixed,
scalable
NN time Item 20.00 8 160.00 Variable
Total 1242.81
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Appendix 10 Literature review results
TABLE 46 Selected studies from literature review
Author Location
Description of
target population
Statement of decision
problem/objective Type of model
Bidus et al.31 USA Active duty women
in the US army
To compare the outcomes of several
cervix cancer screening strategies in a
military population using a model that
considers both direct and indirect costs
of health care
Markov state
transition model
Bistoletti et al.32 Sweden Women in Sweden
from the age of
32 years
To simulate the cost-effectiveness of
different conceivable strategies in the
setting of an organised screening
programme
State transition
model
Goldie et al.33 USA Cohort of women in
the USA
To evaluate the cost-effectiveness of HPV
DNA testing as a primary screening test
in combination with cervical cytology in
women aged ≥ 30 years
A state transition
mathematical
model
Kim et al.34 UK, the
Netherlands,
France and
Italy
Women aged
20–65 years,
30–60 years,
25–65 years and
25–65 years
Assessment of the cost-effectiveness of
incorporating HPV DNA testing into
existing cervical cancer screening
programmes in the UK, the Netherlands,
France and Italy
A state transition
mathematical
model
Vijayaraghavan
et al.35
Canada Cohort of
100,000 women
over their lifetimes,
beginning at age
13 years
Objective was to evaluate the
cost-effectiveness of cervical cancer
screening strategies utilising HPV testing
Markov Monte
Carlo simulation
model
Voko et al.36 Hungary Women aged
25–64 years, on the
basis of participation
in regular screening
To compare the cost-effectiveness of
two national cervical cancer screening
programmes aiming to involve those
who do not regularly participate in the
screening programme in Hungary
Cohort simulation
Markov model
Sherlaw-Johnson
and Philips24
UK Women from the
age of 13 years
To evaluate different options for
introducing LBC within the UK in terms
of cost-effectiveness
A state transition
mathematical
model
Payne et al.37 NICE
appraisal
Women aged
between 21 and
95 years
To evaluate the clinical effectiveness
and cost-effectiveness of liquid-based
cytology for cervical screening compared
with conventional smear testing
Cohort macro
simulation
DNA, deoxyribonucleic acid; LBC, liquid-based cytology.
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It can be seen that the quality scores were variable across the identified studies.
TABLE 47 Study quality scores, and lifetime costs and outcomes in screened and unscreened cohorts, in eight studies
ID Author Screening
CHEERS
quality
score
HTA
quality
score
Lifetime
cost (£)
Adjusted life
expectancy
(years)
Adjusted
QALYs
0 Payne et al.37 Yes 0.95 0.80 280.26 62.355 57.4439
0 Payne et al.37 No 0.95 0.80 9.0405 62.29 57.3922
1 Sherlaw-Johnson and Philips24 Yes 0.90 0.75 535.37 62.349 57.4395
1 Sherlaw-Johnson and Philips24 No 0.90 0.75 288.61 62.29 57.3922
330 Bidus et al.31 Yes 0.68 0.38 1138.9 62.413 57.4908
330 Bidus et al.31 No 0.68 0.38 688.48 62.29 57.3922
342 Bistoletti et al.32 Yes 0.61 0.37 353.24 63.098 58.0328
342 Bistoletti et al.32 No 0.61 0.37 754.05 62.29 57.3922
1233 Goldie et al.33 Yes 0.82 0.51 2388.7 62.496 57.5566
1233 Goldie et al.33 No 0.82 0.51 369.38 62.29 57.3922
1712 Kim et al.34 Yes 0.82 0.55 538.33 62.351 57.4412
1712 Kim et al.34 No 0.82 0.55 175.43 62.29 57.3922
3448 Vijayaraghavan et al.35 Yes 0.66 0.51 1627.4 62.423 57.4984
3448 Vijayaraghavan et al.35 No 0.66 0.51 795.35 62.29 57.3922
3469 Vijayaraghavan et al.35 Yes 0.86 0.66 1118.7 62.329 57.4234
3469 Vijayaraghavan et al.35 No 0.86 0.66 252.36 62.29 57.3922
HTA, health technology assessment; ID, identification.
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Appendix 11 Cost-effectiveness planes from the
secondary cost-effectiveness analysis
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FIGURE 24 Cost-effectiveness plane for the secondary end points of the pre-leaflet assessed at 6 months.
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FIGURE 25 Cost-effectiveness plane for the secondary end points of online booking assessed at 6 months.
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FIGURE 26 Cost-effectiveness plane for the secondary end points SSKs sent on request assessed at 18 months.
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FIGURE 27 Cost-effectiveness plane for the secondary end points of SSKs sent unrequested assessed at 18 months.
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FIGURE 28 Cost-effectiveness plane for the secondary end points of the NN assessed at 18 months.
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
– 200
Incremental QALYs
In
cr
em
en
ta
l c
o
st
s 
(£
)
– 150
– 0.020 – 0.015 – 0.010 – 0.005 0.000 0.005 0.010 0.015 0.020
– 100
– 50
0
50
100
150
200
FIGURE 29 Cost-effectiveness plane for the secondary end points of timed appointments assessed at 18 months.
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FIGURE 30 Cost-effectiveness plane for the secondary end points of the choice between NN or SSK sent on request
assessed at 18 months.
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Appendix 12 Theoretical framework of discrete
choice experiments
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Appendix 13 Topic guide for the STRATEGIC
study qualitative interviews
Acceptability of the three novel interventions
1. Which option (NN, SSK, timed appointments) they were offered and their initial reaction to it.
For those in the group who were given the choice of NN or SSK and those in the NN group who were
then offered SSK, what was the reason for their choice?
2. If they HAVE used it, what happened (how did it go)?
Prompts for NN
l How were you contacted by the NN (telephoned directly, via trial team – e-mail, text, telephone)?
l What was discussed with the NN?
l Who led the conversation?
l How long was the conversation?
l The outcome of the conversation (e.g. referred on to use online booking, SSK).
l How they felt at the end of the conversation with the NN.
l What they liked about the NN.
l What they disliked about NN.
Prompts for SSK
l How they accessed the SSK (via trial team – e-mail, text, telephone, online).
l Understanding the instructions about how to use the kit – how easy or difficult.
l Using the kit – how easy or difficult.
l Sending back the sample – how easy or difficult.
l How they felt about using the kit.
l What they liked about self-sampling.
l What they disliked about self-sampling.
Prompts for timed appointments
l How they received the timed appointment.
l Convenience of the timed appointment they were offered.
l Understanding of how to confirm/change the timed appointment – how easy or difficult.
l What they liked about timed appointments.
l What they disliked about timed appointments.
If they have NOT used it, why was that?
At what point did they decide not to use (explore using the above prompts for each option).
3. How can the NN/SSK/timed appointment options be improved/what would encourage them to use
it (again)?
4. Anything else they want to say about NN/SSK/timed appointments?
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Identifying the attributes and levels for the discrete choice
experiment exploring young women’s preferences for cervical
screening programmes
5. What they see as important features of a cervical screening programme – in other words what would
encourage them to book and attend for screening.
(a) Booking:
How would they prefer to book an appointment?
Prompts
l Online versus telephone – why is that?
l Be given an appointment time versus choosing own appointment time – why is that?
What else is important in terms of booking the appointment?
Prompts:
l Being able to change an appointment.
l Waiting time for appointment – how long is acceptable?
l Information in advance – what information?
l Opportunity to speak to someone about it – who and how (telephone vs. face to face vs. e-mail)?
l Willingness to pay?
(b) Attending screening/doing self-sampling:
How would they prefer to have the screening done?
Prompts
l Go to an appointment with a health professional versus do a test at home – why is that?
l What are the advantages of going to an appointment with a health professional? And what are
the disadvantages?
l Who would they want the appointment to be with – why is that?
l What are the advantages of doing a test at home? And what are the disadvantages?
What else is important in terms of the screening itself?
Prompts
l Willingness to pay?
l Accuracy?
(c) Getting results and acting on them:
How would they prefer to get the results?
Prompts
l Letter versus e-mail versus letter versus appointment/telephone call – why is that?
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What else is important in terms of getting the results?
Prompts
l Waiting time for results – how long is acceptable?
l Accuracy of results – how accurate is acceptable?
l Confidentiality – who should know?
l Opportunity to speak to someone about it – who and how (telephone vs. face to face vs. e-mail)?
l Willingness to pay?
6. Anything else they see as important.
7. Of everything we have discussed, what are the three most important things about the Cervical
Screening Programme that would influence whether they attend or not.
8. Anything else that they want to say.
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Appendix 14 Discrete choice experiment
questionnaire
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Appendix 15 Discrete choice experiment patient
information leaflet
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Appendix 16 Comments
STRATEGIC comments
Code Meaning
DCE comments Participant comments on the DCE
DCE attributes Participant comments on attributes
DCE process Participant comments on the process
General General comments on cervical screening
Location Comments on the location of where the cervical screening will take place
Action Comments on the action participants need to take in attending a cervical screening appointment
CS-N Comments on why participants do not attend cervical screening
CS-Y Comments on why participants do attend cervical screening
Privacy Comments on privacy issues relating to cervical screening
Time Comments on time relating to attending cervical screening
Risk Comments on risk perception
Cost Comments on costs to NHS
Perception/pain Comments of perception of pain
Nurse Comments relating to nurses being a part of the cervical screening process
Code
DCE comments
As a (junior) doctor I think it is important to reiterate the value or cervical screening in SEXUALLY
ACTIVE women[.]
As I’ve already written I feel the first set of questions were too much[.]
I am very grateful this questionnaire was sent to me I genuinely forgot/I was too busy to book a
cervical smear test and this has encouraged/reminded me to do so Thank you, good luck in your
studies[.]
I found the question is a bit confused, but, anyway I tried to answer[e]d it. I hope you understand
me[.]
I have decided to take the questio[n]naire, as my case is a bit different, so I don’t know what bracket
I fall under[.]
I have now attended my smear thanks to this form, luckily my tests came back negative:)!
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I’d encourage more insightful questions regarding the Cervical Screening Process when it comes to
overseas students choosing to do the test within the UK[.]
If you are going to hold surveys like this, could you ph[ra]se ‘women who have screenings but have
not attended’ better or elaborate further? Not all women have skipped these screenings because
they’re afraid, costs or laziness[.]
It would be good to have a section for comments and reasons for peo[p]le to provide for refusing
cervical screening test[.]
Obviously the options were not what I would pick overall. The answers were based on what I thought
were important if doing the test at home or by GP[.]
Personally I’m not sure your proposals will make me more inclined to have a smear.
Questionnaire does not address my main reason for non-participation in Cervical Screening
Programme[.]
Some of the options I didn’t think were viable, and I was asked to choose between two un-realistic
options. I think the questions would have been better in a different format, to get peoples opinions on
specific options/thoughts of the NHS, instead of making them choose between two options that they
would not necessarily choose as an option.//Individual questions would have been better. I do not feel
my t[ru]e opinion has been expressed in this questionnaire due to the format[.]
Some of the questions repeat in a way that is confusing, I’m not sure that my answers will be
interpreted in a way that reflects my real opinions. The questionnaire in general I found somewhat
confusing[.]
Sometimes difficult to make a distinction between questions - variety of questions might be easier to
understand.//Otherwise thank you!
The question[n]aire was really easy to complete and understand[.]
The questionnaire has showed me how important cervical cancer screening is I will book my
appointment with my GP to do my test. Thanks[.]
The questionnaire indicates I am yet to attend a screening test but does not provide questions asking
why women may shy away from undergoing a test. Overall, good questionnaire items[.]
The questionnaire was very easy to follow[.]
This is a great idea [I] am pleased to post my opinions personally[.]
This questionnaire was very easy to answer[.]
[T]his was a fairly complicated questionnaire and can see how some people may become easily
confused[.]
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DCE attributes
[A]n optional question on whether the participant is sexually active or not can affect your study in
terms of the participant possessing adequate knowledge/importance of screening.//
Tweaking the cost etc - would have made more sense to ask people what there options would be
i.e. action require by you? ? No// ?Yes.
as much as it gives service users input into methods best used for cervical screening, it doesn’t ask why
there was a delay in uptake, which [I] think is also important[.]
It’s great that you are doing a study into this, which may encourage better uptake of cervical
screening. However feel it isn’t comprehensive. Clearly you have set parameters which you are
working in. But from my point of view the reasons for not undergoing screening are more complex
than the 4 issues you are studying. Psychological and cultural factors as well as childhood abuse make
it incredibly unlikely that I could allow anyone near me, voluntarily. I see a lack of recognition within
the NHS that for some people screening just isn’t for them, and that there are complex, human
reasons for this.
The options presented to choose from are based around 4 possible reasons why women not want to
undertake cervical screening, but would it not be more pertin[e]nt to ask wo[m]en their own reasons
why? My own reasons for not atten[d]ing screening were not covered by these choices. Also, the
4 simple bullet points do not convey the full pros and cons of each choice, and readers may not be
aware of them. For example, sending a kit home for patients to take the test themselves may avoid
embar[r]assment and time off work to make an appointment, but there are risks that the woman
might do the test wrong, or hurt herself, or it may become contaminated. A professional nurse is
trained to take the test. These pros and cons might not be immediately obvious to people taking the
survey, and may not be taken into account when they are providing their answers.
The questions in section 2 could offer a further option because personally the main reason I chose an
option was the location it was carried out although I don’t agree on the higher costs either therefore
I wouldn’t want there to be a high cost yet also I wouldn’t want the rest to be carried out at the local
surgery therefore I picked out the best option out of the two[.]
DCE process
SITE DID NOT WORK, I DID-NOT GET MY £10 VOUCHER, UNHAPPY WITH.
General
There is no use in screening women who have never been sexually active!
AWARENESS OF THIS SCREENING, NEED IMPROVENING./
Cervical screening (as well as breast examination) is so very important. More and more young adults
are finding they have abnormal smears. My Mum and Grandma were diagnosed with carrying the
BRAC2 gene.//(I have been tested and luckily I am not a carrier.)//
Cervical Screening age should be lowered to 20. This will save young lives.
Cervical screening is a very intrusive procedure which is not necessary for all women.
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I recently went to a ‘lady doctor’s’ appointment, but it was in regards to contraception . . . She had
noticed I hadn’t had my smear test so asked if she could do it at the same time - but it messed up
the contraception by doing so (the coil-copper coil... the wires were lost).//
I Have Not yet had a smear test, but thinking about it. I feel that starting having smears early is
important. I am not sure what age your first test should happen.
I THINK THE TEST AGE SHOULD BE LOWERED TO 16-18[.]
I think you are doing a bril[l]iant job + keep up the hard work, we need more information to be able
to tackle this issue head on. Also I think the age for screening should be lower to help save more lives.
I WHOLLY SUPPORT AND ENCOURAGE CERVICAL SCREENING FROM AN EARLY AGE[.]
Your cervical screening records do need to be updated, as I told my doctor I was screened in a
different country.
Location
I WOULD GLADLY BE SCREENED IF I HAD THE OPT FOR MY LOCAL SURGERY./
I like the idea of a home test as I feel more women would be more [i]nclined to get tested.
I believe more women, especially younger, would take the test if given the option to take the test at
home. Knowing from past experience, some women can feel a bit shy & not vey keen at being poked
& prodded.
I feel if testing was to be done at home by individuals it would be a huge succes[s], avoiding embarras
[s]ment and time issues. It’s a good idea and something I would use.
I feel many women are at risk due to the screening being carried out by CP [GP] which is embar
[a]ssing.
I had a cervical screening, 1 week ago. If there was an option of doing the test at home I would have
done it MANY years ago.
I never new that there was even an option being considered where we would be able to do this from
home[.]
I think offering a home testing kit as an alternative would encourage women who avoid testing
(through embar[a]ssment/forgetting) to test themselves, and could save lives[.]
I WOULD ALWAYS CHOOSE HOME, PROVIDED THAT IT WOULD NOT COST THE NHS TOO MUCH,
AND I FEEL GUIDANCE SHOULD ALWAYS BE AVAILABLE - EVEN IF DONE VIA AN ONLINE VIDEO/FAQ
[frequently asked questions] SECTION.
However I feel I would also be willing to try a home kit first, before this survey I did not know that was
a possible option in the future I hope if becomes available.
Personally I would prefer to take a test at home as I get embarras[s]ed and have a lot of anxiety’s
that’s why I have never atten[d]ed for a test to be done.
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In summary: I would prefer a home testing kit, that I would have to request (rather than just being
sent automatically).
AND I’D PREFER A METHOD THAT IS MORE PRIVATE I.E. THE TEST KIT SENT TO MY HOUSE FOR
SELF TESTING.
THE OPTIONS WHEN CHOOSING WHICH CHOICE I WOULD ALWAYS CHOOSE THE OPTION TO DO
THE TEST AT HOME.
Therefore, testing myself at home would be 100% better all around.
I believe that sending tests in the post so women can do the test themselves would get a lot more
women to do the test.
A LOT of people get put off the idea because of having To go To gp For it but doseNt bother me
Either WAY the Leaflets sh[ou]ld be Eas[i]er To understand and [i]f Anyone cAnt mAke it To gp should
be offer[e]d To have a home Test sent out if they can do it them self’s.
[I] would be more will to do a test at home if it was automatically posted when it was due.
I would prefer if an appointment was booked for me and I would rather have it at a clinic than do
it myself.
Would always say to have screening at surgery.
Action
Young girls are having sexual intercourse at an early age and so I feel they need scree[n]ing and if a
test kit could be sent through the post and is not as invasi[ve] as a normal smear, then I think this is
the way forward.
Not an excuse but appointment times at a GPs doesn’t help, this problem.
I would highly recommend a time/date being sent to women as this would have definitely given it
a higher sense of importance for me personally.
Booking appointments has its pro’s + con’s but if people aren’t going to make an appointment
themselves then it’s likely they won’t call to reschedule or simply won’t turn up.//I would prefer an
online/SMS [short messaging service] booking process. Allowing me to book an appointment at any
time not when the phone line is open.
HOWEVER I DO THINK IF I RECEIVED AN APPOINTMENT ALREADY ARRANGED FOR ME I WOULD
HAVE BEEN MORE LIKELY TO ATTEND.// THE REASON TO BE ABSENT FROM WORK WOULD BE
COVERED BY A CONFIRED DOCTORS APPOINTMENT.//
A LOT of people get put off the idea because of having To go To gp For it but doseNt bother me
Either WAY the Leaflets sh[ou]ld be Eas[i]er To understand and [i]f Anyone cAnt mAke it To gp
should be offer[e]d To have a home Test sent out if they can do it them self’s.
I would prefer if an appointment was booked for me and I would rather have it at a clinic than do
it myself.
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CS-N (why do not attend cervical screening)
The HPV virus is spread by sexual transmission hence if you have never been active sexually it feels like
you are being violated. Also the risk is extremely low to warrant a check in my personal opinion.//I did
try to be screened by I was unable to let the nurse proceed as it was extremely uncomfortable and
violating. This is why I refuse to be screened.
Finding time to attend an appointment is my downfall.
I actually went to my GP surgery to arrange a test, but since I was not at the top of the list to be sent
a reminder I could not organise one. I also did not received any invitation to attend, and to date have
still not. Thus it has been a bit of a nightmare to actually get a test. If I wasn’t presented with
administrative barriers I would have gone ages ago.
I am very grateful this questionnaire was sent to me I genuinely forgot/I was too busy to book a cervical
smear test and this has encouraged/reminded me to do so Thank you, good luck in your studies.
I believe more women, especially younger, would take the test if given the option to take the test at
home. Knowing from past experience, some women can feel a bit shy & not vey keen at being poked
& prodded.
I don’t want anyone to look at my private parts, as they are private . . .
I ignored previous invites to a smear test, as it sounds painful! However in real life, is nothing like the
stories! This lack of information . . . is all it was. It’s a painless procedure! Should be a leaflet!// I wrote
on the first page. You need a leaflet stating is not scary and it’s painless!
I have not attended screening because I suffer from PTSD [post-traumatic stress disorder] related to
sexual traumas so the test would be psychologically traumatic to me. I have never had sex so the
chances of cervical cancer are low. [H]aving this test would likely to therefore be painful and
unnecessary. I also have been diagnosed with high-functioning autism. I do not cope well with touch.
I find many NHS professionals do not make allowances for this.
I can guarantee that most people, certainly my age, don’t go as A. They’re embarrassed and B. We’re
always told by others how painful it is which I know is not true.
I think offering a home testing kit as an alternative would encourage women who avoid testing
(through embar[a]ssment/forgetting) to test themselves, and could save lives[.]
I think the study needs to look further into having tests done by trained gynaecologist rather than GPs.
The reason why I personally haven’t been back to arrange a screening test is because I have previously
had a test done (probably before I was 25 and that’s why I didn’t show up in your records) and it was
horrible. Having lived abroad up until I was 21, I went for regular smear tests (around every 6 months)
as this was the norm for any woman who was on the pill. The tests were done by a gynaecologist,
who I knew and trusted, in his clinic. Of course the test isn’t comfortable but I never felt in pain.
However, when I had the test done at the GP practice I’m registered at now, it was quite painful and
uncomfortable. I didn’t have the impression the doctor was doing this on a regular basis and I didn’t
feel she had the right equipment, such as the correct facilities for me to sit on, to make the procedure
less uncomfortable. I would much rather prefer to pay privately to have the procedure done by a
gynaecologist in their practice, than having this done at my GP, as I don’t think they are equipped for
this. Having a test like that done is very personal and I can imagine that a lot of young women are self
conscious about themselves when going for such a test, so having this done in the right environment,
with the correct equipment and by a doctor who is an expert in that field would, in my opinion, be
much more beneficial and effective. (expertise, pain privacy?)
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I went to my first smear test just the other week at aged 25. For the sake of a couple of minutes and
life. I’m ashamed I’d put it off so long. There need to be much more awareness for how important this
is. (time)
HOWEVER, THE REASON WHY I HAVE NOT YET ATTENDED A SCREENING IS LESS TO DO WITH
CONVENIENCE OR LOCATION BUT MY PERSONAL CIRCUMSTANCES. I AM A VIRGIN WITH VERY
LITTLE EXPERIENCE AND I AM VEY ADVERSE TO BEING TOUCHED BY STRANGERS, TO THE POINT OF
PANIC ATTACKS. AN INTIMATE EXAM WITH A COMPLETE STRANGER WOULD, BY ITS NATURE,
MAKE ME INCREDIBLY UNCOMFORTABLE AND WOULD LIKELY MAKE SUCH A TEST PAINFUL. THERE
ISN’T A LOT OF SUPPORT FOR THIS, AND IF THERE IS, NONE OF IT HAS BEEN OFFERED TO ME.
(risk, location perception-pain)
My first experience of a smear was painful, each attempt after (3 attempts) have been painful due to
being unable to relax. I found the nurses at the G.P. surgery unsympathetic. Oral sedative (valium) did
not help. I feel I would benefit from I.V. [intravenous] [sed]ation (midazolam) as this is also a muscle
relaxant, I would be more likely to return for screening if this was an option.
Reason why I have not gone for cervical screening is because I am not sexually active and therefore
at low risk of cervical cancer.
The main reason for ignoring these screenings is the pain, and that’s the main reason, so just by
having a nurse to help you guide through the process may help the most. A nurse who is encoura[g]
ing and not to put you off. Because the pain puts you off!
THE MAIN REASON FOR NOT BOOKING AN APPOINTMENT FOR SCREENING IS THAT IT’S A BIT
EMBARASSING[.]
I would like to e[m]phasise that I fully understand the importance of screening, but I find the whole
idea of the process far too uncomfortable.
It is mainly embarrassment that has made me put off having the test so far.
The reason I did not accept the invitation to have a cervical screening last year was because I have not
yet ever been sexually active. When I am, I will ask for a cervical screening.
The screening Test is A good thing I didn’t go To Mine because I WAS pregnant[.]
I turned 25 in June and have put off going but I will go its just finding the time. I then had the implant
put in and have been bleeding for 5 weeks so that[‘]s another reason why I have not been.
While I know that cervical screening is important I always have put off booking an appointment,
because I always have other activities I’d put first. I go to the doctors about 4/5 times a year. However,
only once in about 20 appointments has the doctor mentioned that I have not had my screen. This, in
an inadvertent way reaffirms to me that the fact I have delayed my screen isn’t that important/urgent.
Privacy
I feel if testing was to be done at home by individuals it would be a huge succes[s], avoiding embarras
[s]ment and time issues. It’s a good idea and something I would use.
I feel many women are at risk due to the screening being carried out by CP which is embar[ra]ssing.
AND I’D PREFER A METHOD THAT IS MORE PRIVATE I.E. THE TEST KIT SENT TO MY HOUSE FOR
SELF TESTING.
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Time
I feel if testing was to be done at home by individuals it would be a huge success, avoiding embarras
[s]ment and time issues. It’s a good idea and something I would use.
CS-Y (why do attend cervical screening)
I would highly recommend a time/date being sent to women as this would have definitely given it a
higher sense of importance for me personally.
I had a cervical screening, 1 week ago. If there was an option of doing the test at home I would have
done it MANY years ago. I only got the test one week ago as it was a requirement of the fertility clinic
before I could get treatment.
Risk
I find it irritating to be persistently invited for a screening when I am not in an at risk group.
I’ve attended my appointments and was told that was low risk of C.C. [cervical cancer] because I’ve
not had sexual intercourse, therefore no screening had to be done. I understand that I have to make
my own appointments now but the fact that I am getting letters about me ‘missing’ or ‘refusing’ to go
to my screening is getting annoying. I’m sure you don’t mean disrespect you not all women are simply
refusing to go, some our us have gone to our appointments but DO NOT need screening!!!
I am a qualified doctor (surgery) & have taken steps to minimise my risk of cervical cancer
(HPV vaccination prior to being sexually active, protected sex, small number of sexual partners).
I therefore feel my risk of cervi[c]al cancer is low; sufficiently low that the disadvantages of screening
(false positives & importantly time off work to attend appoint for screening test) outweighs the benefits
in my personal case. I support the cervical screening program[m]e on the whole but based on my
personal risk/benefit analysis I have elected not to participate at this stage.//Good luck with your study.
Reason why I have not gone for cervical screening is because I am not sexually active and therefore at
low risk of cervical cancer.
I DO BGELIEVE THERE ARE ALOT OF MYTHS AND STORIES WHICH DISCOURAGE ALOT OF PEOLE TO
ATTEND A SMEAR TEST.
[I] have heard horrific things about smear tests which has put me off but [. . .]
Cost
But on the other hand if it is gonna cost the NHS a lot more money then I think it should be carried
on at your GP by the nurse or the nurse to be there and you do it yourself behind the curtain.
I really don’t want the NHS to invest heavily in this. Although a smear is important there are other
areas of the NHS that need investment.
the cost to the NHS may make me change my view if it was vastly more expensive (to the NHS) to
send out a home test rather than to have an appoin[t]ment at a clinic.
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Perception/pain
The thought of a DIY [do it yourself] kit is quite daunting.
The main reason for ignoring these screenings is the pain, and that’s the main reason, so just by
having a nurse to help you guide through the process may help the most. A nurse who is encoura[g]
ing and not to put you off. Because the pain puts you off!
Nurse
I would really think if someone was available to discuss the test this would make one comfor[t]able to
have it done.
It wouldn’t concern me if I wa[sn’t] able to talk to a nurse PRIOR to the test[.]
The main reason for ignoring these screenings is the pain, and that’s the main reason, so just by
having a nurse to help you guide through the process may help the most. A nurse who is encoura[g]
ing and not to put you off. Because the pain puts you off!
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